



(86) Date de dépôt PCT/PCT Filing Date: 2012/04/05
(87) Date publication PCT/PCT Publication Date: 2012/10/11
(85) Entrée phase nationale/National Entry: 2013/10/01
(86) N° demande PCT/PCT Application No.: US 2012/032438
(87) N° publication PCT/PCT Publication No.: 2012/138938
(30) Priorités/Priorities: 2011/04/05 (US61/471,937);
2011/09/30 (US61/541,862); 2011/11/01 (US61/554,167)


(51) Cl.Int./Int.Cl. *C07D 413/14* (2006.01),
A61K 31/497 (2006.01), *A61P 35/00* (2006.01)

(71) Demandeur/Applicant:
VERTEX PHARMACEUTICALS INCORPORATED, US

(72) Inventeurs/Inventors:
CHARRIER, JEAN-DAMIEN, GB;
MACCORMICK, SOMHAIRLE, GB;
STORCK, PIERRE-HENRI, GB;
PINDER, JOANNE, GB;
O'DONNELL, MICHAEL EDWARD, GB;
KNEGTEL, RONALD MARCELLUS ALPHONSUS, GB;
...

(74) Agent: SMART & BIGGAR

(54) Titre : COMPOSES AMINOPYRAZINES UTILES EN TANT QU'INHIBITEURS DE LA KINASE ATR
(54) Title: AMINOPYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF TRA KINASE



I

(57) **Abrégé/Abstract:**

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula (I); wherein the variables are as defined herein.



(72) **Inventeurs(suite)/Inventors(continued):** YOUNG, STEPHEN CLINTON YOUNG, GB; KAY, DAVID, GB;
REAPER, PHILIP MICHAEL, GB; DURRANT, STEVEN JOHN, GB; TWIN, HEATHER CLARE, GB;
DAVIS, CHRISTOPHER JOHN, GB

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau



WIPO | PCT



(10) International Publication Number

WO 2012/138938 A1

(43) International Publication Date
11 October 2012 (11.10.2012)

(51) International Patent Classification:

C07D 413/14 (2006.01) A61P 35/00 (2006.01)

A61K 31/497 (2006.01)

(21) International Application Number:

PCT/US2012/032438

(22) International Filing Date:

5 April 2012 (05.04.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/471,937 5 April 2011 (05.04.2011) US

61/541,862 30 September 2011 (30.09.2011) US

61/554,167 1 November 2011 (01.11.2011) US

(71) Applicant (for all designated States except US): VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHARRIER, Jean-Damien [FR/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). MACCORMICK, Somhairle [GB/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). STORCK, Pierre-Henri [FR/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). PINDER, Joanne [GB/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). O'DONNELL, Michael, Edward [IE/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). KNEGTEL, Ronald Marcellus, Alphonsus [NL/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire, OX14 4RY (GB). YOUNG, Stephen, Clinton Young [GB/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). KAY, David [GB/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). REAPER, Philip, Michael [GB/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY

(GB). DURRANT, Steven, John [GB/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). TWIN, Heather, Clare [GB/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). DAVIS, Christopher, John [GB/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(74) Agent: CHE, Jennifer, G.; Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: AMINOPYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF TRA KINASE



I

(57) Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in *in vitro* applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula (I): wherein the variables are as defined herein.

AMINOPYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF TRA KINASE**BACKGROUND OF THE INVENTION**

[0001] ATR (“ATM and Rad3 related”) kinase is a protein kinase involved in cellular responses to DNA damage. ATR kinase acts with ATM (“ataxia telangiectasia mutated”) kinase and many other proteins to regulate a cell’s response to DNA damage, commonly referred to as the DNA Damage Response (“DDR”). The DDR stimulates DNA repair, promotes survival and stalls cell cycle progression by activating cell cycle checkpoints, which provide time for repair. Without the DDR, cells are much more sensitive to DNA damage and readily die from DNA lesions induced by endogenous cellular processes such as DNA replication or exogenous DNA damaging agents commonly used in cancer therapy.

[0002] Healthy cells can rely on a host of different proteins for DNA repair including the DDR kinase ATR. In some cases these proteins can compensate for one another by activating functionally redundant DNA repair processes. On the contrary, many cancer cells harbour defects in some of their DNA repair processes, such as ATM signaling, and therefore display a greater reliance on their remaining intact DNA repair proteins which include ATR.

[0003] In addition, many cancer cells express activated oncogenes or lack key tumour suppressors, and this can make these cancer cells prone to dysregulated phases of DNA replication which in turn cause DNA damage. ATR has been implicated as a critical component of the DDR in response to disrupted DNA replication. As a result, these cancer cells are more dependent on ATR activity for survival than healthy cells. Accordingly, ATR inhibitors may be useful for cancer treatment, either used alone or in combination with DNA damaging agents, because they shut down a DNA repair mechanism that is more important for cellular survival in many cancer cells than in healthy normal cells.

[0004] In fact, disruption of ATR function (e.g. by gene deletion) has been shown to promote cancer cell death both in the absence and presence of DNA damaging agents. This

suggests that ATR inhibitors may be effective both as single agents and as potent sensitizers to radiotherapy or genotoxic chemotherapy.

[0005] ATR peptide can be expressed and isolated using a variety of methods known in the literature (see e.g., Ünsal-Kaçmaz et al, *PNAS* 99: 10, pp6673-6678, May 14, 2002; see also Kumagai et al. *Cell* 124, pp943-955, March 10, 2006; Unsal-Kacmaz et al. *Molecular and Cellular Biology*, Feb 2004, p1292-1300; and Hall-Jackson et al. *Oncogene* 1999, 18, 6707-6713).


[0006] For all of these reasons, there is a need for the development of potent and selective ATR inhibitors for the treatment of cancer, either as single agents or as combination therapies with radiotherapy or genotoxic chemotherapy.

SUMMARY OF THE INVENTION

[0007] The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in *in vitro* applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of the invention are surprisingly potent in an ATR inhibition assay. These compounds have an unexpected ability to treat cancer as single agents. These compounds also show surprising synergy with other cancer agents, such as cisplatin or gemcitabine, in combination therapies.

DETAILED DESCRIPTION OF THE INVENTION

[0008] One aspect of the invention provides a compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

Ring D is isoxazolyl or oxadiazolyl;

Ring A is a 5-6 membered monocyclic aryl or heteroaryl ring, wherein said heteroaryl ring has 1 heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur;

J is halo or C₁₋₆alkyl, wherein 0-1 methylene units of said C₁₋₆alkyl is replaced with -O-.

J¹ is halo or -(X)_q-Y;

X is C₁₋₁₀alkyl wherein 0-2 methylene units of said C₁₋₆alkyl are replaced with NR, O, or S; X is optionally substituted with 1-2 occurrences of C₁₋₃alkyl or halo;

Y is hydrogen, C₁₋₄alkyl, or a 3-7 membered saturated or partially unsaturated cycloaliphatic or heterocyclyl, wherein said heterocyclyl has 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C₁₋₃alkyl;

or J and J¹ join together to form a 5-7 heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C₁₋₃alkyl; wherein 0-1 methylene units of said C₁₋₃alkyl is replaced with -O-, -NR-, -S-, or -CO-.

p is 0, 1, or 2;

q is 0 or 1;

J² is H or C₁₋₆alkyl;

J³ is H or C₁₋₆alkyl;

or J² and J³ join together to form a 3-7 membered monocyclic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or a 8-10 membered bicyclic or bridged ring having 0-4 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein said monocyclic, bicyclic, or bridged ring is optionally substituted with 1-2 occurrences of halo or C₁₋₃alkyl;

J⁴ is CN, OH, or L-Z;

J⁵ is H or fluoro;

L is C(O), S(O)₂, or C(O)NR;

Z is (U)_tQ or C₁₋₆alkyl wherein 0-2 methylene units of said C₁₋₆alkyl are replaced with O or NR;


U is C₁₋₂alkyl;

t is 0 or 1;

Q is C₃₋₆cycloalkyl or 4-6 membered saturated or partially saturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; and

R is H or C₁₋₄alkyl.

[0009] Another embodiment provides a compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein

Ring D is isoxazolyl or oxadiazolyl;

Ring A is a 5-6 membered monocyclic aryl or heteroaryl ring, wherein said heteroaryl ring has 1 heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur;

J is halo, C₁₋₄alkyl, or C₁₋₄alkoxy;

J¹ is -(X)_q-Y;

X is C₁₋₆alkyl wherein 0-2 methylene units of said C₁₋₆alkyl are replaced with NH, O, or S; X is optionally substituted with 1-2 occurrences of C₁₋₃alkyl or halo;

Y is hydrogen, C₁₋₄alkyl, or a 3-7 membered saturated or partially unsaturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C₁₋₃alkyl.

or J and J¹ join together to form a 5-7 heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C₁₋₃alkyl.

p is 0, 1, or 2;

q is 0 or 1;

J² is H or C₁₋₆alkyl;

J³ is H or C₁₋₆alkyl;

or J² and J³ join together to form a 3-7 membered monocyclic saturated ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein said monocyclic ring is optionally substituted with 1-2 occurrences of halo or C₁₋₃alkyl.

J⁴ is CN, OH, or L-Z;

J⁵ is H or fluoro;

L is C(O), S(O)₂, or C(O)NR;

Z is $(U)_tQ$ or C_{1-6} alkyl wherein 0-2 methylene units of said C_{1-6} alkyl are replaced with O or NR;


U is C_{1-2} alkyl;

t is 0 or 1;

Q is C_{3-6} cycloalkyl or 4-6 membered saturated or partially saturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;

R is H or C_{1-4} alkyl.

[0010] Yet another embodiment provides a compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein

Ring D is isoxazolyl or oxadiazolyl;

Ring A is a 5-6 membered monocyclic aryl or heteroaryl ring, wherein said heteroaryl ring has 1 heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur;

J is halo, C_{1-4} alkyl, or C_{1-4} alkoxy;

J^1 is $-(X)_q-Y$;

X is C_{1-6} alkyl wherein 0-2 methylene units of said C_{1-6} alkyl are replaced with NH, O, or S; X is optionally substituted with 1-2 occurrences of C_{1-3} alkyl or halo;

Y is hydrogen, C_{1-4} alkyl, or a 3-6 membered saturated or partially unsaturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C_{1-3} alkyl.

or J and J^1 join together to form a 5-7 heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C_{1-3} alkyl.

p and q are each independently 0 or 1;

J^2 is H or C_{1-6} alkyl;

J^3 is C_{1-6} alkyl;

or J² and J³ join together to form a 3-7 membered monocyclic saturated ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein said monocyclic ring is optionally substituted with 1-2 occurrences of halo or C₁₋₃alkyl.

J⁴ is CN or L-Z;

L is C(O), S(O)₂, or C(O)NR;

Z is (U)_tQ or C₁₋₆alkyl wherein 0-2 methylene units of said C₁₋₆alkyl are replaced with O or NR;

U is C₁₋₂alkyl;

t is 0 or 1;

Q is C₃₋₆cycloalkyl or 4-6 membered saturated or partially saturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;

R is H or C₁₋₄alkyl.

[0011] The compound of claim 1, wherein

J⁴ is CN or L-Z;

J⁵ is H;

J³ is C₁₋₆alkyl;

Y is hydrogen, C₁₋₄alkyl, or a 3-6 membered saturated or partially unsaturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C₁₋₃alkylp; and

p is 0 or 1.

[0012]

[0013] According to one embodiment,

J is halo, C₁₋₄alkyl, or C₁₋₄alkoxy;

J¹ is -(X)_q-Y;

X is C₁₋₆alkyl wherein 0-2 methylene units of said C₁₋₆alkyl are replaced with NH, O, or S; X is optionally substituted with 1-2 occurrences of C₁₋₃alkyl or halo;

Y is hydrogen, C₁₋₄alkyl, or a 3-7 membered saturated or partially unsaturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C₁₋₃alkyl.

or J and J¹ join together to form a 5-7 heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C₁₋₃alkyl;

J⁴ is CN or L-Z;

L is C(O), S(O)₂, or C(O)NR;

Z is (U)_tQ or C₁₋₆alkyl wherein 0-2 methylene units of said C₁₋₆alkyl are replaced with O or NR;

U is C₁₋₂alkyl;

t is 0 or 1;

Q is C₃₋₆cycloalkyl or 4-6 membered saturated or partially saturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; and

R is H or C₁₋₄alkyl.

[0014] According to another embodiment,



J⁴ is CN or L-Z;


J⁵ is H;

J³ is C₁₋₆alkyl;

Y is hydrogen, C₁₋₄alkyl, or a 3-6 membered saturated or partially unsaturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C₁₋₃alkyl; and

p is 0 or 1.

[0015] According to some embodiments, Ring  is  or




. In some embodiments, Ring A is phenyl or thienyl. In other embodiments, Ring A is phenyl.


[0016] Another aspect of the invention provides compounds wherein J¹ is -(X)_q-Y. In some embodiments, q is 1. In other embodiments, X is C₁₋₆alkyl wherein one methylene unit is replaced with NH or -O-. In yet other embodiments, X is -O- and Y is H. In some embodiments, X is -CH₂NH-.

[0017] Another aspect provides compounds wherein Y is H, C₁₋₄alkyl, or a 5-6 membered saturated monocyclic heterocyclyl having 1-2 heteroatoms selected from the group

consisting of O and N. In some embodiments, Y is C₁₋₄alkyl, cyclopropyl, or tetrahydrofuranyl.

[0018] According to yet another embodiment, J¹ is H, halo, CH₃, OH, OCH₃, CH₂OH, CH₂NHCH₃, CH₂CH₂NH₂, CH(NH₂)CH₂OCH₃, CH₂NHCH₂CH(CH₂OH)CH₂OCH₃, CH(CH₂F)NH₂, CH(CH₃)NH₂, NHCH₂CH₂NH₂, NHCH₂CH(CH₃)NH₂, NHCH₂CH₂N(CH₃)₂, NHCH₂CH₂NHCH₃, N(CH₃)CH₂CH₂NH₂, N(CH₃)CH₂CH₂NHCH₃, N(CH₃)CH₂CH₂N(CH₃)₂, NHCH₂CH₂OH, -OCH₂CH₂NH₂, -OCH₂CH₂N(CH₃)₂,

CH₂NHCH₂C(O)OH, -CH₂-(piperazinyl), CH₂NH-cyclopropyl, ,





, CH₂NH-(tetrahydrofuranyl), CH₂NH-(tetrahydropyranyl), CH₂NH-(oxetanyl), CH₂NHCH₂(oxetanyl), CH₂NH(tetrahydropyranyl), -O-(azetidiny), NHCH₂(azetidiny), NHCH₂(pyrrolidiny), -OCH₂CH₂(pyrrolidiny), -O-pyrrolidiny, NH-(azetidiny), -O-(azetidiny), NHCH₂CH₂(morpholiny), NHCH₂CH₂(morpholiny), azetidiny, pyrrolidiny, piperidiny, piperazinyl, or morpholiny (where said azetidiny, pyrrolidiny, piperidiny, or piperazinyl, is optionally substituted with CH₃, CH₂NH₂ or NH₂, NH(CH₃), or N(CH₃)₂).




[0019] In some embodiments, J¹ is H, CH₃, OH, OCH₃, CH₂OH, CH₂NHCH₃, CH₂NH-cyclopropyl, CH(CH₂F)NH₂, CH(CH₃)NH₂, CH₂NH-(tetrahydrofuranyl), CH₂NH-(oxetanyl), or piperazinyl.

[0020] In some embodiments, p is 0. In other embodiments, p is 1 and J is halo, CH₃, OH, or OCH₃. In yet other embodiments, J and J¹ join together to form a 5-6 heterocyclyl having one nitrogen atom.

[0021] In some embodiments, Ring A, together with J and J¹, form an indole ring, and isoindoline ring, or a tetrahydroisoquinoliny ring. In some embodiments, Ring A, together with J and J¹, form an indole ring or a tetrahydroisoquinoliny ring.

[0022] According to some embodiments, Ring  is bonded as shown in formulae Ia or Ib:



[0023] In some embodiments Ring  is  or ; Ring A is phenyl; and X is C₁₋₆alkyl wherein one methylene unit is replaced with NH or -O-.

[0024] According to another aspect of the invention, J⁴ is CN or L-Z. In some embodiments, J⁴ is CN. In other embodiments, J⁴ is L-Z.


[0025] According to another aspect of the invention, J² is H or C₁₋₆alkyl; J³ is C₁₋₆alkyl; or J² and J³ join together to form a 3-7 membered monocyclic saturated ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein said monocyclic ring is optionally substituted with 1-2 occurrences of halo or C₁₋₃alkyl.

[0026] In some embodiments, J² is H, C₁₋₄alkyl; and J³ is C₁₋₄alkyl. In other embodiments, J² and J³ join together to form a 3-6 membered fully saturated monocyclic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur. In yet another embodiment, J² is hydrogen, methyl or ethyl; J³ is methyl or ethyl; or J² and J³ join together to form cyclopropyl, cyclobutyl, cyclopentyl, piperidinyl, or tetrahydropyranyl.

[0027] In some embodiments, J² is methyl and J³ is methyl. In other embodiments, J² and J³ join together to form cyclopropyl, cyclobutyl, cyclopentyl, piperidinyl, or tetrahydropyranyl.


[0028] In some embodiments, L is C(O), S(O)₂, or C(O)NR and Z is C₁₋₆alkyl, C₁₋₄alkyl)-N(R)₂, (C₁₋₄alkyl)-OR, OR, or wherein two R groups attached to the same nitrogen atom optionally join to form Q. In some embodiments, Q is azetidiny, piperazinyl, morpholinyl, or piperidinyl.

[0029] In another embodiment, J⁴ is CN, OH, C(O)NH₂, C(O)NHCH₃, C(O)NH(CH₃)₂, C(O)NHCH₂CH₂NH₂, C(O)NHCH₂CH₂NHCH₃, C(O)NHCH₂CH₂N(CH₃)₂,



[0030]

[0031] Another embodiment provides a compound of formula I wherein






Ring A is phenyl or thienyl;

 J^2 is methyl and J^3 is methyl. J^4 is CN;

p is 0; and





q is 1.

















[0032] In some embodiments, Ring  is . In other embodiments,



















[0033] Another embodiment provides a compound selected from the following table:





Table 1



			
I-1	I-2	I-3	I-4















			
I-5	I-6	I-7	I-8
			
I-9	I-10	I-11	I-12
			
I-13	I-14	I-15	I-16
			
I-17	I-18	I-19	I-20

















			
I-21	I-22	I-23	I-24
			
I-25	I-26	I-27	I-28
			
I-29	I-30	I-31	I-32
			
I-33		I-34	

	
I-35	I-36
















			
I-37	I-38	I-39	I-40

















	
I-41	I-42
















			
I-43		I-44	
			
I-45	I-46	I-47	I-48
			
I-49	I-50	I-51	I-52
			
I-53	I-54	I-55	I-56



			
I-57	I-58	I-59	I-60
			
I-61	I-62	I-63	I-64
			
I-65	I-66	I-67	I-68
			
I-69	I-70	I-71	I-72

I-73	I-74	I-75	I-76
I-77	I-78	I-79	I-80
I-81	I-82	I-83	I-84
I-85	I-86	I-87	I-88


			
I-89	I-90		I-92
			
I-93	I-94	I-95	I-96
			
I-97	I-98	I-99	I-100
			
I-101	I-102	I-103	I-104

			
I-105	I-106	I-107	I-108
			
I-109	I-110	I-111	I-112
			
I-113	I-114	I-115	I-116
			
I-117	I-118	I-119	I-120

			
I-121	I-122	I-123	I-124
			
I-125	I-126	I-127	I-128
			
I-129	I-130	I-131	
			
I-133	I-134	I-135	I-136

		
I-137	I-138	I-139

[0034] Another embodiment provides a compound selected from the following:



I-91 and I-132.

[0035] In some embodiments, the variables are as depicted in the compounds of the disclosure including compounds in the tables above.



[0036] Compounds of this invention include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[0037] As described herein, a specified number range of atoms includes any integer therein. For example, a group having from 1-4 atoms could have 1, 2, 3, or 4 atoms.

[0038] As described herein, compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally herein, or as exemplified by particular classes, subclasses, and species of the invention. It will be appreciated that the

phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.” In general, the term “substituted”, whether preceded by the term “optionally” or not, refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.

[0039] Unless otherwise indicated, a substituent connected by a bond drawn from the center of a ring means that the substituent can be bonded to any position in the ring. In example **i** below, for instance, J^1 can be bonded to any position on the pyridyl ring. For bicyclic rings, a bond drawn through both rings indicates that the substituent can be bonded from any position of the bicyclic ring. In example **ii** below, for instance, J^1 can be bonded to the 5-membered ring (on the nitrogen atom, for instance), and to the 6-membered ring.

**i****ii**

[0040] The term “stable”, as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.

[0041] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched), branched, or cyclic, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation that has a single point of attachment to the rest of the molecule.

[0042] Unless otherwise specified, aliphatic groups contain 1-20 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, and in yet other embodiments aliphatic groups contain 1-4 aliphatic carbon atoms. Aliphatic groups may be

linear or branched, substituted or unsubstituted alkyl, alkenyl, or alkynyl groups. Specific examples include, but are not limited to, methyl, ethyl, isopropyl, n-propyl, sec-butyl, vinyl, n-butenyl, ethynyl, and tert-butyl. Aliphatic groups may also be cyclic, or have a combination of linear or branched and cyclic groups. Examples of such types of aliphatic groups include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, -CH₂-cyclopropyl, CH₂CH₂CH(CH₃)-cyclohexyl.

[0043] The term “cycloaliphatic” (or “carbocycle” or “carbocyclyl”) refers to a monocyclic C₃-C₈ hydrocarbon or bicyclic C₈-C₁₂ hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members. Examples of cycloaliphatic groups include, but are not limited to, cycloalkyl and cycloalkenyl groups. Specific examples include, but are not limited to, cyclohexyl, cyclopropenyl, and cyclobutyl.

[0044] The term “heterocycle”, “heterocyclyl”, or “heterocyclic” as used herein means non-aromatic, monocyclic, bicyclic, or tricyclic ring systems in which one or more ring members are an independently selected heteroatom. In some embodiments, the “heterocycle”, “heterocyclyl”, or “heterocyclic” group has three to fourteen ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the system contains 3 to 7 ring members.

[0045] Examples of heterocycles include, but are not limited to, 3-1H-benzimidazol-2-one, 3-(1-alkyl)-benzimidazol-2-one, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-tetrahydropiperazinyl, 2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-thiazolidinyl, 3-thiazolidinyl, 4-thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 5-imidazolidinyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzothiolane, benzodithiane, and 1,3-dihydro-imidazol-2-one.

[0046] Cyclic groups, (e.g. cycloaliphatic and heterocycles), can be linearly fused, bridged, or spirocyclic.

[0047] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a

heterocyclic ring, for example N (as in 3,4-dihydro-2*H*-pyrrolyl), NH (as in pyrrolidinyl) or NR⁺ (as in N-substituted pyrrolidinyl).

[0048] The term "unsaturated", as used herein, means that a moiety has one or more units of unsaturation. As would be known by one of skill in the art, unsaturated groups can be partially unsaturated or fully unsaturated. Examples of partially unsaturated groups include, but are not limited to, butene, cyclohexene, and tetrahydropyridine. Fully unsaturated groups can be aromatic, anti-aromatic, or non-aromatic. Examples of fully unsaturated groups include, but are not limited to, phenyl, cyclooctatetraene, pyridyl, thienyl, and 1-methylpyridin-2(1*H*)-one.

[0049] The term "alkoxy", or "thioalkyl", as used herein, refers to an alkyl group, as previously defined, attached through an oxygen ("alkoxy") or sulfur ("thioalkyl") atom.

[0050] The terms "haloalkyl", "haloalkenyl", "haloaliphatic", and "haloalkoxy" mean alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms. This term includes perfluorinated alkyl groups, such as -CF₃ and -CF₂CF₃.


[0051] The terms "halogen", "halo", and "hal" mean F, Cl, Br, or I.

[0052] The term "aryl" used alone or as part of a larger moiety as in "aralkyl", "aralkoxy", or "aryloxyalkyl", refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring".

[0053] The term "heteroaryl", used alone or as part of a larger moiety as in "heteroaralkyl" or "heteroarylalkoxy", refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members. The term "heteroaryl" may be used interchangeably with the term "heteroaryl ring" or the term "heteroaromatic". Examples of heteroaryl rings include, but are not limited to, 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, benzofuryl, benzothiophenyl, indolyl (e.g., 2-indolyl), pyrazolyl (e.g., 2-pyrazolyl), isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl,

purinyl, pyrazinyl, 1,3,5-triazinyl, quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), and isoquinolinyl (e.g., 1-isoquinolinyl, 3-isoquinolinyl, or 4-isoquinolinyl).

[0054] It shall be understood that the term “heteroaryl” includes certain types of heteroaryl rings that exist in equilibrium between two different forms. More specifically, for example, species such as hydropyridine and pyridinone (and likewise hydroxypyrimidine and pyrimidinone) are meant to be encompassed within the definition of “heteroaryl.”



[0055] The term “protecting group” and “protective group” as used herein, are interchangeable and refer to an agent used to temporarily block one or more desired functional groups in a compound with multiple reactive sites. In certain embodiments, a protecting group has one or more, or preferably all, of the following characteristics: a) is added selectively to a functional group in good yield to give a protected substrate that is b) stable to reactions occurring at one or more of the other reactive sites; and c) is selectively removable in good yield by reagents that do not attack the regenerated, deprotected functional group. As would be understood by one skilled in the art, in some cases, the reagents do not attack other reactive groups in the compound. In other cases, the reagents may also react with other reactive groups in the compound. Examples of protecting groups are detailed in Greene, T.W., Wuts, P. G in “Protective Groups in Organic Synthesis”, Third Edition, John Wiley & Sons, New York: 1999 (and other editions of the book), the entire contents of which are hereby incorporated by reference. The term “nitrogen protecting group”, as used herein, refers to an agent used to temporarily block one or more desired nitrogen reactive sites in a multifunctional compound. Preferred nitrogen protecting groups also possess the characteristics exemplified for a protecting group above, and certain exemplary nitrogen protecting groups are also detailed in Chapter 7 in Greene, T.W., Wuts, P. G in “Protective Groups in Organic Synthesis”, Third Edition, John Wiley & Sons, New York: 1999, the entire contents of which are hereby incorporated by reference.

[0056] In some embodiments, a methylene unit of an alkyl or aliphatic chain is optionally replaced with another atom or group. Examples of such atoms or groups include, but are not limited to, nitrogen, oxygen, sulfur, -C(O)-, -C(=N-CN)-, -C(=NR)-, -C(=NOR)-, -SO-, and -SO₂-. These atoms or groups can be combined to form larger groups. Examples of such larger groups include, but are not limited to, -OC(O)-, -C(O)CO-, -CO₂-, -C(O)NR-, -C(=N-

CN), -NRCO-, -NRC(O)O-, -SO₂NR-, -NRSO₂-, -NRC(O)NR-, -OC(O)NR-, and -NRSO₂NR-, wherein R is, for example, H or C₁₋₆aliphatic. It should be understood that these groups can be bonded to the methylene units of the aliphatic chain via single, double, or triple bonds. An example of an optional replacement (nitrogen atom in this case) that is bonded to the aliphatic chain via a double bond would be -CH₂CH=N-CH₃. In some cases, especially on the terminal end, an optional replacement can be bonded to the aliphatic group via a triple bond. One example of this would be CH₂CH₂CH₂C≡N. It should be understood that in this situation, the terminal nitrogen is not bonded to another atom.


[0057] It should also be understood that, the term “methylene unit” can also refer to branched or substituted methylene units. For example, in an isopropyl moiety [-CH(CH₃)₂], a nitrogen atom (e.g. NR) replacing the first recited “methylene unit” would result in dimethylamine [-N(CH₃)₂]. In instances such as these, one of skill in the art would understand that the nitrogen atom will not have any additional atoms bonded to it, and the “R” from “NR” would be absent in this case.

[0058] Unless otherwise indicated, the optional replacements form a chemically stable compound. Optional replacements can occur both within the chain and/or at either end of the chain; i.e. both at the point of attachment and/or also at the terminal end. Two optional replacements can also be adjacent to each other within a chain so long as it results in a chemically stable compound. For example, a C₃ aliphatic can be optionally replaced by 2 nitrogen atoms to form -C-N≡N. The optional replacements can also completely replace all of the carbon atoms in a chain. For example, a C₃ aliphatic can be optionally replaced by -NR-, -C(O)-, and -NR- to form -NRC(O)NR- (a urea).


[0059] Unless otherwise indicated, if the replacement occurs at the terminal end, the replacement atom is bound to a hydrogen atom on the terminal end. For example, if a methylene unit of -CH₂CH₂CH₃ were optionally replaced with -O-, the resulting compound could be -OCH₂CH₃, -CH₂OCH₃, or -CH₂CH₂OH. It should be understood that if the terminal atom does not contain any free valence electrons, then a hydrogen atom is not required at the terminal end (e.g., -CH₂CH₂CH=O or -CH₂CH₂C≡N).

[0060] Unless otherwise indicated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, geometric, conformational, and rotational) forms of the structure. For example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers are included in this invention. As would be understood to one skilled in the art, a substituent can freely rotate

around any rotatable bonds. For example, a substituent drawn as



also



[0061] Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, geometric, conformational, and rotational mixtures of the present compounds are within the scope of the invention.

[0062] Unless otherwise indicated, all tautomeric forms of the compounds of the invention are within the scope of the invention.

[0063] Additionally, unless otherwise indicated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a ^{13}C - or ^{14}C -enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.

Pharmaceutically Acceptable Salts

[0064] The compounds of this invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable salt.

[0065] A "pharmaceutically acceptable salt" means any non-toxic salt of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. As used herein, the term "inhibitorily active metabolite or residue thereof" means that a metabolite or residue thereof is also an inhibitor of the ATR protein kinase.

[0066] Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge *et al.*, describe pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, **1977**, *66*, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. These salts can be prepared *in situ* during the final isolation and purification of the compounds. Acid addition salts can be prepared by 1) reacting the purified compound in its free-based form with a suitable organic or inorganic acid and 2) isolating the salt thus formed.

[0067] Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, glycolate, gluconate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.

[0068] Base addition salts can be prepared by 1) reacting the purified compound in its acid form with a suitable organic or inorganic base and 2) isolating the salt thus formed. Salts derived from appropriate bases include alkali metal (e.g., sodium, lithium, and potassium), alkaline earth metal (e.g., magnesium and calcium), ammonium and $N^+(C_{1-4}alkyl)_4$ salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.

[0069] Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate. Other acids and bases, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid or base addition salts.

Abbreviations

[0070] The following abbreviations are used:

DMSO	dimethyl sulfoxide
ATP	adenosine triphosphate
^1H NMR	proton nuclear magnetic resonance
HPLC	high performance liquid chromatography
LCMS	liquid chromatography-mass spectrometry

TLC thin layer chromatography
Rt retention time

Compound Uses

[0071] One aspect of this invention provides compounds that are inhibitors of ATR kinase, and thus are useful for treating or lessening the severity of a disease, condition, or disorder where ATR is implicated in the disease, condition, or disorder.

[0072] Another aspect of this invention provides compounds that are useful for the treatment of diseases, disorders, and conditions characterized by excessive or abnormal cell proliferation. Such diseases include, a proliferative or hyperproliferative disease. Examples of proliferative and hyperproliferative diseases include, without limitation, cancer and myeloproliferative disorders.

[0073] In some embodiments, said compounds are selected from the group consisting of a compound of formula I. The term "cancer" includes, but is not limited to the following cancers. Oral: buccal cavity, lip, tongue, mouth, pharynx; Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel or small intestines (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel or large intestines (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colon, colon-rectum, colorectal; rectum, Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, biliary passages; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple

myeloma, malignant giant cell tumor chordoma, osteochondroma (osteochondrogenous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma), breast; Hematologic: blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma] hairy cell; lymphoid disorders; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis, Thyroid gland: papillary thyroid carcinoma, follicular thyroid carcinoma, undifferentiated thyroid cancer, medullary thyroid carcinoma, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma; and Adrenal glands: neuroblastoma.

[0074] In some embodiments, the cancer is selected from a cancer of the lung or the pancreas. In other embodiments, the cancer is selected from lung cancer, head and neck cancer, pancreatic cancer, gastric cancer, or brain cancer. In yet other embodiments, the cancer is selected from non-small cell lung cancer, small cell lung cancer, pancreatic cancer, biliary tract cancer, head and neck cancer, bladder cancer, colorectal cancer, glioblastoma, esophageal cancer, breast cancer, hepatocellular carcinoma, or ovarian cancer.

[0075] Thus, the term "cancerous cell" as provided herein, includes a cell afflicted by any one of the above-identified conditions. In some embodiments, the cancer is selected from colorectal, thyroid, or breast cancer.

[0076] The term "myeloproliferative disorders", includes disorders such as polycythemia vera, thrombocythemia, myeloid metaplasia with myelofibrosis, hypereosinophilic syndrome,

juvenile myelomonocytic leukemia, systemic mast cell disease, and hematopoietic disorders, in particular, acute-myelogenous leukemia (AML), chronic-myelogenous leukemia (CML), acute-promyelocytic leukemia (APL), and acute lymphocytic leukemia (ALL).

Pharmaceutically Acceptable Derivatives or Prodrugs

[0077] In addition to the compounds of this invention, pharmaceutically acceptable derivatives or prodrugs of the compounds of this invention may also be employed in compositions to treat or prevent the herein identified disorders.

[0078] The compounds of this invention can also exist as pharmaceutically acceptable derivatives.

[0079] A “pharmaceutically acceptable derivative” is an adduct or derivative which, upon administration to a patient in need, is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof. Examples of pharmaceutically acceptable derivatives include, but are not limited to, esters and salts of such esters.

[0080] A “pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable ester, salt of an ester or other derivative or salt thereof of a compound, of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. Particularly favoured derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.

[0081] Pharmaceutically acceptable prodrugs of the compounds of this invention include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.

Pharmaceutical Compositions

[0082] The present invention also provides compounds and compositions that are useful as inhibitors of ATR kinase.

[0083] One aspect of this invention provides pharmaceutically acceptable compositions that comprise any of the compounds as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle.

[0084] The pharmaceutically acceptable carrier, adjuvant, or vehicle, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention.

[0085] Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.

Combination Therapies

[0086] Another aspect of this invention is directed towards a method of treating cancer in a subject in need thereof, comprising administration of a compound of this invention or a

pharmaceutically acceptable salt thereof, and an additional therapeutic agent. In some embodiments, said method comprises the sequential or co-administration of the compound or a pharmaceutically acceptable salt thereof, and the additional therapeutic agent.

[0087] In some embodiments, said additional therapeutic agent is an anti-cancer agent. In other embodiments, said additional therapeutic agent is a DNA-damaging agent. In yet other embodiments, said additional therapeutic agent is selected from radiation therapy, chemotherapy, or other agents typically used in combination with radiation therapy or chemotherapy, such as radiosensitizers and chemosensitizers. In yet other embodiments, said additional therapeutic agent is ionizing radiation.

[0088] As would be known by one of skill in the art, radiosensitizers are agents that can be used in combination with radiation therapy. Radiosensitizers work in various different ways, including, but not limited to, making cancer cells more sensitive to radiation therapy, working in synergy with radiation therapy to provide an improved synergistic effect, acting additively with radiation therapy, or protecting surrounding healthy cells from damage caused by radiation therapy. Likewise chemosensitizers are agents that can be used in combination with chemotherapy. Similarly, chemosensitizers work in various different ways, including, but not limited to, making cancer cells more sensitive to chemotherapy, working in synergy with chemotherapy to provide an improved synergistic effect, acting additively to chemotherapy, or protecting surrounding healthy cells from damage caused by chemotherapy.

[0089] Examples of DNA-damaging agents that may be used in combination with compounds of this invention include, but are not limited to Platinating agents, such as Carboplatin, Nedaplatin, Satraplatin and other derivatives; Topo I inhibitors, such as Topotecan, irinotecan/SN38, rubitecan and other derivatives; Antimetabolites, such as Folic family (Methotrexate, Pemetrexed and relatives); Purine antagonists and Pyrimidine antagonists (Thioguanine, Fludarabine, Cladribine, Cytarabine, Gemcitabine, 6-Mercaptopurine, 5-Fluorouracil (5FU) and relatives); Alkylating agents, such as Nitrogen mustards (Cyclophosphamide, Melphalan, Chlorambucil, mechlorethamine, Ifosfamide and relatives); nitrosoureas (eg Carmustine); Triazines (Dacarbazine, temozolomide); Alkyl sulphonates (eg Busulfan); Procarbazine and Aziridines; Antibiotics, such as Hydroxyurea, Anthracyclines (doxorubicin, daunorubicin, epirubicin and other derivatives); Anthracenediones (Mitoxantrone and relatives); Streptomyces family (Bleomycin, Mitomycin C, actinomycin); and Ultraviolet light.

[0090] Other therapies or anticancer agents that may be used in combination with the inventive agents of the present invention include surgery, radiotherapy (in but a few

examples, gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes, to name a few), endocrine therapy, biologic response modifiers (interferons, interleukins, and tumor necrosis factor (TNF) to name a few), hyperthermia and cryotherapy, agents to attenuate any adverse effects (e.g., antiemetics), and other approved chemotherapeutic drugs, including, but not limited to, the DNA damaging agents listed herein, spindle poisons (Vinblastine, Vincristine, Vinorelbine, Paclitaxel), podophyllotoxins (Etoposide, Irinotecan, Topotecan), nitrosoureas (Carmustine, Lomustine), inorganic ions (Cisplatin, Carboplatin), enzymes (Asparaginase), and hormones (Tamoxifen, Leuprolide, Flutamide, and Megestrol), Gleevec™, adriamycin, dexamethasone, and cyclophosphamide.

[0091] A compound of the instant invention may also be useful for treating cancer in combination with any of the following therapeutic agents: abarelix (Plenaxis depot®); aldesleukin (Prokin®); Aldesleukin (Proleukin®); Alemtuzumab (Campath®); alitretinoin (Panretin®); allopurinol (Zyloprim®); altretamine (Hexalen®); amifostine (Ethyol®); anastrozole (Arimidex®); arsenic trioxide (Trisenox®); asparaginase (Elspar®); azacitidine (Vidaza®); bevacuzimab (Avastin®); bexarotene capsules (Targretin®); bexarotene gel (Targretin®); bleomycin (Blenoxane®); bortezomib (Velcade®); busulfan intravenous (Busulfex®); busulfan oral (Myleran®); calusterone (Methosarb®); capecitabine (Xeloda®); carboplatin (Paraplatin®); carmustine (BCNU®, BiCNU®); carmustine (Gliadel®); carmustine with Polifeprosan 20 Implant (Gliadel Wafer®); celecoxib (Celebrex®); cetuximab (Erbix®); chlorambucil (Leukeran®); cisplatin (Platinol®); cladribine (Leustatin®, 2-CdA®); clofarabine (Clolar®); cyclophosphamide (Cytosan®, Neosar®); cyclophosphamide (Cytosan Injection®); cyclophosphamide (Cytosan Tablet®); cytarabine (Cytosan-U®); cytarabine liposomal (DepoCyt®); dacarbazine (DTIC-Dome®); dactinomycin, actinomycin D (Cosmegen®); Darbepoetin alfa (Aranesp®); daunorubicin liposomal (DanuoXome®); daunorubicin, daunomycin (Daunorubicin®); daunorubicin, daunomycin (Cerubidine®); Denileukin diftitox (Ontak®); dexrazoxane (Zinecard®); docetaxel (Taxotere®); doxorubicin (Adriamycin PFS®); doxorubicin (Adriamycin®, Rubex®); doxorubicin (Adriamycin PFS Injection®); doxorubicin liposomal (Doxil®); dromostanolone propionate (dromostanolone®); dromostanolone propionate (masterone injection®); Elliott's B Solution (Elliott's B Solution®); epirubicin (Ellence®); Epoetin alfa (epogen®); erlotinib (Tarceva®); estramustine (Emcyt®); etoposide phosphate

(Etopophos[®]); etoposide, VP-16 (Vepesid[®]); exemestane (Aromasin[®]); Filgrastim (Neupogen[®]); floxuridine (intraarterial) (FUDR[®]); fludarabine (Fludara[®]); fluorouracil, 5-FU (Adrucil[®]); fulvestrant (Faslodex[®]); gefitinib (Iressa[®]); gemcitabine (Gemzar[®]); gemtuzumab ozogamicin (Mylotarg[®]); goserelin acetate (Zoladex Implant[®]); goserelin acetate (Zoladex[®]); histrelin acetate (Histrelin implant[®]); hydroxyurea (Hydrea[®]); Ibritumomab Tiuxetan (Zevalin[®]); idarubicin (Idamycin[®]); ifosfamide (IFEX[®]); imatinib mesylate (Gleevec[®]); interferon alfa 2a (Roferon A[®]); Interferon alfa-2b (Intron A[®]); irinotecan (Camptosar[®]); lenalidomide (Revlimid[®]); letrozole (Femara[®]); leucovorin (Wellcovorin[®], Leucovorin[®]); Leuprolide Acetate (Eligard[®]); levamisole (Ergamisol[®]); lomustine, CCNU (CeeBU[®]); meclorethamine, nitrogen mustard (Mustargen[®]); megestrol acetate (Megace[®]); melphalan, L-PAM (Alkeran[®]); mercaptopurine, 6-MP (Purinethol[®]); mesna (Mesnex[®]); mesna (Mesnex tabs[®]); methotrexate (Methotrexate[®]); methoxsalen (Uvadex[®]); mitomycin C (Mutamycin[®]); mitotane (Lysodren[®]); mitoxantrone (Novantrone[®]); nandrolone phenpropionate (Durabolin-50[®]); nelarabine (Arranon[®]); Nofetumomab (Verluma[®]); Oprelvekin (Neumega[®]); oxaliplatin (Eloxatin[®]); paclitaxel (Paxene[®]); paclitaxel (Taxol[®]); paclitaxel protein-bound particles (Abraxane[®]); palifermin (Kepivance[®]); pamidronate (Aredia[®]); pegademase (Adagen (Pegademase Bovine)[®]); pegaspargase (Oncaspar[®]); Pegfilgrastim (Neulasta[®]); pemetrexed disodium (Alimta[®]); pentostatin (Nipent[®]); pipobroman (Vercyte[®]); plicamycin, mithramycin (Mithracin[®]); porfimer sodium (Photofrin[®]); procarbazine (Matulane[®]); quinacrine (Atabrine[®]); Rasburicase (Elitek[®]); Rituximab (Rituxan[®]); sargramostim (Leukine[®]); Sargramostim (Prokine[®]); sorafenib (Nexavar[®]); streptozocin (Zanosar[®]); sunitinib maleate (Sutent[®]); talc (Sclerosol[®]); tamoxifen (Nolvadex[®]); temozolomide (Temodar[®]); teniposide, VM-26 (Vumon[®]); testolactone (Teslac[®]); thioguanine, 6-TG (Thioguanine[®]); thiotepa (Thioplex[®]); topotecan (Hycamtin[®]); toremifene (Fareston[®]); Tositumomab (Bexxar[®]); Tositumomab/I-131 tositumomab (Bexxar[®]); Trastuzumab (Herceptin[®]); tretinoin, ATRA (Vesanoid[®]); Uracil Mustard (Uracil Mustard Capsules[®]); valrubicin (Valstar[®]); vinblastine (Velban[®]); vincristine (Oncovin[®]); vinorelbine (Navelbine[®]); zoledronate (Zometa[®]) and vorinostat (Zolinza[®]).

[0092] For a comprehensive discussion of updated cancer therapies see, <http://www.nci.nih.gov/>, a list of the FDA approved oncology drugs at

<http://www.fda.gov/cder/cancer/druglistframe.htm>, and The Merck Manual, Seventeenth Ed. 1999, the entire contents of which are hereby incorporated by reference.

Compositions for Administration into a Subject

[0093] The ATR kinase inhibitors or pharmaceutical salts thereof may be formulated into pharmaceutical compositions for administration to animals or humans. These pharmaceutical compositions, which comprise an amount of the ATR inhibitor effective to treat or prevent the diseases or conditions described herein and a pharmaceutically acceptable carrier, are another embodiment of the present invention.

[0094] The exact amount of compound required for treatment will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.

[0095] In some embodiments, these compositions optionally further comprise one or more additional therapeutic agents. For example, chemotherapeutic agents or other anti-proliferative agents may be combined with the compounds of this invention to treat proliferative diseases and cancer. Examples of known agents with which these compositions can be combined are listed above under the "Combination Therapies" section and also throughout the specification. Some embodiments provide a simultaneous, separate or sequential use of a combined preparation.

Modes of Administration and Dosage Forms

[0096] The pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.

[0097] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0098] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

[0099] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[00100] In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.

[00101] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

[00102] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar--agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[00103] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets,

dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

[00104] The active compounds can also be in microencapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[00105] Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

[00106] The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an

implanted reservoir. The term "parenteral" as used herein includes, but is not limited to, subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously.

[00107] Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

[00108] The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include, but are not limited to, lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

[00109] Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but

liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.

[00110] The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[00111] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

[00112] For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

[00113] For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.

[00114] The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

[00115] The amount of protein kinase inhibitor that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, the particular mode of administration. Preferably, the compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.

[00116] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of inhibitor will also depend upon the particular compound in the composition.

Administering with another Agent

[00117] Depending upon the particular protein kinase-mediated conditions to be treated or prevented, additional drugs, which are normally administered to treat or prevent that condition, may be administered together with the compounds of this invention.

[00118] Those additional agents may be administered separately, as part of a multiple dosage regimen, from the protein kinase inhibitor-containing compound or composition. Alternatively, those agents may be part of a single dosage form, mixed together with the protein kinase inhibitor in a single composition.

[00119] Another aspect of this invention is directed towards a method of treating cancer in a subject in need thereof, comprising the sequential or co-administration of a compound of this invention or a pharmaceutically acceptable salt thereof, and an anti-cancer agent. In some embodiments, said anti-cancer agent is selected from Platinating agents, such as Cisplatin, Oxaliplatin, Carboplatin, Nedaplatin, or Satraplatin and other derivatives; Topo I inhibitors, such as Camptothecin, Topotecan, irinotecan/SN38, rubitecan and other derivatives; Antimetabolites, such as Folic family (Methotrexate, Pemetrexed and relatives); Purine family (Thioguanine, Fludarabine, Cladribine, 6-Mercaptopurine and relatives); Pyrimidine family (Cytarabine, Gemcitabine, 5-Fluorouracil and relatives); Alkylating agents, such as Nitrogen mustards (Cyclophosphamide, Melphalan, Chlorambucil, mechlorethamine, Ifosfamide, and relatives); nitrosoureas (e.g. Carmustine); Triazines (Dacarbazine, temozolomide); Alkyl sulphonates (e.g. Busulfan); Procarbazine and Aziridines; Antibiotics, such as Hydroxyurea; Anthracyclines (doxorubicin, daunorubicin, epirubicin and other derivatives); Anthracenediones (Mitoxantrone and relatives); Streptomyces family (Bleomycin, Mitomycin C, actinomycin) and Ultraviolet light.

[00120] Another embodiment provides administering a compound of this invention with an additional therapeutic agent that inhibits or modulates a base excision repair protein. In some embodiments, the base excision repair protein is selected from UNG, SMUG1, MBD4, TDG, OGG1, MYH, NTH1, MPG, NEIL1, NEIL2, NEIL3 (DNA glycosylases); APE1,

APEX2 (AP endonucleases); LIG1, LIG3 (DNA ligases I and III); XRCC1 (LIG3 accessory); PNK, PNKP (polynucleotide kinase and phosphatase); PARP1, PARP2 (Poly(ADP-Ribose) Polymerases); PolB, PolG (polymerases); FEN1 (endonuclease) or Aprataxin. In other embodiments, the base excision repair protein is selected from PARP1, PARP2, or PolB. In yet other embodiments, the base excision repair protein is selected from PARP1 or PARP2. In some embodiments, the agent is selected from Olaparib (also known as AZD2281 or KU-0059436), Iniparib (also known as BSI-201 or SAR240550), Veliparib (also known as ABT-888), Rucaparib (also known as PF-01367338), CEP-9722, INO-1001, MK-4827, E7016, BMN673, or AZD2461.

Biological Samples

[00121] As inhibitors of ATR kinase, the compounds and compositions of this invention are also useful in biological samples. One aspect of the invention relates to inhibiting ATR kinase activity in a biological sample, which method comprises contacting said biological sample with a compound described herein or a composition comprising said compound. The term “biological sample”, as used herein, means an *in vitro* or an *ex vivo* sample, including, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof. The term “compounds described herein” includes compounds of formula I.

[00122] Inhibition of ATR kinase activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ-transplantation, and biological specimen storage.

Study of Protein Kinases

[00123] Another aspect of this invention relates to the study of protein kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such protein kinases; and the comparative evaluation of new protein kinase inhibitors. Examples of such uses include, but are not limited to, biological assays such as enzyme assays and cell-based assays.

[00124] The activity of the compounds as protein kinase inhibitors may be assayed *in vitro*, *in vivo* or in a cell line. *In vitro* assays include assays that determine inhibition of either the kinase activity or ATPase activity of the activated kinase. Alternate *in vitro* assays quantitate the ability of the inhibitor to bind to the protein kinase and may be measured either

by radiolabelling the inhibitor prior to binding, isolating the inhibitor/kinase complex and determining the amount of radiolabel bound, or by running a competition experiment where new inhibitors are incubated with the kinase bound to known radioligands. Detailed conditions for assaying a compound utilized in this invention as an inhibitor of ATR is set forth in the Examples below.

[00125] Another aspect of the invention provides a method for modulating enzyme activity by contacting a compound described herein with ATR kinase.

Methods of Treatment

[00126] In one aspect, the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where ATR kinase is implicated in the disease state. In another aspect, the present invention provides a method for treating or lessening the severity of an ATR kinase disease, condition, or disorder where inhibition of enzymatic activity is implicated in the treatment of the disease. In another aspect, this invention provides a method for treating or lessening the severity of a disease, condition, or disorder with compounds that inhibit enzymatic activity by binding to the ATR kinase. Another aspect provides a method for treating or lessening the severity of a kinase disease, condition, or disorder by inhibiting enzymatic activity of ATR kinase with an ATR kinase inhibitor.

[00127] One aspect of the invention relates to a method of inhibiting ATR kinase activity in a patient, which method comprises administering to the patient a compound described herein, or a composition comprising said compound. In some embodiments, said method is used to treat or prevent a condition selected from proliferative and hyperproliferative diseases, such as cancer.

[00128] Another aspect of this invention provides a method for treating, preventing, or lessening the severity of proliferative or hyperproliferative diseases comprising administering an effective amount of a compound, or a pharmaceutically acceptable composition comprising a compound, to a subject in need thereof. In some embodiments, said subject is a patient. The term “patient”, as used herein, means an animal, preferably a human.

[00129] In some embodiments, said method is used to treat or prevent cancer. In some embodiments, said method is used to treat or prevent a type of cancer with solid tumors. In yet another embodiment, said cancer is selected from the following cancers: Oral: buccal cavity, lip, tongue, mouth, pharynx; Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell,

undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel or small intestines (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel or large intestines (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colon, colon-rectum, colorectal; rectum, Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, biliary passages; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteochondrogenous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma), breast; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis, Thyroid gland: papillary thyroid carcinoma, follicular thyroid carcinoma; medullary thyroid carcinoma, multiple endocrine neoplasia type 2A, multiple endocrine

neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma; and Adrenal glands: neuroblastoma.

[00130] In some embodiments, the cancer is selected from the cancers described herein. In some embodiments, said cancer is lung cancer, head and neck cancer, pancreatic cancer, gastric cancer, or brain cancer. In other embodiments, the cancer is selected from a cancer of the lung or the pancreas.

[00131] In yet other embodiments, the cancer is selected from non-small cell lung cancer, small cell lung cancer, pancreatic cancer, biliary tract cancer, head and neck cancer, bladder cancer, colorectal cancer, glioblastoma, esophageal cancer, breast cancer, hepatocellular carcinoma, or ovarian cancer.

[00132] In certain embodiments, an "effective amount" of the compound or pharmaceutically acceptable composition is that amount effective in order to treat said disease. The compounds and compositions, according to the method of the present invention, may be administered using any amount and any route of administration effective for treating or lessening the severity of said disease.

[00133] One aspect provides a method for inhibiting ATR in a patient comprising administering a compound described herein as described herein. Another embodiment provides a method of treating cancer comprising administering to a patient a compound described herein, wherein the variables are as defined herein.

[00134] Some embodiments comprising administering to said patient an additional therapeutic agent selected from a DNA-damaging agent; wherein said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said compound as a single dosage form or separately from said compound as part of a multiple dosage form.

[00135] In some embodiments, said DNA-damaging agent is selected from ionizing radiation, radiomimetic neocarzinostatin, a platinating agent, a Topo I inhibitor, a Topo II inhibitor, an antimetabolite, an alkylating agent, an alkyl sulphonates, an antimetabolite, or an antibiotic. In other embodiments, said DNA-damaging agent is selected from ionizing radiation, a platinating agent, a Topo I inhibitor, a Topo II inhibitor, or an antibiotic.

[00136] Examples of Platinating agents include Cisplatin, Oxaliplatin, Carboplatin, Nedaplatin, Satraplatin and other derivatives. Other platinating agents include Lobaplatin, and Triplatin. Other platinating agents include Tetranitrate, Picoplatin, Satraplatin, ProLindac and Aroplatin.

[00137] Examples of Topo I inhibitor include Camptothecin, Topotecan, irinotecan/SN38, rubitecan and other derivatives. Other Topo I inhibitors include Belotecan.

[00138] Examples of Topo II inhibitors include Etoposide, Daunorubicin, Doxorubicin, Aclarubicin, Epirubicin, Idarubicin, Amrubicin, Pirarubicin, Valrubicin, Zorubicin and Teniposide.

[00139] Examples of Antimetabolites include members of the Folic family, Purine family (purine antagonists), or Pyrimidine family (pyrimidine antagonists). Examples of the Folic family include methotrexate, pemetrexed and relatives; examples of the Purine family include Thioguanine, Fludarabine, Cladribine, 6-Mercaptopurine, and relatives; examples of the Pyrimidine family include Cytarabine, gemcitabine, 5-Fluorouracil (5FU) and relatives.

[00140] Some other specific examples of antimetabolites include Aminopterin, Methotrexate, Pemetrexed, Raltitrexed, Pentostatin, Cladribine, Clofarabine, Fludarabine, Thioguanine, Mercaptopurine, Fluorouracil, Capecitabine, Tegafur, Carmofur, Floxuridine, Cytarabine, Gemcitabine, Azacitidine and Hydroxyurea.

[00141] Examples of alkylating agents include Nitrogen mustards, Triazenes, alkyl sulphonates, Procarbazine and Aziridines. Examples of Nitrogen mustards include Cyclophosphamide, Melphalan, Chlorambucil and relatives; examples of nitrosoureas include Carmustine; examples of triazenes include Dacarbazine and temozolomide; examples of alkyl sulphonates include Busulfan.

[00142] Other specific examples of alkylating agents include Mechlorethamine, Cyclophosphamide, Ifosfamide, Trofosfamide, Chlorambucil, Melphalan, Prednimustine, Bendamustine, Uramustine, Estramustine, Carmustine, Lomustine, Semustine, Fotemustine, Nimustine, Ranimustine, Streptozocin, Busulfan, Mannosulfan, Treosulfan, Carboquone, ThioTEPA, Triaziquone, Triethylenemelamine, Procarbazine, Dacarbazine, Temozolomide, Altretamine, Mitobronitol, Actinomycin, Bleomycin, Mitomycin and Plicamycin.

[00143] Examples of antibiotics include Mitomycin, Hydroxyurea; Anthracyclines, Anthracenediones, Streptomyces family. Examples of Anthracyclines include doxorubicin, daunorubicin, epirubicin and other derivatives; examples of Anthracenediones include Mitoxantrone and relatives; examples of Streptomyces family include Bleomycin, Mitomycin C, and actinomycin.

[00144] In certain embodiments, said platinating agent is Cisplatin or Oxaliplatin; said Topo I inhibitor is Camptothecin; said Topo II inhibitor is Etoposide; and said antibiotic is Mitomycin. In other embodiments, said platinating agent is selected from Cisplatin, Oxaliplatin, Carboplatin, Nedaplatin, or Satraplatin; said Topo I inhibitor is selected from

Camptothecin, Topotecan, irinotecan/SN38, rubitecan; said Topo II inhibitor is selected from Etoposide; said antimetabolite is selected from a member of the Folic Family, the Purine Family, or the Pyrimidine Family; said alkylating agent is selected from nitrogen mustards, nitrosoureas, triazenes, alkyl sulfonates, Procarbazine, or aziridines; and said antibiotic is selected from Hydroxyurea, Anthracyclines, Anthracenediones, or Streptomyces family.

[00145] In some embodiments, the additional therapeutic agent is ionizing radiation. In other embodiments, the additional therapeutic agent is Cisplatin or Carboplatin. In yet other embodiments, the additional therapeutic agent is Etoposide. In yet other embodiments, the additional therapeutic agent is Temozolomide.

[00146] In certain embodiments, the additional therapeutic agent is selected from one or more of the following: Cisplatin, Carboplatin, gemcitabine, Etoposide, Temozolomide, or ionizing radiation.

[00147] Another embodiment provides methods for treating pancreatic cancer by administering an ATR inhibitor in combination with another known pancreatic cancer treatment. One aspect of the invention includes administering a compound described herein in combination with gemcitabine. In some embodiments, the pancreatic cancer comprises one of the following cell lines: PSN-1, MiaPaCa-2 or Panc-1. According to another aspect, the cancer comprises one of the following primary tumor lines: Panc-M or MRC5.

[00148] Another aspect of the invention includes administering a compound described herein in combination with radiation therapy. Yet another aspect provides a method of abolishing radiation-induced G2/M checkpoint by administering a compound described herein in combination with radiation treatment.

[00149] Another aspect provides a method of treating pancreatic cancer by administering to pancreatic cancer cells a compound described herein in combination with one or more cancer therapies. In some embodiments, the compound is combined with chemoradiation, chemotherapy, and/or radiation therapy. As would be understood by one of skill in the art, chemoradiation refers to a treatment regime that includes both chemotherapy (such as gemcitabine) and radiation. In some embodiments, the chemotherapy is gemcitabine.

[00150] Yet another aspect provides a method of increasing the sensitivity of pancreatic cancer cells to a cancer therapy selected from gemcitabine or radiation therapy by administering a compound described herein in combination with the cancer therapy.

[00151] In some embodiments, the cancer therapy is gemcitabine. In other embodiments, the cancer therapy is radiation therapy. In yet another embodiment the cancer therapy is chemoradiation.

[00152] Another aspect provides a method of inhibiting phosphorylation of Chk1 (Ser 345) in a pancreatic cancer cell comprising administering a compound described herein after treatment with gemcitabine (100 nM) and/or radiation (6 Gy) to a pancreatic cancer cell.

[00153] Another aspect provides method of radiosensitizing hypoxic PSN-1, MiaPaCa-2 or PancM tumor cells by administering a compound described herein to the tumor cell in combination with radiation therapy.

[00154] Yet another aspect provides a method of sensitizing hypoxic PSN-1, MiaPaCa-2 or PancM tumor cells by administering a compound described herein to the tumor cell in combination with gemcitabine.

[00155] Another aspect provides a method of sensitizing PSN-1 and MiaPaCa-2 tumor cells to chemoradiation by administering a compound described herein to the tumor cells in combination with chemoradiation.

[00156] Another aspect provides a method of disrupting damage-induced cell cycle checkpoints by administering a compound described herein in combination with radiation therapy to a pancreatic cancer cell.

[00157] Another aspect provides a method of inhibiting repair of DNA damage by homologous recombination in a pancreatic cancer cell by administering an ATR inhibitor selected from a compound described herein in combination with one or more of the following treatments: chemoradiation, chemotherapy, and radiation therapy.

[00158] In some embodiments, the chemotherapy is gemcitabine.

[00159] Another aspect provides a method of inhibiting repair of DNA damage by homologous recombination in a pancreatic cancer cell by administering a compound described herein in combination with gemcitabine and radiation therapy.

[00160] In some embodiments, the pancreatic cancer cells are derived from a pancreatic cell line selected from PSN-1, MiaPaCa-2 or Panc-1.

[00161] In other embodiments, the pancreatic cancer cells are in a cancer patient.

[00162] Another aspect of the invention provides a method of treating non-small cell lung cancer comprising administering to a patient a compound described herein in combination with one or more of the following additional therapeutic agents: Cisplatin or Carboplatin, Etoposide, and ionizing radiation. Some embodiments comprise administering to a patient a compound described herein in combination with Cisplatin or Carboplatin, Etoposide, and ionizing radiation. In some embodiments the combination is Cisplatin, Etoposide, and ionizing radiation. In other embodiments the combination is Carboplatin, Etoposide, and ionizing radiation.

[00163] Another embodiment provides a method of promoting cell death in cancer cells comprising administering to a patient a compound described herein, , or a composition comprising said compound.

[00164] Yet another embodiment provides a method of preventing cell repair of DNA damage in cancer cells comprising administering to a patient a compound described herein, or a composition comprising said compound. Yet another embodiment provides a method of preventing cell repair caused by of DNA damage in cancer cells comprising administering to a patient a compound of formula I, or composition comprising said compound.

[00165] Another embodiment provides a method of sensitizing cells to DNA damaging agents comprising administering to a patient a compound described herein, or a composition comprising said compound.

[00166] In some embodiments, the method is used on a cancer cell having defects in the ATM signaling cascade. In some embodiments, said defect is altered expression or activity of one or more of the following: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1/BRIT1, CTIP, or SMC1. In other embodiments, said defect is altered expression or activity of one or more of the following: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1 or H2AX.

[00167] According to another embodiment, the method is used on a cancer, cancer cell, or cell expressing DNA damaging oncogenes. In another embodiment, the cell is a cancer cell expressing DNA damaging oncogenes. In some embodiments, said cancer cell has altered expression or activity of one or more of the following: K-Ras, N-Ras, H-Ras, Raf, Myc, Mos, E2F, Cdc25A, CDC4, CDK2, Cyclin E, Cyclin A and Rb.

[00168] According to another embodiment, the method is used on a cancer, cancer cell, or cell has a defect in a protein involved in base excision repair (“base excision repair protein”). There are many methods known in the art for determining whether a tumor has a defect in base excision repair. For example, sequencing of either the genomic DNA or mRNA products of each base excision repair gene (e.g., UNG, PARP1, or LIG1) can be performed on a sample of the tumor to establish whether mutations expected to modulate the function or expression of the gene product are present (Wang et al., Cancer Research 52:4824 (1992)). In addition to the mutational inactivation, tumor cells can modulate a DNA repair gene by hypermethylating its promoter region, leading to reduced gene expression. This is most commonly assessed using methylation-specific polymerase chain reaction (PCR) to quantify methylation levels on the promoters of base excision repair genes of interest. Analysis of base

excision repair gene promoter methylation is available commercially

(http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-421A.html).

[00169] Finally, the expression levels of base excision repair genes can be assessed by directly quantifying levels of the mRNA and protein products of each gene using standard techniques such as quantitative reverse transcriptase-coupled polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC), respectively (Shinmura et al., Carcinogenesis 25: 2311 (2004); Shinmura et al., Journal of Pathology 225:414 (2011)).

[00170] In some embodiments, the base excision repair protein is UNG, SMUG1, MBD4, TDG, OGG1, MYH, NTH1, MPG, NEIL1, NEIL2, NEIL3 (DNA glycosylases); APE1, APEX2 (AP endonucleases); LIG1, LIG3 (DNA ligases I and III); XRCC1 (LIG3 accessory); PNK, PNKP (polynucleotide kinase and phosphatase); PARP1, PARP2 (Poly(ADP-Ribose) Polymerases); PolB, PolG (polymerases); FEN1 (endonuclease) or Aprataxin.

[00171] In some embodiments, the base excision repair protein is PARP1, PARP2, or PolB. In other embodiments, the base excision repair protein is PARP1 or PARP2.

[00172] The methods described above (gene sequence, promoter methylation and mRNA expression) may also be used to characterize the status (e.g., expression or mutation) of other genes or proteins of interest, such as DNA-damaging oncogenes expressed by a tumor or defects in the ATM signaling cascade of a cell.

[00173] Yet another embodiment provides use of a compound described herein as a radio-sensitizer or a chemo-sensitizer.

[00174] Yet other embodiment provides use of a compound of formula I as a single agent (monotherapy) for treating cancer. In some embodiments, the compounds of formula I are used for treating patients having cancer with a DNA-damage response (DDR) defect. In other embodiments, said defect is a mutation or loss of ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, or H2AX.

Compounds and compositions for Use

[00175] One embodiment provides a compound or composition as described herein for use as a radio-sensitizer or a chemo-sensitizer. Another embodiment provides a compound or composition as described herein for use as a single agent (monotherapy) for treating cancer.

[00176] Another embodiment provides a compound or composition as described herein for treating patients having cancer with a DNA-damage response (DDR) defect. In some embodiments, said defect is a mutation or loss of ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, or H2AX. In other embodiments, said defect is a mutation or loss of

ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1/BRIT1, CTIP, or SMC1.

[00177] Another embodiment provides compounds or compositions described herein for treating cancer. In some embodiments, the compound or composition is further combined with an additional therapeutic agent described herein. In some embodiments, the compound or composition is further combined with a DNA damaging agent described herein.

[00178] In some embodiments, the cancer has a defect in a pathway described herein.

Manufacture of Medicaments

[00179] One embodiment provides the use of a compound or composition described herein for the manufacture of a medicament for use as a radio-sensitizer or a chemo-sensitizer.

Another embodiment provides the use of a compound or composition described herein for the manufacture of a medicament for the manufacture of a medicament for use as a single agent (monotherapy) for treating cancer.

[00180] Yet another embodiment provides the use of a compound or composition described herein for the manufacture of a medicament for the manufacture of a medicament for treating patients having cancer with a DNA-damage response (DDR) defect.


[00181] In some embodiments, said defect is a mutation or loss of ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, or H2AX. In other embodiments, said defect is a mutation or loss of ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1/BRIT1, CTIP, or SMC1.

[00182] Another embodiment provides the use of a compound or composition described herein for the manufacture of a medicament for treating cancer. In some embodiments, the compound or composition is combined with an additional therapeutic agent, such as a DNA damaging agent, described herein. In another embodiment, the cancer has a defect in a pathway described herein.


SCHEMES AND EXAMPLES

[00183] The compounds of the disclosure may be prepared in light of the specification using steps generally known to those of ordinary skill in the art. Those compounds may be analyzed by known methods, including but not limited to LCMS (liquid chromatography mass spectrometry) and NMR (nuclear magnetic resonance). The following generic schemes and examples illustrate how to prepare the compounds of the present disclosure. The examples are for the purpose of illustration only and are not to be construed as limiting the

scope of the invention in any way. ^1H -NMR spectra were recorded at 400 MHz using a Bruker DPX 400 instrument. Mass spec. samples were analyzed on a MicroMass Quattro Micro mass spectrometer operated in single MS mode with electrospray ionization.



SCHEME A



[00184] Scheme A depicts general methods for making compounds of Formula **I-A** and **I-B** where ring **A** is isoxazole. Compound **A-i** contains amine protecting groups PG and an alkyne protecting group PG'. Suitable amine protecting groups PG can be, but not limited to, Boc (tert-butoxycarbonyl). Suitable alkyne protecting groups PG' orthogonal to PG such as, but not limited to, TMS, TES or TIPS. The pyridine ring system is introduced at position 5 of the aminopyrazine core, under metal-mediated coupling conditions, including but not limited to Suzuki coupling of **A-i** with an appropriate boronic acid/ester to provide intermediates of Formula **A-ii**. Intermediates of Formula **A-ii** are then selectively deprotected under standard conditions known to those skilled in the art such as, but not limited to, treatment with base such as K₂CO₃ or fluoride to remove the alkyne protecting group PG' to yield intermediates of Formula **A-iii**. 1,3-Dipolar cycloaddition of the terminal acetylene of intermediate **A-iii** with an appropriate chloro-oxime, under basic conditions, provides the desired 3,5-disubstituted isoxazole intermediates of Formula **A-iv**. Removal of the amine protecting group(s) PG from compounds of Formula **A-iv** takes place under standard conditions known to those skilled in the art such as, but not limited to, treatment with HCl or TFA (in case of a Boc protecting group) to provide compounds of Formula **I-A** of this invention in which Ring **A** is isoxazole.

[00185] In a slightly different sequence, compounds of Formula **A-i** can also be selectively deprotected utilizing the standard conditions described above to remove the alkyne protecting group PG' to yield intermediates of Formula **A-v**. Intermediates of Formula **A-v** react with appropriate coupling partners (e.g. boronic acid/ester) utilising the metal-mediated coupling conditions described above to form intermediates of formula **A-iii**.

[00186] 1,3-dipolar cycloaddition of the terminal acetylene of intermediate **A-v** with an appropriate chloro-oxime, under basic conditions, provides the desired 3,5-disubstituted isoxazole intermediates of Formula **A-vi**. Intermediates of Formula **A-vi** react with appropriate coupling partners (e.g. boronic acid/ester) utilising the metal-mediated coupling conditions described above to form intermediates of formula **A-iv**. In addition, intermediate **A-vi** may undergo a deprotection of the amine protecting groups as described above, followed by a metal-mediated coupling with an appropriate coupling partner (e.g. boronic acid/ ester) as described above to form compounds of Formula **I-A** of this invention.

1,3-Dipolar cycloaddition of the terminal acetylene of intermediate **A-v** with an appropriate chloro-oxime, wherein the chloro oxime building block is functionalised with the appropriate leaving group (X), under basic conditions, provides the desired 3,5-disubstituted isoxazole intermediates of Formula **A-ix**. Suitable leaving groups include but are not limited to

halogens, mesylates or triflates. Isoxazole intermediate **A-ix** is further functionalised through the nucleophilic displacement of the leaving group (X) with the amine HNR_3R_4 (R_3/R_4 can be but are not limited to alkyl, H or PG) to form intermediates of Formula **A-viii**. Intermediates of Formula **A-viii** react with appropriate coupling partners (e.g. boronic acid/ester) utilising the metal-mediated coupling conditions described above to form intermediates of Formula **A-x**. Removal of the amine protecting group PG from intermediates of Formula **A-x** takes place under standard conditions as described above to provide compounds of Formula **I-B** of this invention in which Ring A is isoxazole.


[00187] Removal of the amine protecting group PG from intermediates of Formula **A-viii** and **A-ix** could and can take place under standard conditions described above to provide intermediates of Formula **A-xiii** and **A-xi** respectively. Isoxazole intermediate **A-xi** is then further functionalised through the nucleophilic displacement of the leaving group (X) with the amine HNR_3R_4 (R_3/R_4 can be but are not limited to alkyl, H or PG) to form intermediates of Formula **A-xiii**. Intermediates of Formula **A-xiii** are then reacted with appropriate coupling partners (e.g. boronic acid/ester) utilising the metal-mediated coupling conditions described above to provide compounds of Formula **I-B** of this invention in which Ring A is isoxazole.

[00188] Intermediates of formula **A-ix** and **A-xi** may react with appropriate coupling partners (e.g. boronic acid/ester) utilising the metal-mediated coupling conditions described above to provide intermediates of formula **A-xii** and **A-xiv** respectively. Removal of the amine protecting group PG from intermediates of Formula **A-xii** could take place under standard conditions described above to provide compounds of Formula **A-xiv**. Isoxazole intermediate **A-xiv** could be further functionalised through the nucleophilic displacement of the leaving group (X) with the amine HNR_3R_4 (R_3/R_4 can be but are not limited to alkyl, H or PG) to form compounds of Formula **I-B** of this invention in which Ring A is isoxazole.

[00189] 1,3-Dipolar cycloaddition of the terminal acetylene of intermediate **A-iii** with an appropriate chloro-oxime, wherein the chloro oxime building block is functionalised with the appropriate leaving group (X), under basic conditions, may provide the desired 3,5-disubstituted isoxazole intermediates of Formula **A-xii**. Suitable leaving groups include but are not limited to halogens, mesylates or triflates. Isoxazole intermediate **A-xii** may be further functionalised through the nucleophilic displacement of the leaving group (X) with the amine HNR_3R_4 (R_3/R_4 can be but are not limited to alkyl, H or PG) to form intermediates of Formula **A-x**. Removal of the amine protecting group PG from intermediates of Formula **A-x** could take place under standard conditions described above to provide compounds of Formula **I-B** of this invention in which Ring A is isoxazole.

Preparations 1 – 8 and Examples 1- 6 relate to Scheme A

Preparation 1. Synthesis of Di-*tert*-butyl 5-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]-3-ethynyl-pyrazin-2-yl] carbamate




[00190] Step 1: 2-(4-iodo-2-pyridyl)-2-methyl-propanenitrile (8.549 g, 31.42 mmol), bis(dipinacolato)diboron (10.12 g, 39.84 mmol), potassium acetate (Potassium Ion (1)) (9.024 g, 91.95 mmol) in dioxane (80 mL). The reaction mixture was degassed with 5 x vacuum/nitrogen cycles, then treated with $\text{PdCl}_2(\text{PCy}_3)_2$ (2.1 g, 2.845 mmol), degassed again and stirred at 100 °C under nitrogen for 17 hours. Reaction mixture was washed onto a mixture of *tert*-butyl *N*-[5-bromo-3-(2-triisopropylsilylethynyl)pyrazin-2-yl]-*N*-*tert*-butoxycarbonyl-carbamate (17 g, 30.65 mmol) and tripotassium phosphate (13.01 g, 61.30 mmol) with acetonitrile (250 mL)/water (55 mL). The reaction mixture was degassed with 5 x vacuum/nitrogen cycles then treated with $\text{Pd}[\text{P}(\text{tBu})_3]_2$ (1 g, 1.957 mmol), degassed further 5 x vacuum/nitrogen cycles and stirred under nitrogen for 4.5 hours at 60 °C. Reaction mixture was cooled to ambient temperature and then diluted with ethyl acetate and washed with aqueous sodium bicarbonate/sodium chloride. Organic extracts were dried over MgSO_4 and concentrated *in vacuo* to a dark oil. Purified by silica gel column chromatography (600 ml) eluted with 10 to 30% ethyl acetate/petroleum ether. Product fractions were combined and concentrated *in vacuo* to give an amber oil (16 g). This was re-dissolved in hot ethyl acetate (10 ml) diluted with petroleum ether (50 ml) and allowed to crystallise giving a colourless powder (7.2 g, 37.9%). The mother liquors were pre-absorbed onto silica gel and purified by silica gel column chromatography (600 ml) eluted with 20 to 40% ethyl acetate/petroleum ether. Product fractions were combined and concentrated *in vacuo* to give Di-*tert*-butyl [5-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]-3-(2-triisopropylsilylethynyl)pyrazin-2-yl]carbamate as a colourless solid (5.34 g, 28.1%) Total yield (12.54 g, 66%). ^1H

NMR (400.0 MHz, DMSO- d_6) δ 1.09 - 1.15 (m, 21H), 1.35 (s, 18H), 1.80 (s, 6H), 8.15 (d, 1H), 8.29 (s, 1H), 8.85 (d, 1H) and 9.42 (s, 1H) ppm; LC/MS m/z 620.3 $[M+H]^+$.

[00191] Step 2: Di-*tert*-butyl [5-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]-3-(2-triisopropylsilylethynyl)pyrazin-2-yl]carbamate (11.85 g, 19.12 mmol) in tetrahydrofuran (241.9 mL) was stirred in an ice bath and treated with tetrabutylammonium fluoride in tetrahydrofuran (19.12 mL of 1 M, 19.12 mmol). Stirred at 0 °C for 5 minutes then ice/ethyl acetate added. Separated and washed with brine (x 2), followed by aqueous sodium metabisulphite (to deactivate any Pd species carried over from Suzuki) (x 1), then aqueous sodium bicarbonate (x 1) and then brine (x 1). Organic extracts were dried over $MgSO_4$ and concentrated *in vacuo* to give a brown gum. This gum was purified by silica gel column chromatography eluted with 25 to 35% ethyl acetate/petroleum ether. Product fractions were combined and concentrated *in vacuo* to give di-*tert*-butyl 5-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]-3-ethynyl-pyrazin-2-yl] carbamate as a pale gum which solidified on standing (7.70 g, 86.9%). ^1H NMR (400.0 MHz, DMSO- d_6) δ 1.39 (s, 18H), 1.80 (s, 6H), 5.04 (s, 1H) 8.15 (d, 1H), 8.27 (s, 1H), 8.85 (d, 1H) and 9.44 (s, 1H) ppm; LC/MS m/z 464.1 $[M+H]^+$.

Preparation 2. Synthesis of *tert*-butyl (4-[4-[5-[bis(*tert*-butoxycarbonyl)amino]-6-ethynyl-pyrazin-2-yl]-2-pyridyl]-4-cyano-piperidine-1-carboxylate)




[00192] Step 1: Sodium carbonate (77.30 mL of 2 M, 154.6 mmol) was added to a suspension of *tert*-butyl *N*-[5-bromo-3-(2-trimethylsilylethynyl)pyrazin-2-yl]-*N*-*tert*-butoxycarbonyl-carbamate (60.6 g, 128.8 mmol) in *N,N*-dimethylformamide (303.0 mL) and heated at 75 °C for 45 minutes. The reaction mixture was allowed to cool and then diluted with water (3 vols, 900 mL). The precipitate was left to stand for 30 minutes and was isolated by filtration the precipitate was washed with water (300 mL) and dried under vacuum. The yellow powder was transferred to a flask and triturated with ethyl acetate (300 mL) to give *tert*-butyl 4-cyano-4-(4-iodo-2-pyridyl)piperidine-1-carboxylate as a white powder (48.39 g,

94% yield). ^1H NMR (400.0 MHz, DMSO- d_6) δ 1.43 (s, 18H), 3.53 (s, 1H), 8.55 (s, 1H) ppm; LC/MS m/z 243.9 $[\text{M}+\text{H}]^+$.


[00193] Step 2: *tert*-butyl 4-cyano-4-(4-iodo-2-pyridyl)piperidine-1-carboxylate (1.01 g, 2.444 mmol) was dissolved in dioxane (15 mL) and bis(pinacolato)diboron (934.0 mg, 3.678 mmol) followed by potassium acetate (721.9 mg, 7.356 mmol) were added. The reaction mixture was degassed with 5 x vacuum/nitrogen cycles. $[\text{PdCl}_2(\text{dppf})]$.dichloromethane (199.6 mg, 0.2444 mmol) was then added and the reaction heated to 90 °C for 15 hours. The reaction mixture was cooled to ambient temperature and *tert*-butyl *N*-[5-bromo-3-(2-trimethylsilylethynyl)pyrazin-2-yl]-*N*-*tert*-butoxycarbonyl-carbamate (1.150 g, 2.444 mmol) and a 2 M aqueous solution of sodium carbonate (3.666 mL of 2 M, 7.332 mmol) were added. The reaction mixture was degassed with 3 x vacuum/nitrogen cycles then $\text{Pd}(\text{PPh}_3)_4$ (283.2 mg, 0.2451 mmol) was added. The reaction mixture was degassed with 5 x vacuum/nitrogen cycles and then heated to 90 °C for 2 hours. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water. The aqueous layer was extracted with ethyl acetate (x 1) and the combined organic extracts washed with brine (x 2), dried over MgSO_4 , filtered and concentrated *in vacuo*. The residue was purified by column chromatography (ISCO Companion, 120 g column), loaded in dichloromethane eluted with 0 to 50% ethyl acetate/petroleum ether. Product fractions were combined and concentrated *in vacuo* to give the sub-title product as a beige solid (749 mg, 51% Yield). ^1H NMR (400.0 MHz, DMSO- d_6) δ 1.33 (s, 18H), 1.38 (s, 9H), 2.07 (dt, 2H), 2.21 (d, 2H), 3.01 (br s, 2H), 4.10 (br d, 2H), 4.99 (s, 1H), 8.11 (dd, 1H), 8.25 (s, 1H), 8.78 (d, 1H) and 9.40 (s, 1H) ppm; LC/MS m/z 605.3 $[\text{M}+\text{H}]^+$.

Preparation 3. Synthesis of Di-*tert*-butyl (4-[4-[5-amino-6-[3-(2-fluorophenyl)isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]piperidine-4-carbonitrile) carbamate



[00194] Step 1. Diethylamide (16.56 mg, 22.81 μ L, 0.1637 mmol) was added drop wise to a solution of *tert*-butyl 4-[4-[5-[bis(*tert*-butoxycarbonyl)amino]-6-ethynyl-pyrazin-2-yl]-2-pyridyl]-4-cyano-piperidine-1-carboxylate (75 mg, 0.1240 mmol) and ((*Z*)-2-fluoro-*N*-hydroxybenzimidoyl chloride (24.38 mg, 0.1567 mmol) in dichloromethane (26.24 mL). The mixture was stirred at ambient temperature for 45 minutes then heated to 65 °C for 1 hour. The reaction mixture cooled to ambient temperature and diluted with dichloromethane and water. The organic layer was separated using a phase separation cartridge. The aqueous layer was extracted with dichloromethane the organic layers were combined, dried over MgSO₄, filtered and concentrated *in vacuo* to give the crude product as an oil. Taken onto the next step as is (91.98 mg, assumed 100% yield). LC/MS *m/z* 410.9 [M+H]⁺.

Example 1: Synthesis of 4-(4-(5-amino-6-(3-(2-fluorophenyl)isoxazol-5-yl)pyrazin-2-yl)pyridin-2-yl) piperidine-4-carbonitrile **Compound I-28**



[00195] Step 1: *Di-tert*-butyl (4-[4-[5-amino-6-[3-(2-fluorophenyl)isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl] piperidine-4-carbonitrile) carbamate (91.98 mg, 0.1240 mmol) was dissolved in dichloromethane (2 mL) followed by the addition of trifluoroacetic acid (500 μ L, excess). The mixture was stirred at ambient temperature for 5 hours and then concentrated under a stream of nitrogen. Compound was purified by reverse phase preparative HPLC [Waters Sunfire C18, 10 mM, 100 Å column, gradient 10% - 95% B (solvent A: 0.05% trifluoroacetic acid in water; solvent B: acetonitrile) over 16 minutes at 25 mL/minutes], combined fractions were freeze-dried to give 4-(4-(5-amino-6-(3-(2-fluorophenyl)isoxazol-5-yl)pyrazin-2-yl)pyridin-2-yl) piperidine-4-carbonitrile **Compound I-28** as a yellow solid (23.3 mg, 33.83% yield). ¹H NMR (400.0 MHz, DMSO-d₆) δ 2.55 - 2.40 (m, 4H), 3.23 - 3.15 (m, 2H), 3.55 (br d, 2H), 7.37 (s, 2H), 7.50 - 7.41 (m, 2H), 7.58 (d,

1H), 7.67 - 7.64 (m, 1H), 8.03 (td, 1H), 8.14 (dd, 1H), 8.27 (s, 1H), 8.57 (br s, 1H), 8.74 (d, 1H), 8.77 (br s, 1H) and 9.04 (s, 1H) ppm; F NMR (376.0 MHz, DMSO) δ -113.10 ppm; LC/MS m/z 442.2 [M+H]⁺

The following compounds were prepared using procedure analogous to that described above in preparations 2-3 and example 1

4-[4-[5-amino-6-[3-(3-methyl-2-thienyl)isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]piperidine-4-carbonitrile **Compound I-24**

4-[4-[5-amino-6-[3-(o-tolyl)isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]piperidine-4-carbonitrile **Compound I-25**

4-[4-[5-amino-6-[3-(2-hydroxyphenyl)isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]piperidine-4-carbonitrile **Compound I-26**

4-[4-[5-amino-6-[3-(2-methoxyphenyl)isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]piperidine-4-carbonitrile **Compound I-27**


4-[4-[5-amino-6-[3-(2-methoxy-6-methyl-phenyl)isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]piperidine-4-carbonitrile **Compound I-29**

4-[4-[5-amino-6-[3-(2-thienyl)isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]piperidine-4-carbonitrile **Compound I-30**

4-[4-[5-amino-6-[3-[4-(hydroxymethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]piperidine-4-carbonitrile **Compound I-31**

4-[4-[5-amino-6-[3-(4-hydroxyphenyl)isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]piperidine-4-carbonitrile **Compound I-32**

Preparation 4. Synthesis of *tert*-butyl *N-tert*-butoxycarbonyl-*N*-[3-[3-[4-[1-(*tert*-butoxycarbonylamino)-2-fluoro-ethyl]phenyl]isoxazol-5-yl]-5-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]pyrazin-2-yl]carbamate



[00196] Step 1: Triethylamine (252.5 mg, 347.8 μ L, 2.495 mmol) was added drop wise to a solution of *tert*-butyl *N*-(5-bromo-3-ethynyl-pyrazin-2-yl)-*N*-*tert*-butoxycarbonyl-carbamate (828 mg, 2.079 mmol) and *tert*-butyl (1-(4-(chloro(hydroxyimino)methyl)phenyl)-2-fluoroethyl)carbamate (658.5 mg, 2.079 mmol) in anhydrous tetrahydrofuran (10 mL) and the reaction mixture heated at 65 °C (external temperature) for 2.5 hours. The reaction mixture was diluted with ethyl acetate and the organic layer washed with water (x 1) and brine (x 2). The organic layer was dried over MgSO_4 , filtered and concentrated *in vacuo*. Purification by column chromatography (ISCO Companion, 120 g column) dry loaded and eluted with 0 to 30% ethyl acetate/petroleum ether. Product fractions were combined and concentrated *in vacuo* to give *tert*-butyl *N*-[5-bromo-3-[3-[4-[1-(*tert*-butoxycarbonylamino)-2-fluoro-ethyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-*N*-*tert*-butoxycarbonyl-carbamate as a cream solid (809 mg, 57% yield). ^1H NMR (400.0 MHz, CDCl_3) δ 1.21 (s, 18H), 1.31 (d, J = 7.0 Hz, 9H), 4.29 - 4.41 (m, 1H), 4.48 - 4.52 (m, 1H), 4.83 - 4.90 (m, 1H), 7.47 (d, 2H), 7.70 (d, 1H), 7.81 (s, 1H), 7.92 (d, 2H) and 8.96 (s, 1H) ppm; LC/MS m/z 679.11 $[\text{M}+\text{H}]^+$.

[00197] The following intermediates were prepared using procedure analogous to that described above:

tert-butyl *N*-[[4-[5-[3-[bis(*tert*-butoxycarbonyl)amino]-6-bromo-pyrazin-2-yl]isoxazol-3-yl]phenyl] methyl]-*N*-methyl-carbamate ^1H NMR (400.0 MHz, CDCl_3) δ 1.41 (s, 18H), 1.51 (d, 9H), 2.84 - 2.91 (m, 3H), 4.94 (br s, 2H), 7.36 (s, 1H), 7.37 (br s, 2H), 7.85 (d, 2H) and 8.66 (s, 1H) ppm

tert-butyl *N*-[5-bromo-3-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-*N*-*tert*-butoxycarbonyl-carbamate ^1H NMR (400.0 MHz, $\text{DMSO}-d_6$) δ 1.30 (s, 18H), 7.55 - 7.57 (m, 3H), 7.89 (s, 1H), 8.01 - 8.04 (m, 2H) and 9.04 (s, 1H) ppm; LC/MS m/z 417.0 $[\text{M}+\text{H}]^+$.

tert-butyl*N*-[5-bromo-3-[3-(3-methyl-2-thienyl)isoxazol-5-yl]pyrazin-2-yl]-*N*-*tert*-butoxycarbonyl-carbamate ¹H NMR (400.0 MHz, DMSO -d₆) δ 1.30 (s, 18H), 2.47 (s, 3H), 7.12 (d, 1H), 7.45 (s, 1H), 7.72 (d, 1H) and 9.05 (s, 1H) ppm; LC/MS m/z 539.1 [M+H]⁺.

Ditert-butyl2-[4-[5-[3-[bis(*tert*-butoxycarbonyl)amino]-6-bromo-pyrazin-2-yl]isoxazol-3-yl]phenyl] piperazine-1,4-dicarboxylate ¹H NMR (400.0 MHz, CDCl₃) δ 1.41 (d, J = 4.1 Hz, 18H), 1.50 (s, 18H), 3.03 (br s, 2H), 3.42 - 3.37 (m, 1H), 4.01 - 3.98 (m, 2H), 4.49 (br s, 1H), 5.33 - 5.32 (d, 1H), 7.35 (s, 1H), 7.47 - 7.45 (d, 2H), 7.87 - 7.85 (d, 2H) and 8.65 (s, 1H) ppm

[00198] Step 2: To a solution of 2-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl] propanenitrile (99.04mg, 0.3639 mmol) in dioxane (1.089 mL) was added *tert*-butyl *N*-[5-bromo-3-[3-[4-[1-(*tert*-butoxycarbonylamino)-2-fluoro-ethyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-*N*-*tert*-butoxycarbonyl -carbamate (152 mg, 0.2240 mmol) and reaction was treated with 2 M aqueous solution of sodium carbonate (546.0 μL of 2 M, 1.092 mmol). The reaction mixture was degassed with 5 x vacuum/nitrogen cycles. Then Pd(PPh₃)₄ (42.05 mg, 0.03639 mmol) was added to the reaction mixture. The reaction mixture was degassed further with 5 x vacuum/nitrogen cycles and the reaction mixture was stirred under nitrogen at 90 °C for 3 hours. The reaction was cooled to ambient temperature and diluted with ethyl acetate and aqueous sodium bicarbonate solution. The organic extracts were separated and washed with brine (x 1). The organic extracts were dried over MgSO₄, filtered and concentrated *in vacuo* to give the sub-title compound as a black oil. Taken onto the next step without further purification (166.6 mg, assumed 100% yield). LC/MS m/z 744.48, 688.40, 588.32 [M+H]⁺.

[00199] The following compounds were prepared using procedure analogous to that described above in preparation 4 and example 1

2-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile

Compound I-5

4-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]piperidine-4-carbonitrile

Compound I-6

4-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]tetrahydropyran-4-carbonitrile **Compound I-7**

2-[4-[5-amino-6-[3-(3-methyl-2-thienyl)isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile **Compound I-8**

3-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]piperidine-3-carbonitrile **Compound I-12**

2-[4-[5-amino-6-[3-[4-(1-amino-2-fluoro-ethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile **Compound I-16**

2-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-2-methyl-1-piperazin-1-yl-propan-1-one **Compound I-20**

2-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-2-methyl-N-(2-morpholinoethyl)propanamide **Compound I-21**

5-[2-(1-methyl-1-methylsulfonyl-ethyl)-4-pyridyl]-3-(3-phenylisoxazol-5-yl)pyrazin-2-amine **Compound I-22**

5-[2-[1-methyl-1-(4-piperidylsulfonyl)ethyl]-4-pyridyl]-3-(3-phenylisoxazol-5-yl)pyrazin-2-amine **Compound I-23**

4-[4-[5-amino-6-[3-(1H-indol-5-yl)isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]piperidine-4-carbonitrile **Compound I-33**

2-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-N-(2-methoxyethyl)-2-methyl-propanamide **Compound I-38**


2-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-N,N,2-trimethyl-propanamide **Compound I-39**

2-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-N-(3-aminopropyl)-2-methyl-propanamide **Compound I-40**

2-[4-[5-amino-6-[3-(4-piperazin-2-ylphenyl)isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile **Compound I-41**


2-[4-[5-amino-6-[3-(4-hydroxyphenyl)isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile **Compound I-51**

Preparation 5. Synthesis of *tert*-butyl 5-[5-[3-[bis(*tert*-butoxycarbonyl)amino]-6-bromopyrazin-2-yl] isoxazol-3-yl]indole-1-carboxylate




[00200] Step 1: A solution of *tert*-butyl 5-((hydroxyimino)methyl)-1H-indole-1-carboxylate (260.3 mg, 1 mmol) in methanol (1 mL) was added slowly to a stirred solution of *tert*-butyl *N*-(5-bromo-3-ethynylpyrazin-2-yl)-*N*-*tert*-butoxycarbonylcarbamate (438.1 mg, 1.100 mmol) and (diacetoxyiodo)benzene (354.3 mg, 1.100 mmol) in methanol (2 mL) containing trifluoroacetic acid (15 μ L, 0.1947 mmol) at ambient temperature. The reaction was stirred at this temperature for 17 hours then concentrated *in vacuo*. The residue was purified by column chromatography (ISCO Companion, 40 g column) loaded with dichloromethane and eluted with 0 to 50% ethyl acetate/petroleum ether. Product fractions were combined and concentrate *in vacuo* to give the sub-title product as a white solid (108 mg, 16% Yield). ^1H NMR (400.0 MHz, DMSO- d_6) δ 1.22 (s, 18H), 1.57 (s, 9H), 6.73 (d, 1H), 7.69 (d, 1H), 7.80 (s, 1H), 7.89 (dd, 1H), 8.11 (d, 1H), 8.23 (d, 1H) and 8.94 (s, 1H) ppm.

Preparation 6. Synthesis of Di-*tert*-butyl (5-bromo-3-(3-[4-(chloromethyl)phenyl]isoxazol-5-yl)pyrazin-2-yl)carbamate



[00201] Step 1: Triethylamine (1.128 g, 1.554 mL, 11.15 mmol) was added to a solution of *tert*-butyl *N*-(5-bromo-3-ethynyl-pyrazin-2-yl)-*N*-*tert*-butoxycarbonyl-carbamate (3.7 g, 9.291 mmol) and (*1Z*)-4-(chloromethyl)-*N*-hydroxy-benzimidoyl chloride (1.994 g, 9.774 mmol) in dichloromethane (26.24 mL). The mixture was stirred at ambient temperature for 18 hours. The reaction mixture was partitioned between dichloromethane and water. The organic layer was separated, dried over MgSO_4 , filtered and concentrated *in vacuo* to give the crude product as an oil. Purified by silica chromatography loaded in dichloromethane and eluted with 10 to 40% ethyl acetate/petroleum ether. Product fractions were combined and concentrated *in vacuo* to give the sub-titled product as a pale yellow solid (3.19 g, 66% yield). ^1H NMR (400.0 MHz, CDCl_3) δ 1.41 (s, 18H), 4.66 (s, 2H), 7.37 (s, 1H), 7.54 (d, $J = 8.2$ Hz, 2H), 7.90 (d, $J = 8.2$ Hz, 2H) and 8.66 (s, 1H) ppm; LC/MS m/z 410.9 $[\text{M}+\text{H}]^+$.

Preparation 7. Synthesis of Di-*tert*-butyl (5-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]-3-[3-4-[[[(3*S*)-tetra hydrofuran-3-yl]amino]methyl] phenyl]isoxazol-5-yl]pyrazin-2-yl) carbamate



[00202] Step 1: *tert*-butyl *N*-[5-bromo-3-[3-[4-(chloromethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-*N*-*tert*-butoxycarbonyl-carbamate (1 g, 1.767 mmol), (3*S*)-tetrahydrofuran-3-amine (Hydrochloric Acid (1)) (873.5 mg, 7.068 mmol) and potassium iodide (293.3 mg, 93.71 μL , 1.767 mmol) in *N,N*-dimethylformamide (13.33 mL) was treated with diisopropyl ethylamine (913.5 mg, 1.231 mL, 7.068 mmol). The mixture was stirred at 40 °C for 3 hours to completion. After this time the reaction mixture was diluted with ethyl acetate and washed with brine. The organic layer was separated, dried over MgSO_4 , filtered and concentrated *in vacuo* to give the crude product as a pale yellow oil. Purified by silica chromatography eluted with 2-5% methanol/ethyl acetate/0.2-0.5% ammonium hydroxide. Product fractions were combined and concentrated *in vacuo* to give di-*tert*-butyl (5-bromo-3-(3-(4-[[[(3*S*)-tetrahydrofuran-3-yl]amino]methyl]phenyl]isoxazol-5-yl)pyrazin-2-yl)carbamate as a solid.

This material was not completely clean and was used as such in the next step (0.84 g, 77% yield). LC/MS m/z 618.1 $[M+H]^+$.

[00203] The following intermediates were prepared using procedure analogous to that described above:


tert-butyl *N*-[5-bromo-3-[3-[4-[(cyclopropylamino)methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-*N*-*tert*-butoxycarbonyl-carbamate LC/MS m/z 587.99 $[M+H]^+$.

tert-butyl *N*-[5-bromo-3-[3-[4-[(oxetan-3-ylamino)methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-*N*-*tert*-butoxycarbonyl-carbamate LC/MS m/z 604.1 $[M+H]^+$.

tert-butyl *N*-[5-bromo-3-[3-[4-[[[(3*R*)-tetrahydrofuran-3-yl]amino]methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-*N*-*tert*-butoxycarbonyl-carbamate LC/MS m/z 618.04 $[M+H]^+$.

[00204] Step 2: 2-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]propanenitrile (286.4 mg, 0.4209 mmol) and di-*tert*-butyl (5-bromo-3-(3-(4-[[[(3*S*)-tetrahydrofuran-3-yl]amino]methyl]phenyl) isoxazol-5-yl)pyrazin-2-yl)carbamate (173 mg, 0.2806 mmol) in acetonitrile (1.730 mL), water (1.730 mL) was treated with 2 M aqueous solution of sodium carbonate (140.3 μ L of 2 M, 0.2806 mmol). The reaction mixture was degassed with 5 x vacuum/nitrogen cycles. Pd[P(*t*Bu)₃]₂ (14.40 mg, 0.02806 mmol) was then added to the reaction mixture. The reaction mixture was degassed further with 5 x vacuum/nitrogen cycles and the reaction mixture was stirred under nitrogen at 60 °C for 80 minutes. The reaction was cooled to ambient temperature and diluted with ethyl acetate and aqueous sodium bicarbonate solution. The organic extracts were separated and washed with brine (x 1), dried over MgSO₄, filtered and concentrated *in vacuo* to give a brown gum. Purified by silica gel chromatography eluted with 5% methanol/dichloromethane/0.5% ammonium hydroxide. Product fractions were combined and concentrated *in vacuo* to give the partially pure sub-titled product as a brown oil (72 mg, 56% yield). LC/MS m/z 482.2, 582.2, 682.4 $[M+H]^+$.


Preparation 8. Synthesis of 5-bromo-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine



[00205] Step 1: Trifluoroacetic Acid (2.500 mL) was added to a solution of *tert*-butyl *N*-[5-bromo-3-[3-[4-(chloromethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-*N*-*tert*-butoxycarbonyl-carbamate (500 mg, 0.8836 mmol) in dichloromethane (20.00 mL) and the mixture was stirred at ambient temperature for 10 minutes. The reaction mixture was concentrated *in vacuo* to give 5-bromo-3-[3-[4-(chloromethyl)phenyl]isoxazol-5-yl]pyrazin-2-amine (323.1 mg, assumed 100% yield) which was used as such in next step. LC/MS *m/z* 365.4 [M-H]⁺

Step 2: 5-bromo-3-[3-[4-(chloromethyl)phenyl]isoxazol-5-yl]pyrazin-2-amine was dissolved in ethanol, methanamine in ethanol (2.495 g, 3.300 mL, 26.51 mmol) was added and the mixture was stirred at 70 °C in a microwave. The reaction mixture was concentrated *in vacuo*. The residue was partitioned between dichloromethane and saturated aqueous sodium bicarbonate. Combined organic extract was dried (MgSO₄) and concentrated *in vacuo* yielding 5-bromo-3-(3-(4-((methylamino)methyl)phenyl) isoxazol-5-yl)pyrazin-2-amine as an oil that was used without further purification.

Example 2: Synthesis of 2-[4-[5-amino-6-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile **Compound I-1**




[00206] Step 1: The reaction mixture was cooled and N₂ bubbled through for 10 minutes. Then 5-bromo-3-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-amine (28.83 mg, 0.08005 mmol) and an aqueous solution of sodium carbonate (120.0 µL of 2 M, 0.2401 mmol) was added. N₂ was bubbled through for a further 10 minutes then Pd(PPh₃)₄ (9.278 mg, 0.008029 mmol) was added and the reaction heated to 150 °C in a microwave reactor for 30 minutes. Compound was purified by reverse phase preparative HPLC [Waters Sunfire C18, 10 mM, 100 Å column, gradient 10% - 95% B (solvent A: 0.05% trifluoroacetic acid in water; solvent B: acetonitrile) over 16 minutes at 25 mL/minutes], combined fractions

were freeze-dried to give 2-[4-[5-amino-6-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile (Trifluoroacetic Acid (1)) **Compound I-1** as a yellow solid. ^1H NMR (400.0 MHz, DMSO- d_6) δ 1.80 (s, 6H), 2.63 (t, J = 5.3 Hz, 3H), 4.24 (t, J = 5.8 Hz, 2H), 7.34 (s, 1H), 7.68 (d, J = 8.2 Hz, 2H), 7.82 (s, 1H), 8.12 - 8.08 (m, 3H), 8.20 (s, 1H), 8.70 (d, J = 5.2 Hz, 1H), 8.85 (s, 1H) and 9.05 (s, 1H) ppm; LC/MS m/z 425.2 $[\text{M}+\text{H}]^+$.

Example 3: Synthesis of 2-[4-[5-amino-6-[3-[4-[[[(3*S*)-tetrahydrofuran-3-yl]amino]methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile

Compound I-19



[00207] Step 1: Di-*tert*-butyl (5-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]-3-[3-4-[[[(3*S*)-tetrahydrofuran-3-yl] amino]methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl)carbamate (72 mg, 0.1056 mmol) was dissolved in dichloromethane (5 mL) followed by the addition of trifluoroacetic acid (500 μL , excess). The mixture was stirred at ambient temperature for 2 hours and then concentrated *in vacuo* to an oil. Azeotroped with dichloromethane/methanol. Compound was purified by reverse phase preparative HPLC [Waters Sunfire C18, 10 mM, 100 Å column, gradient 10% - 95% B (solvent A: 0.05% trifluoroacetic acid in water; solvent B: acetonitrile) over 16 minutes at 25 mL/minutes], combined fractions were then passed through a sodium bicarbonate cartridge and freeze-dried to give 2-[4-[5-amino-6-[3-[4-[[[(3*S*)-tetrahydrofuran-3-yl]amino]methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-2-methylpropane nitrile **Compound I-19** as a pale yellow powder (33 mg, 36% yield). ^1H NMR (400.0 MHz, DMSO- d_6) δ 1.65 - 1.75 (m, 1H), 1.80 (s, 6H), 1.90-2.00 (m, 1H), 3.24 - 3.32 (m, 1H), 3.41 - 3.50 (m, 1H), 3.61 - 3.82 (m, 5H), 7.32 (br s, 2H), 7.53 (d, 2H), 7.77 (s, 1H), 7.96 (d, 2H), 8.09 (d, 1H), 8.19 (s, 1H), 8.68 (d, 1H), 9.03 (s, 1H) ppm; LC/MS m/z 482.2 $[\text{M}+\text{H}]^+$.

[00208] The following compounds were prepared using procedure analogous to that described above in preparation 7 and example 2.

2-[4-[5-amino-6-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-2-ethyl-butanenitrile **Compound I-2**

2-[4-[5-amino-6-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]butanenitrile **Compound I-3**

4-[4-[5-amino-6-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]tetrahydropyran-4-carbonitrile **Compound I-9**

2-[4-[5-amino-6-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanamide **Compound I-10**

2-[4-[5-amino-6-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-N,N,2-trimethyl-propanamide **Compound I-11**

3-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]-5-[2-(1-methyl-1-methylsulfonyl-ethyl)-4-pyridyl]pyrazin-2-amine **Compound I-14**

3-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]-5-[2-(1-methylsulfonyl-ethyl)-4-pyridyl]pyrazin-2-amine **Compound I-15**

2-[4-[5-amino-6-[3-[4-[[[(3R)-tetrahydrofuran-3-yl]amino]methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile **Compound I-17**

2-[4-[5-amino-6-[3-[4-[(oxetan-3-ylamino)methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile **Compound I-18**

1-[4-[5-amino-6-[3-[4-[[[(3S)-tetrahydrofuran-3-yl]amino]methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]cyclopropanecarbonitrile **Compound I-34**

1-[4-[5-amino-6-[3-[4-[[[(3S)-tetrahydrofuran-3-yl]amino]methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]cyclobutanecarbonitrile **Compound I-35**

1-[4-[5-amino-6-[3-[4-[[[(3S)-tetrahydrofuran-3-yl]amino]methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]cyclopentanecarbonitrile **Compound I-36**


4-[4-[5-amino-6-[3-[4-[[[(3S)-tetrahydrofuran-3-yl]amino]methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]tetrahydropyran-4-carbonitrile **Compound I-42**

2-[4-[5-amino-6-[3-[4-[(cyclopropylamino)methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile **Compound I-48**

2-[4-[5-amino-6-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]propanenitrile **Compound I-49**

2-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]propanenitrile **Compound I-50**

Example 3a: Synthesis of 2-(4-(5-amino-6-(3-(4-(((tetrahydro-2*H*-pyran-4-yl)amino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-yl)pyridin-2-yl)-2-methylpropanenitrile **Compound I-53**




Step 1: A mixture of tert-butyl *N*-tert-butoxycarbonyl-*N*-[5-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]-3-ethynyl-pyrazin-2-yl]carbamate (300 mg, 0.6472 mmol), 4-(chloromethyl)-*N*-hydroxybenzimidoyl chloride (158.5 mg, 0.7766 mmol) and Et₃N (98.24 mg, 135.3 μ L, 0.9708 mmol) were stirred at ambient temperature for 60 hours. A further aliquot of 4-(chloromethyl)-*N*-hydroxybenzimidoyl chloride (50.0 mg, 0.2450 mmol) and Et₃N (36.30 mg, 50.0 μ L, 0.3587 mmol) were added and the reaction mixture stirred at ambient

temperature for a further 24 hours. The reaction mixture was partitioned between DCM and saturated aqueous NaHCO₃ and the layers separated. The aqueous layer was extracted with DCM (x 3) and the combined organic extracts dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was dissolved in DCM (10 mL) and TFA (2mL) was added. The reaction mixture was stirred at ambient temperature for 1 hour then concentrated *in vacuo*. The residue was partitioned between DCM and saturated aqueous NaHCO₃ and the layers separated. The aqueous layer was extracted with DCM (x 3) and the combined organic extracts dried (MgSO₄), filtered and concentrated *in vacuo* yielding 2-(4-(5-amino-6-(3-(4-(chloromethyl)phenyl)isoxazol-5-yl)pyrazin-2-yl)pyridin-2-yl)-2-methylpropanenitrile as a yellow solid that was used without further purification

Step 2: A mixture of 2-(4-(5-amino-6-(3-(4-(chloromethyl)phenyl)isoxazol-5-yl)pyrazin-2-yl)pyridin-2-yl)-2-methylpropanenitrile (280 mg, 0.6498 mmol) tetrahydropyran-4-amine (525.8 mg, 5.198 mmol) and DIPEA (251.9 mg, 339.5 μ L, 1.949 mmol) in ethanol (4 mL) were stirred at 120 °C in a microwave for 30 minutes. The reaction mixture was concentrated *in vacuo* and the residue partitioned between DCM and saturated aqueous NaHCO₃. The layers were separated and the aqueous layer extracted with DCM (x 3). The combined organic extracts were dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified by reverse phase preparative HPLC [Waters Sunfire C18, 10 mM, 100 Å column, gradient 10% - 95% B (solvent A: 0.05% trifluoroacetic acid in water; solvent B: acetonitrile) over 16 minutes at 25 mL/minutes], and the combined fractions were freeze-dried to give the di-TFA salt of 2-[4-[5-amino-6-[3-[4-[(tetrahydropyran-4-ylamino)methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile **Compound I-53** as a pale yellow powder (175 mg, 37% yield). ¹H NMR (400.0 MHz, DMSO-d₆) δ 9.06 (bs, 2H), 9.05 (s, 1H), 8.69 (d, J = 5.0 Hz, 1H), 8.20 (s, 1H), 8.11 (d, J = 8.3 Hz, 2H), 8.09 (dd, J = 4.8, 3.2 Hz, 1H), 7.83 (s, 1H), 7.72 (d, J = 8.3 Hz, 2H), 4.30 (t, J = 5.9 Hz, 2H), 3.96 (dd, J = 4.0, 11.1 Hz, 2H), 3.37 - 3.31 (m, 3H), 2.05 (dd, J = 2.3, 12.3 Hz, 2H), 1.80 (s, 6H) and 1.64 (m, 2H) ppm; LC/MS m/z 496.0 [M+H]⁺.

Example 4: Synthesis of 4-[4-[5-amino-6-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]tetrahydropyran-4-carboxamide **Compound I-13**




[00209] Step 1: 4-[4-[5-amino-6-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl] tetrahydropyran-4-carbonitrile (Trifluoroacetic Acid (1)) (18 mg, 0.03002 mmol) was dissolved in methanol (1 mL) and then 1 M sodium hydroxide solution (300.2 μ L of 1 M, 0.3002 mmol) was added. The reaction mixture was heated in the microwave to 100 °C for 45 minutes. The reaction mixture was diluted with water and extracted with ethyl acetate. The extracted organic layer was dried over MgSO_4 , filtered and concentrated *in vacuo* to a solid. Compound was purified by reverse phase preparative HPLC [Waters Sunfire C18, 10 mM, 100 Å column, gradient 10% - 95% B (solvent A: 0.05% trifluoroacetic acid in water; solvent B: acetonitrile) over 16 minutes at 25 mL/minutes], combined fractions were then freeze-dried to give 4-[4-[5-amino-6-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-yl]-2-pyridyl]tetrahydropyran-4-carboxamide **Compound I-13** as a yellow solid (6 mg, 31.37%). ^1H NMR (400.0 MHz, DMSO-d_6) δ 2.2 - 2.25 (m, 2H), 2.45 - 2.5 (m, 2H), 2.65 - 2.7 (m, 3H), 3.6 - 3.75 (m, 4H), 4.28 - 4.33 (m, 2H), 7.18 - 7.2 (m, 1H), 7.27 - 7.3 (m, 1H), 7.35 - 7.39 (m, 1H), 7.7 (d, 2H), 7.85 (s, 1H), 8.05 (d, 1H), 8.1 (s, 1H), 8.18 (d, 2H), 8.7 (d, 1H), 8.88 (br s, 2H), 9.05 (s, 1H); LC/MS m/z 486.2 $[\text{M}+\text{H}]^+$.

[00210] The following compounds were prepared using procedure analogous to that described above in example 3


2-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-2-methyl-propanamide
Compound I-45

Example 5: Synthesis of 3-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-1-methyl-piperidine-3-carbonitrile **Compound I-37**



[00211] Step 1: Iodomethane (17.09 mg, 7.496 μ L, 0.1204 mmol) was added to a stirred solution of 3-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]piperidine-3-carbonitrile (51 mg, 0.1204 mmol) and triethyl amine (30.46 mg, 41.96 μ L, 0.3010 mmol) in chloroform (1 mL) and the reaction stirred at ambient temperature for 23 hours. A further portion of iodomethane (213.6 mg, 93.68 μ L, 1.505 mmol) was added and the reaction stirred at ambient temperature for a further 5.5 hours. The solvent was removed *in vacuo* and the residue re-dissolved in dichloromethane and filtered. The filtrate was concentrated *in vacuo* and the residue purified by reverse phase preparative HPLC [Waters Sunfire C18, 10 μ M, 100 Å column, gradient 0% - 100% B (solvent A: 10 mM ammonium formate in water; solvent B: 10 mM ammonium formate in 1:1 MeOH: CH₃ CN) over 14 minutes at 25 mL/min]. The relevant fractions were concentrated *in vacuo* and partitioned between dichloromethane/saturated aqueous sodium bicarbonate. The layers were separated and the aqueous layer extracted with dichloromethane (x 3). The combined organic extracts were dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was freeze-dried to give 3-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-1-methyl-piperidine-3-carbonitrile **Compound I-37** as a yellow solid (14.1 mg, 27% Yield). ¹H NMR (400.0 MHz, DMSO-d₆) δ 1.96 - 1.71 (m, 4H), 2.20 (s, 3H), 2.21 - 2.19 (m, 1H), 2.68 (br d, 1H), 2.75 (br d, 1H), 3.22 - 3.20 (m, 1H), 7.21 (br s, 2H), 7.51 - 7.44 (m, 3H), 7.68 (s, 1H), 7.94 - 7.91 (m, 2H), 8.00 (dd, 1H), 8.12 (s, 1H), 8.59 (d, 1H) and 8.93 (s, 1H) ppm LC/MS m/z 438.2 [M+H]⁺.

Example 6: Synthesis of 2-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-N-(2-hydroxy ethyl)-2-methyl-propanamide **Compound I-46**




[00212] Step 1: 2-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile (90 mg, 0.2353 mmol) was added to methanol (3 mL) followed by the addition of 1 M sodium hydroxide (705.9 μ L of 1 M, 0.7059 mmol). The mixture was heated in the microwave for 90 minutes at 110 $^{\circ}$ C. The reaction was cooled to ambient temperature and diluted with ethyl acetate/water. The organic layer was washed with brine (x 1). The aqueous layer was acidified to pH3 with 1 M hydrochloric acid, extracted with ethyl acetate (x 3) and the combined organic extracts washed with brine (x 1). The extracted organic layer was dried over MgSO_4 , filtered and concentrated *in vacuo* to yield 2-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-2-methyl-propanoic acid as white solid (40 mg, 42%) LC/MS m/z 401.1 $[\text{M}+\text{H}]^+$.

[00213] Step 2: (benzotriazol-1-yloxy-dimethylamino-methylene)-dimethyl-ammonium tetrafluoroborate (10.40 mg, 0.03239 mmol) was added to a stirred solution of 2-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-2-methyl-propanoic acid (13 mg, 0.03239 mmol), diisopropyl ethyl amine (5.442 mg, 7.334 μ L, 0.04211 mmol) and 2-aminoethanol (9.895 mg, 9.778 μ L, 0.1620 mmol) in dichloromethane (15 mL) and the reaction allowed to stir at ambient temperature for 1 hour. The reaction was diluted with ethyl acetate/brine. The aqueous layer was extracted with ethyl acetate (x 1) and the combined organic extracts washed with brine (x 1). The organic extracts were then dried over MgSO_4 , filtered and concentrated *in vacuo*. Compound was purified by reverse phase preparative HPLC [Waters Sunfire C18, 10 mM, 100 $\text{\AA}$ column, gradient 10% - 95% B (solvent A: 0.05% trifluoroacetic acid in water; solvent B: acetonitrile) over 16 minutes at 25 mL/minutes], combined fractions were then freeze-dried to give 2-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-N-(2-hydroxyethyl)-2-methyl-propanamide **Compound I-46** as a yellow solid (4 mg, 21.67%). ^1H NMR (400.0 MHz, MeOD) δ 1.8 (s, 6H), 3.4 (t, 2H), 3.7 (t, 2H), 7.53 - 7.57 (m, 3H), 7.62 (s, 1H), 8.0 - 8.05 (m, 2H), 8.42 (d, 1H), 8.48 (s, 1H), 8.7 (d, 1H), 9.03 (s, 1H); LC/MS m/z 445.1 $[\text{M}+\text{H}]^+$.

[00214] The following Compound were prepared using procedure analogous to that described above 2-[4-[5-amino-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl]-2-pyridyl]-1-(azetidin-1-yl)-2-methyl-propan-1-one **Compound I-47** ^1H NMR (400.0 MHz, MeOD) δ 1.7 (6H, s), 1.9 - 1.95 (2H, m), 3.7 - 3.75 (2H, m), 3.85 - 3.9 (2H, m), 7.55 - 7.58 (3H, m), 7.67 (1H, s), 8.05 - 8.1 (2H, m), 8.35 - 8.4 (2H, m), 8.68 (1H,d), 9.1 (1H, s). LC/MS m/z 441.2 $[\text{M}+\text{H}]^+$.

SCHEME B



[00215] Scheme B depicts general methods for making compounds of Formula **I-C** and **I-D** where ring **A** is oxadiazole. Compound **B-i** preferably the methyl ester, is reacted with hydrazine to form the acyl hydrazide **B-ii**. From intermediates of Formula **B-ii** and an appropriately substituted benzoic acid, the corresponding coupled carbohydrazide **B-iii** is obtained using a base. Cyclisation of intermediates of Formula **B-iii** can be obtained using reagents such as, but not limited to, PPh_3Br_2 , POCl_3 or T3P® to give the corresponding 1,3,4-oxadiazole **B-iv**. The pyridine ring system is introduced at position 5 of the aminopyrazine

core, under metal-mediated coupling conditions, including but not limited to Suzuki coupling of **B-iv** with an appropriate boronic acid/ester to provide compounds of Formula **I-C** of this invention in which ring A is oxadiazole.

[00216] In a slightly different sequence, intermediates of Formula **B-ii** react with appropriate coupling partners (e.g. boronic acid/ester) utilising the metal-mediated coupling conditions described above to form intermediates of formula **B-vi**. From intermediates of Formula **B-vi** and an appropriately substituted benzoic acid, the corresponding coupled carbohydrazide **B-vii** is obtained using a base. Cyclisation of intermediates of Formula **B-vii** can be obtained using reagents such as, but not limited to, PPh_3Br_2 , POCl_3 or T3P®, to give the corresponding 1,3,4-oxadiazole **I-C** of this invention in which ring A is oxadiazole.

[00217] Intermediates of Formula **B-iv** may be protected with a suitable amine protecting group PG such as, but not limited to BOC (*tert*-butoxycarbonyl), to give intermediates of Formula **B-v**. Intermediates of Formula **B-v** may then undergo metal-mediated coupling conditions as described above with the appropriate pyridine boronic acid/ester to give intermediates of Formula **B-viii**. Removal of the amine protecting group(s) PG from intermediates of Formula **B-viii** takes place under standard conditions known to those skilled in the art such as, but not limited to, treatment with HCl or TFA (in case of a BOC protecting group) to provide compounds of Formula **I-C** of this invention in which ring A is oxadiazole.

[00218] In a slightly different sequence, intermediates of Formula **B-ii** react with an appropriately substituted benzoic acid which is functionalised with the appropriate leaving group (X), to give the corresponding coupled carbohydrazide **B-ix** using a base. Suitable leaving groups include but are not limited to halogens, mesylates or triflates. Cyclisation of intermediates of Formula **B-ix** can be obtained using reagents such as, but not limited to, PPh_3Br_2 , POCl_3 or T3P®, to give the corresponding 1,3,4-oxadiazole **B-x**. Intermediates of Formula **B-x** are then protected with a suitable amine protecting group PG such as, but not limited to BOC, to give intermediates of Formula **B-xi**. Intermediates of Formula **B-xi** may then undergo metal-mediated coupling conditions as described above with the appropriate pyridine boronic acid/ester to give intermediates of Formula **B-xv**. Oxadiazole intermediate **B-xv** may be further functionalised through the nucleophilic displacement of the leaving group (X) with the amine HNR_3R_4 (R_3/R_4 can be but are not limited to alkyl, H or PG) to form intermediates of Formula **B-xvi**. Removal of the amine protecting group(s) PG from


intermediates of Formula **B-xvi** may take place under standard conditions described above to provide compounds of Formula **I-D** of this invention where ring A is oxadiazole.

[00219] Oxadiazole intermediates **B-x** and **B-xi** can be further functionalised through the nucleophilic displacement of the leaving group (X) with the amine HNR_3R_4 (R_3/R_4 can be but are not limited to alkyl, H or PG) to form intermediates of Formula **B-xii** and **B-xiv** respectively. Intermediate **B-xii** is then protected with a suitable amine protecting group PG such as, but not limited to BOC, to give intermediates of Formula **B-xiv**. Intermediates of Formula **B-xiv** may then undergo metal-mediated coupling conditions as described above with the appropriate pyridine boronic acid/ester to give intermediates of Formula **B-xvi**. In a slightly different sequence, removal of the amine protecting group(s) PG from intermediates of Formula **B-xiv** may take place under standard conditions described above to provide intermediates of Formula **B-xii**. Intermediates of Formula **B-xii** may then undergo metal-mediated coupling conditions as described above with the appropriate pyridine boronic acid/ester to give compounds of Formula **I-D** of this invention where ring A is oxadiazole.

[00220] In a slightly different sequence, Intermediates of Formula **B-x** may then undergo metal-mediated coupling conditions as described above with the appropriate pyridine boronic acid/ester to give intermediates of Formula **B-xiii**. Oxadiazole intermediate **B-xiii** may be further functionalised through the nucleophilic displacement of the leaving group (X) with the amine HNR_3R_4 (R_3/R_4 can be but are not limited to alkyl, H or PG) to provide compounds of Formula **I-D** of this invention where ring A is oxadiazole.

[00221] Preparations 9 – 17 and Example 7 relate to Scheme B


Preparation 9. Synthesis of 3-amino-6-bromopyrazine-2-carbohydrazide



[00222] Step 1: To a suspension of methyl 3-amino-6-bromo-pyrazine-2-carboxylate (2.5 g, 10.8 mmol) in ethanol (50 mL) was added hydrazine hydrate (3.2 g, 3 mL, 64.6 mmol) and the reaction mixture heated at 70 °C for 1.5 hours forming a thick yellow solid. The reaction mixture was filtered and the solid washed with water (20 mL) and ethanol (40 mL). The solid was dried *in vacuo* to yield 3-amino-6-bromo-pyrazine-2-carbohydrazide (2.7 g,

94% yield) as a light yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ 4.53 (d, J = 3.5 Hz, 2H), 7.62 (s, 2H), 8.31 (s, 1H) and 9.78 (s, 1H) ppm; LC/MS m/z 233.1 $[\text{M}+\text{H}]^+$

Preparation 10. Synthesis of *tert*-butyl *N*-[[4-[5-(3-amino-6-bromo-pyrazin-2-yl)-1,3,4-oxadiazol-2-yl] phenyl]methyl]-*N*-methyl-carbamate




[00223] Step 1: 3-amino-6-bromo-pyrazine-2-carbohydrazide (12.91 g, 55.64 mmol), 4-[[*tert*-butoxycarbonyl (methyl)amino]methyl]benzoic acid (14.76 g, 55.64 mmol) and triethylamine (12.39 g, 17.07 mL, 122.4 mmol) were suspended in *N,N*-dimethylformamide (200 mL) and stirred at ambient temperature for 30 minutes. A further 3-amino-6-bromo-pyrazine-2-carbohydrazide (3 g, 12.93 mmol) was added and left to stir for 18 hours at ambient temperature. The reaction mixture was concentrated *in vacuo* to remove most of the *N,N*-dimethylformamide. The residue was then diluted with ethyl acetate and water. The organic layer was separated and washed with saturated aqueous sodium bicarbonate solution followed by a brine wash. The organic extracts were dried over MgSO_4 , filtered and concentrated *in vacuo* to a yellow sticky solid. The solid was triturated with ethyl acetate to give a beige solid (this is the hydrazide starting material), the crude mother liquors were concentrated and purified by column chromatography (ISCO Companion XL, 330 g gold column) dry loaded and eluted with 30 to 70% ethyl acetate/petroleum ether to give a yellow sticky gum. This gum was then crystallised from petroleum ether to give *tert*-butyl 4-(2-(3-amino-6-bromopyrazine-2-carbonyl)hydrazinecarbonyl)benzyl(methyl)carbamate as a yellow powder (14.16 g, 53% yield). ^1H NMR (400 MHz, DMSO- d_6) δ 1.16 - 1.20 (m, 1H), 1.38 - 1.45 (br d, 9H), 2.80 (br s, 3H), 4.02 - 4.04 (m, 1H), 4.45 (s, 2H), 7.34 (d, 2H), 7.69 (br s, 2H), 7.89 (d, 2H), 8.44 (s, 1H) ppm.

[00224] Step 2. *tert*-butyl *N*-[[4-[[3-amino-6-bromo-pyrazine-2-carbonyl)amino]carbonyl]phenyl]methyl]-*N*-methyl-carbamate (7.66g, 15.98 mmol) was dissolved in dry acetonitrile (114.9 mL) and cooled in an ice bath and put under a nitrogen atmosphere. Diisopropylethylamine (6.196 g, 8.350 mL, 47.94 mmol) was added via a syringe followed by dibromo(triphenyl)phosphorane (8.767 g, 20.77 mmol) portion wise. Reaction mixture started to precipitate out therefore left to stir for 45 minutes in an ice bath and isolated precipitated product by filtration as a beige powder (4.5 g). This material was then sonicated, triturated in acetonitrile, filtered and dried to give the sub-titled compound as yellow solid. (3.17 g, 40.9%). ^1H NMR (400 MHz, DMSO- d_6) δ 1.38 - 1.45 (br d, 9H), 2.80

(s, 3H), 4.45 (s, 2H), 7.48 - 7.51 (br s, 2H), 7.80 (br s, 2H), 8.10 - 8.20 (m, 2H), 8.45 (s, 1H) ppm; LC/MS m/z 463.1, 464.2 [M+H]⁺.

Preparation 11. Synthesis of tert-butyl 6-[[[3-amino-6-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]pyrazine-2-carbonyl]amino]carbamoyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate




[00225] Step 1: 2-(4-iodo-2-pyridyl)-2-methyl-propanenitrile (100 mg, 0.3675 mmol), PdCl₂(PCy₃)₂ (20.87 mg, 0.02827 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (96.90 mg, 0.3816 mmol), potassium acetate (83.23 mg, 0.8481 mmol) in 1,4-dioxane (1.615 mL). The reaction mixture was degassed with 5 x vacuum/nitrogen cycles then heated at 110 °C for 4 hours. 3-amino-6-bromo-pyrazine-2-carbohydrazide (65.60 mg, 0.2827 mmol), potassium carbonate (136.7 mg, 0.9894 mmol), [PdCl₂(dppf)].dichloromethane (23.09 mg, 0.02827 mmol) and water (0.89 mL) was added and the mixture was heated at 100 °C for 18 hours. The reaction mixture was concentrated *in vacuo*. The residue was partitioned between dichloromethane and water. Combined organic extract were dried over MgSO₄ and concentrated *in vacuo* yielding an oil. Purified by silica gel chromatography eluted with 5% methanol/dichloromethane. Product fractions were combined and concentrated *in vacuo* to yield 3-amino-6-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]pyrazine-2-carbohydrazide as a beige solid (49.5 mg, 57.1%) LC/MS m/z 298.1 [M+H]⁺.

[00226] Step 2: 3-amino-6-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]pyrazine-2-carbohydrazide (49.5 mg, 0.1665 mmol), 2-tert-butoxycarbonyl-3,4-dihydro-1H-isoquinoline-6-carboxylic acid (50.80 mg, 0.1832 mmol), diisopropyl ethyl amine (25.82 mg, 34.80 µL, 0.1998 mmol) and (benzotriazol-1-yloxy-dimethylamino-methylene)-dimethyl-ammonium tetrafluoroborate (58.82 mg, 0.1832 mmol) was stirred at ambient temperature in N,N-dimethyl formamide (495.0 µL) for 1 hour. The reaction mixture was partitioned between water and ethyl acetate. The combined organic extracts were washed with aqueous saturated sodium bicarbonate, then 0.5 N hydrochloric acid, followed by brine. The organic


extracts were then dried over MgSO_4 and concentrated *in vacuo* to give the sub-titled product. (92 mg, 99.27%) LC/MS m/z 557.2 $[\text{M}+\text{H}]^+$.

Preparation 12. Synthesis of *tert*-butyl 6-(5-(3-amino-6-(2-(2-cyanopropan-2-yl)pyridin-4-yl)pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)-3,4-dihydroisoquinoline-2(1*H*)-carboxylate




[00227] Step 1: PS-PPh₃ (145.6 mg, 0.3042 mmol) was suspended in dichloromethane (6.269 mL). Iodine (77.21 mg, 15.66 μL , 0.3042 mmol) was added and the mixture was stirred for 10 minutes before triethyl amine (63.10 mg, 86.91 μL , 0.6236 mmol) was added. After 5 minutes *tert*-butyl 6-[[[3-amino-6-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]pyrazine-2-carbonyl]amino]carbamoyl]-3,4-dihydro-1*H*-isoquinoline-2-carboxylate (92 mg, 0.1521 mmol) was added as a solution in dichloromethane (3.919 mL) the mixture was stirred at ambient temperature for 1 hour. The resin was filtered off and the filtrate was washed with aqueous saturated sodium bicarbonate. The extracted organic phase was then dried over MgSO_4 and concentrated *in vacuo*. The residue was taken onto the next step as is. (118.7 mg, assumed 100% yield). LC/MS m/z 539.2 $[\text{M}+\text{H}]^+$.

Preparation 13. Synthesis of *tert*-butyl *N*-[[4-[5-[3-amino-6-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]pyrazin-2-yl]-1,3,4-oxadiazol-2-yl]phenyl]methyl]-*N*-methyl-carbamate



[00228] Step 1: To a solution of 2-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]propane nitrile (103 mg, 0.3784 mmol) in dioxane (1.133 mL) was added of *tert*-butyl *N*-[[4-[5-(3-amino-6-bromo-pyrazin-2-yl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-*N*-methyl-carbamate (174.6 mg, 0.3784 mmol) and reaction was treated with 2 M aqueous solution of sodium carbonate (567.5 μ L of 2 M, 1.135 mmol). The reaction mixture was degassed with 5 x vacuum/nitrogen cycles. Then $\text{Pd}(\text{PPh}_3)_4$ (43.85 mg, 0.03795 mmol) was added to the reaction mixture. The reaction mixture was degassed further with 5 x vacuum/nitrogen cycles and the reaction mixture was stirred in a microwave at 150 °C for 30 minutes. The reaction was diluted with ethyl acetate and aqueous sodium bicarbonate solution. The organic extracts were separated and washed with brine (x 1), dried over MgSO_4 , filtered and concentrated *in vacuo* to give a black oil. Taken onto the next step without further purification (199.3 mg, assumed 100% yield).

Example 7. Synthesis of 2-[4-[5-amino-6-[5-[4-(methylaminomethyl)phenyl]-1,3,4-oxadiazol-2-yl] pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile **Compound I-4**



[00229] Step 1: *tert*-butyl *N*-[[4-[5-[3-amino-6-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]pyrazin-2-yl]-1,3,4-oxadiazol-2-yl]phenyl]methyl]-*N*-methyl-carbamate (199.3 mg, 0.3785 mmol) was dissolved in dichloromethane (5 mL) followed by the addition of trifluoroacetic acid (500 μ L, excess). The mixture was stirred at ambient temperature for 2

hours and then concentrated *in vacuo* to an oil. Azeotroped with dichloromethane/methanol. Compound was purified by reverse phase preparative HPLC [Waters Sunfire C18, 10 mM, 100 Å column, gradient 10% - 95% B (solvent A: 0.05% trifluoroacetic acid in water; solvent B: acetonitrile) over 16 minutes at 25 mL/minutes], combined fractions were then freeze-dried to give 2-[4-[5-amino-6-[5-[4-(methylaminomethyl)phenyl]-1,3,4-oxadiazol-2-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile **Compound I-4** as a pale yellow powder (mono trifluoroacetic acid salt) (88.6 mg, 43.32% yield). ¹H NMR (400.0 MHz, DMSO-d₆) δ 1.80 (s, 6H), 2.64 (t, J = 5.0 Hz, 3H), 4.28 (t, J = 5.4 Hz, 2H), 7.76 (d, J = 8.3 Hz, 2H), 8.12 (dd, J = 1.5, 5.3 Hz, 1H), 8.25 (d, J = 8.3 Hz, 2H), 8.41 (s, 1H), 8.73 (d, J = 5.2 Hz, 1H), 8.91 (s, 2H) and 9.18 (s, 1H) ppm; LC/MS m/z 427.0 [M+H]⁺.

[00230] The following compounds were prepared using procedure analogous to that described above in preparation 10, 13 and example 7.


1-[4-[5-amino-6-[5-[4-[(1S)-1-aminoethyl]phenyl]-1,3,4-oxadiazol-2-yl]pyrazin-2-yl]-2-pyridyl]cyclobutanecarbonitrile **Compound I-43**

2-[4-[5-amino-6-[5-[4-[(1S)-1-aminoethyl]phenyl]-1,3,4-oxadiazol-2-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile **Compound I-44**

[00231] The following compounds were prepared using procedure analogous to that described above in preparation 12 and example 7


2-[4-[5-amino-6-[5-(1,2,3,4-tetrahydroisoquinolin-6-yl)-1,3,4-oxadiazol-2-yl]pyrazin-2-yl]-2-pyridyl]-2-methyl-propanenitrile **Compound I-52**

Preparation 13. Synthesis of 5-bromo-3-[5-[4-(bromomethyl)phenyl]-1,3,4-oxadiazol-2-yl]pyrazin-2-amine



[00232] Step 1: A 1 L 3 neck round bottom flask was fitted with a mechanical stirrer, a cooling bath used as secondary containment, an addition funnel, a J-Kem temperature probe and a nitrogen inlet/outlet. The vessel was charged under nitrogen with 3-amino-6-bromopyrazine-2-carbohydrazide (12 g, 51.72 mmol), 4-(bromomethyl)benzoic acid (11.12 g, 51.72 mmol) and acetonitrile (460 ml, 20 ml/g based on the mass of the two reagents). Stirring was commenced and the pot temperature was recorded at 21 °C. The suspension was then treated with dibromo(triphenyl)phosphorane (98.22 g, 232.7 mmol) added as a solid in one portion. The suspension was continued to stir at ambient temperature for 1 hour. The addition funnel was then charged with diisopropylethylamine (54 ml, 310.3 mmol) which was added neat drop wise over 1 hour, which resulted in an exotherm to 30 °C. The resulting light brown suspension was continued to stir at ambient temperature for 20 hours. The reaction mixture was vacuum filtered through a glass frit buchner funnel and the filter cake was displacement washed with acetonitrile (2 x 150 ml) followed by hexane (250 ml). The material was further dried under vacuum to provide the product 5-bromo-3-(5-(4-(bromomethyl)phenyl)-1,3,4-oxadiazol-2-yl)pyrazin-2-amine as a yellow solid (16.4 g, 39.89 mmol, 77% yield). ¹H NMR (400.0 MHz, DMSO-d₆) δ 4.82 (s, 2H), 7.72 (d, J = 8.2 Hz, 2H), 7.80 (s, 2H), 8.11 (d, J = 8.1 Hz, 2H), 8.45 (s, 1H)


Preparation 14. Synthesis of *tert*-butyl *N*-[5-bromo-3-[5-[4-(bromomethyl)phenyl]-1,3,4-oxadiazol-2-yl] pyrazin-2-yl]-*N*-*tert*butoxy carbonyl-carbamate



[00233] Step 1: To a mixture of 5-bromo-3-[5-[3-(bromomethyl)phenyl]-1,3,4-oxadiazol-2-yl]pyrazin-2-amine (1.0 g, 2.43 mmol) and dimethylaminopyridine (30 mg, 0.24 mmol) in tetrahydrofuran (31 mL) was added di *tert* butyl dicarbonate (2.2 g, 2.3 mL, 9.73 mmol). The reaction mixture was heated at 50 °C for 3 hours, then allowed to cool to room temperature and partitioned between ethyl acetate and 1 M hydrogen chloride. The organic layer was washed with saturated aqueous bicarbonate solution and brine. The organic layer was extracted, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography loaded with dichloromethane and eluted with 0


to 10% ethyl acetate/hexanes. Product fractions were combined and concentrated *in vacuo* to give *tert*-butyl *N*-[5-bromo-3-[5-[3-(bromomethyl)phenyl]-1,3,4-oxadiazol-2-yl]pyrazin-2-yl]-*N**tert*-butoxycarbonyl-carbamate (0.7 g, 45%) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 1.29 (s, 18H), 4.88 (s, 2H), 7.68 (t, $J = 7.8$ Hz, 1H), 7.79 (d, $J = 8.0$ Hz, 1H), 8.07 (d, $J = 7.7$ Hz, 1H), 8.22 (s, 1H) and 9.7 (d, $J = 5.3$ Hz, 1H); LC/MS m/z 512.5, 412.3 $[\text{M}+\text{H}]^+$.

Preparation 15. Synthesis of 5-bromo-3-[5-[4-(methylaminomethyl)phenyl]-1,3,4-oxadiazol-2-yl]pyrazin-2-amine



[00234] Step 1: 5-bromo-3-[5-[4-(bromomethyl)phenyl]-1,3,4-oxadiazol-2-yl]pyrazin-2-amine (100 mg, 0.2433 mmol) and sodium carbonate (77.36 mg, 0.7299 mmol) were suspended in and treated with methanamine (182.5 μL of 2 M, 0.3650 mmol). The reaction was heated at 60 $^{\circ}\text{C}$ for 10 minutes. The remaining excess of methanamine (425.8 μL of 2 M, 0.8515 mmol) was then added and the reaction heated at 60 $^{\circ}\text{C}$ for a further 10 minutes. The reaction was cooled, diluted with water and extracted into dichloromethane. The organic layer was dried over Na_2SO_4 , filtered and concentrated *in vacuo* to yield 5-bromo-3-[5-[4-(methylaminomethyl)phenyl]-1,3,4-oxadiazol-2-yl]pyrazin-2-amine (75 mg, 0.2076 mmol, 85.34%) as a yellow solid. LC/MS m/z 362.3 $[\text{M}+\text{H}]^+$.

Preparation 16. Synthesis of *tert*-butyl *N*-[[4-[5-[3-[bis(*tert*-butoxycarbonyl)amino]-6-bromopyrazin-2-yl]-1,3,4-oxadiazol-2-yl]phenyl]methyl]-*N*-methyl-carbamate




[00235] Step 1: *Tert*-butoxycarbonyl *tert*-butyl carbonate (2.115 g, 2.226 mL, 9.690 mmol) was added to a stirred solution of 5-bromo-3-[5-[4-(methylaminomethyl)phenyl]-1,3,4-oxadiazol-2-yl]pyrazin-2-amine (700 mg, 1.938 mmol) and *N,N*-dimethylpyridin-4-

amine (23.68 mg, 0.1938 mmol) in anhydrous tetrahydrofuran (20.00 mL) at ambient temperature. The reaction mixture was allowed to stir at this temperature for 2 hours. The solvent was removed *in vacuo*. The residue was purified by column chromatography (ISCO Companion, 40 g column) loaded with dichloromethane and eluted with 0 to 50% ethyl acetate/petroleum ether. Product fractions were combined and concentrated *in vacuo* to give the sub-titled product as an off-white solid (679 mg, 53% yield). ^1H NMR (400.0 MHz, DMSO) δ 1.13 (s, 18H), 1.21 - 1.30 (2 x s, 9H), 2.68 (s, 3H), 4.34 (s, 2H), 7.34 (d, 2H), 7.96 (d, 2H) and 9.00 (s, 1H) ppm.

[00236] Compounds I-54 to I-134 can be made according to the methods disclosed in Scheme A (for isoxazoles) or Scheme B (oxadiazoles).

SCHEME C



[00237] Scheme C depicts general methods for the preparation of intermediates of the Formula **C-viii** and **C-ix** of this invention where the parameter Z of the claim is a nitrile and an amide respectively. Compound **C-i** is reacted with an alkyl nitrile under coupling conditions using a base such as but not limited to NaHMDS to give intermediates of Formula **C-ii**, **C-iii** or **C-iv**. Under basic conditions, **C-ii** can be further functionalised into **C-iii** or **C-iv**. Additionally, under basic conditions, **C-iii** can be further functionalised into **C-iv**. Intermediates of Formula **C-ii**, **C-iii** and **C-iv** are converted to the corresponding boronic


acid/ester **C-viii** utilising standard conditions known to those skilled in the art such as, but not limited to, treatment with bis(pinacolato)diboron, Pd-catalyst and a base.

[00238] Intermediates of Formula **C-ii**, **C-iii** and **C-iv** can also be subjected to hydrolysis in the presence of a base such as, but not limited to NaOH to give acid intermediate of Formula **C-v**. Intermediates of Formula **C-v** are reacted with an amine NHR_3R_4 (R_3/R_4 can be but are not limited to alkyl, H or PG) using standard amide coupling conditions known to those skilled in the art such as, but not limited to, treatment with TBTU and a base to provide intermediates of Formula **C-vi**. Intermediates of Formula **C-vi** are then converted to the corresponding boronic acid/ester **C-ix** utilising standard conditions described above.

[00239] In a slightly different sequence, intermediates of Formula **C-ii**, **C-iii** and **C-iv** can be subjected to aminolysis, in the presence of an amine, to provide intermediates of Formula **C-vii**. Intermediates of Formula **C-vii** may then be converted to the corresponding boronic acid/ester **C-ix** utilising standard conditions described above.

Preparation 17 – 22 relate to Scheme C


Preparation 17. Synthesis of 2-(4-iodo-2-pyridyl)-2-methyl-propanenitrile



[00240] Step 1: An oven-dried flask was evacuated and back-filled with nitrogen three times. The flask was charged with 2-chloro-4-iodo-pyridine (3 g, 12.53 mmol) and isobutyronitrile (865.9 mg, 1.125 mL, 12.53 mmol) in anhydrous toluene (30.00 mL). The reaction mixture was cooled to 0°C and treated with bis(trimethylsilyl)azanide in tetrahydrofuran (sodium ion (1)) (12.53 mL of 1 M, 12.53 mmol) over a period of 5 minutes. The reaction mixture was allowed to warm to ambient temperature and stirred at this temperature for 3 hours. The reaction mixture was diluted with ethyl acetate and washed with 1 M hydrochloric acid. The aqueous layer was extracted with ethyl acetate (x 3) and the combined organic extracts dried MgSO_4 , filtered and concentrated *in vacuo*. The residue was purified by column chromatography (ISCO Companion, 80 g column) loaded with dichloromethane and eluted with 0 to 30% ethyl acetate/petroleum ether. Product fractions

were combined and concentrated *in vacuo* to give the sub-title product as an off-white solid (2.22 g, 65% Yield). ^1H NMR (400.0 MHz, DMSO- d_6) δ 1.70 (s, 6H), 7.84 (dd, 1H), 7.98 (d, 1H) and 8.31 (d, 1H) ppm; LC/MS m/z 273.0 $[\text{M}+\text{H}]^+$


Preparation 17-1. Synthesis of 2-(3-fluoro-4-iodopyridin-2-yl)-2-methylpropanenitrile



[00241] Step 1: [bis(trimethylsilyl)amino]sodium (32.46 mL of 1 M, 32.46 mmol) was slowly added to solution of 2-chloro-3-fluoro-pyridine (4270 mg, 32.46 mmol) and 2-methylpropanenitrile (2.243 g, 2.913 mL, 32.46 mmol) in toluene (100mL) at 0C. The mixture was stirred 1h at 0C then quenched with a saturated aqueous solution of NH_4Cl . Layers were separated and the organic extract was dried and concentrated in vacuo. The residue was purified by chromatography on silica (PE/EtOAc 9/1 to 1/1) yielding a pale yellow oil.


[00242] Step 2: (diisopropylamino)lithium (670 μL of 1 M, 0.67 mmol) was added to a solution of 2-(3-fluoro-2-pyridyl)-2-methyl-propanenitrile (100 mg, 0.6091 mmol) in THF (3 mL) at -78 C. The mixture was stirred for 2h at -78C then a THF (1 mL) solution of I_2 (170.1 mg, 34.50 μL , 0.6700 mmol) was added. At the end of the addition decoloration was complete. A saturated solution of NH_4Cl was added and the reaction mixture was stirred at RT overnight. The reaction mixture was concentrated in vacuo, the residue partitioned between DCM and water and combined organic extract was dried (MgSO_4) and concentrated in vacuo, yielding an oil that was purified by chromatography on silica (PE/EtOAc 9/1 to 1/1). The title product was obtained as a white powder. The title product can be used in the preparation of Compounds I-138 and I-139.

Preparation 18. Synthesis of 2-ethyl-2-(4-iodo-2-pyridyl)butanenitrile




[00243] Step 1: Crude 2-(4-iodo-2-pyridyl)butanenitrile (270 mg, 0.9923 mmol) was added to a solution of iodoethane (309.6 mg, 158.8 μ L, 1.985 mmol) and bis(trimethylsilyl)azanide (sodium ion (1)) (992.3 μ L of 1 M, 0.9923 mmol) in toluene (2 mL) at 0 °C. The solution was stirred at 0 °C for 10 minutes. Reaction mixture was diluted with water and the product extracted with dichloromethane (x3). Organic extracts were combined, dried over MgSO_4 , filtered and concentrated *in vacuo*. (297.8 mg, assumed 100% yield). LC/MS m/z 301.02 $[\text{M}+\text{H}]^+$

Preparation 19. Synthesis of 2-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl] propanenitrile




[00244] Step 1: 2-(4-iodo-2-pyridyl)-2-methyl-propanenitrile (78.88 mg, 0.2899 mmol) was dissolved in dioxane (1 mL) and bis(pinacolato)diboron (36.82 mg, 0.1450 mmol) and potassium acetate (28.45 mg, 0.2899 mmol) were added. The reaction mixture was degassed with 5 x vacuum/nitrogen cycles then $[\text{PdCl}_2(\text{dppf})]$.dichloromethane (7.864 mg, 0.009630 mmol) was added and the reaction heated to 90 °C for 16 hours. The reaction mixture was cooled to ambient temperature and taken onto the next step as is. (78.90 mg, assumed 100% yield). LC/MS m/z 272.99 $[\text{M}+\text{H}]^+$

Preparation 20. Synthesis of 2-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl] propanenitrile



[00245] Step 1: 2-(4-iodo-2-pyridyl)-2-methyl-propanenitrile (1.8 g, 6.616 mmol) was dissolved in methanol (20.00 mL) followed by the addition of aqueous 1 M sodium hydroxide (33.08 mL of 1 M, 33.08 mmol). The mixture was heated in the microwave at 100 °C for 2 hours. The mixture was diluted with ethyl acetate and water. The organic layer was washed with brine. The aqueous layer was slowly acidified with 1 M hydrochloric acid to pH3 and extracted with ethyl acetate (x 2). The organic layer was separated, washed with a small amount of brine, collected, dried over MgSO₄, filtered and concentrated *in vacuo* to a solid. (600 mg, 31.15%). LC/MS m/z 292.1 [M+H]⁺.

Preparation 21. Synthesis of *tert*-butyl 4-[2-(4-iodo-2-pyridyl)-2-methyl-propanoyl]piperazine-1-carboxylate



[00246] Step 1: 2-(4-iodo-2-pyridyl)-2-methyl-propanoic acid (100 mg, 0.3435 mmol) was added to dichloromethane (5 mL) followed by the addition of [benzotriazol-1-yloxy(dimethylamino)methylene]-dimethyl-ammonium tetrafluoroborate (110.3 mg, 0.3435 mmol), diisopropyl ethyl amine (88.79 mg, 119.7 µL, 0.6870 mmol) and *tert*-butyl piperazine-1-carboxylate (83.18 mg, 0.4466 mmol). Some *N,N*-dimethylformamide (1 ml) was added to help dissolution. The mixture was stirred at ambient temperature for 1 hour. The mixture was diluted with dichloromethane, washed with water (x 2). The extracted organic layer was dried over MgSO₄, filtered and concentrated *in vacuo* to a solid. The residue was purified by column chromatography (ISCO Companion, 80 g column) loaded with dichloromethane and eluted with 100% diethyl ether. Product fractions were combined and concentrated *in vacuo* to give the sub-title product as an off-white solid (90 mg, 57.03% Yield). LC/MS m/z 460.1 [M+H]⁺


[00247] The following Iodopyridine intermediates were prepared using procedures analogous to that described above and then converted to the respective boronates *in situ* using preparation 22

tert-butyl N-[3-[[2-(4-iodo-2-pyridyl)-2-methyl-propanoyl]amino]propyl]carbamate LC/MS m/z 448.20 $[M+H]^+$.

2-(4-iodo-2-pyridyl)-N-(2-methoxyethyl)-2-methyl-propanamide LC/MS m/z 349.0 $[M+H]^+$.


2-(4-iodo-2-pyridyl)-2-methyl-N-(2-morpholinoethyl)propanamide LC/MS m/z 404.1 $[M+H]^+$.

Preparation 22. Synthesis of *tert*-butyl 4-(2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)propanoyl)piperazine-1-carboxylate



[00248] Step 1: *tert*-butyl 4-[2-(4-iodo-2-pyridyl)-2-methyl-propanoyl]piperazine-1-carboxylate (100 mg, 0.2177 mmol) was dissolved in dioxane (1.369 mL) followed by the addition of bis(pinacolato)diboron (110.6 mg, 0.4354 mmol) and potassium acetate (64.10 mg, 0.6531 mmol). The reaction mixture was degassed with 5 x vacuum/nitrogen cycles and then $[PdCl_2(dppf)]$.dichloromethane (35.56 mg, 0.04354 mmol). The mixture was heated at 85 °C for 3 hours. The reaction mixture was cooled to ambient temperature and taken onto the next step as is. (100 mg, assumed 100% yield).


SCHEME D



[00249] Scheme D depicts a general method for making intermediates of Formula **D-vi** where Z is a sulfone. Commercially available compounds **D-i** is brominated in the presence of halogenating reagents such as, but not limited to, NBS to give intermediates of Formula **D-ii**. Intermediates of Formula **D-ii** are reacted with an appropriate sodium thiolate to form sulfides of Formula **D-iii**. Subsequent reaction of intermediates of Formula **D-iii** with an oxidising reagent such as, but not limited to, *m*CPBA to provide intermediates of Formula **D-iv**. Intermediates of Formula **D-iv** are then alkylated in the presence of the alkyl halide and NaHMDS to give intermediates of Formula **D-v**. Intermediates of Formula **D-v** are converted to the corresponding boronic acid/ester **D-vi** utilising standard conditions known to those skilled in the art such as, but not limited to, treatment with bis(pinacolato)diboron, Pd-catalyst and base.

Preparation 23 – 27 relate to Scheme D


Preparation 23. Synthesis of 4-bromo-2-(bromomethyl)pyridine



[00250] Step 1: 4-bromo-2-methyl-pyridine (5 g, 29.07 mmol), 2-[(*E*)-(1-cyano-1-methyl-ethyl)azo]-2-methyl-propanenitrile (954.7 mg, 5.814 mmol) and *N*-bromosuccinimide (7.244 g, 40.70 mmol) were added to fluorobenzene (8 mL) and the mixture heated to 90 °C for 1 hour. Reaction mixture was purified by filtering through a silica gel pad and eluting with 50% diethylether/petroleum ether. Product fractions were combined and concentrated *in*


vacuo to give the crude sub-title product (7.294 g, assumed 100% yield). ^1H NMR (400.0 MHz, DMSO- d_6) δ 4.52 (s, 2H), 7.42 (d, 1H), 7.65 (s, 1H) and 8.42 (d, 1H) ppm.

Preparation 24. Synthesis of 4-bromo-2-(methylsulfanylmethyl)pyridine




[00251] Step 1: Crude 4-bromo-2-(bromomethyl)pyridine was dissolved in *N,N*-dimethylformamide (3.000 mL), and mixture was cooled on an ice bath followed by the portion wise addition of methylsulfanylsodium (2.037 g, 29.07 mmol). Reaction mixture was left to stir for 10 minutes. The mixture was diluted with ethyl acetate, organic layer was washed with water and brine. Organic layer was extracted, dried over MgSO_4 and concentrated *in vacuo* to a solid. Residue was purification by silica gel column chromatography loaded with dichloromethane and eluted with 50% diethylether/petroleum ether. Product fractions were combined and concentrated *in vacuo* to give the sub-titled product (0.8 g, 12.6%). ^1H NMR (400.0 MHz, DMSO- d_6) δ 2.25 (s, 3H), 3.80 (s, 2H), 7.4 (d, 1H), 7.6 (s, 1H), 8.4 (d, 1H); LC/MS m/z 220.1 $[\text{M}+\text{H}]^+$.


Preparation 25. Synthesis of 4-bromo-2-(methylsulfonylmethyl)pyridine



[00252] Step 1: 4-bromo-2-(methylsulfanylmethyl)pyridine (0.8000 g, 3.668 mmol) was dissolved in dichloromethane (30 mL) and cooled in an ice bath. 3-chloroperoxybenzoic acid (1.799 g, 9.904 mmol) was added portion wise over 20 minutes. The mixture was stirred at 0 °C for 30 minutes and allowed to warm to ambient temperature for another 30 minutes. The mixture was washed with a 50:50 mix of sodiumthiosulfite/sodium bicarbonate. The organic layer was extracted, dried over MgSO_4 , filtered and concentrated *in vacuo* to a solid. Purified by silica gel column chromatography loaded with dichloromethane and eluted with 40 to 60% diethyl ether/petroleum ether. Product fractions were combined and concentrated *in vacuo* to give the sub-title product as a solid (0.8 g, 87.2%) ^1H NMR (400.0 MHz, CDCl_3) δ 3.00 (s, 3H), 4.40 (s, 2H), 7.58 (d, 1H), 7.7 (s, 1H), 8.48 (d, 1H); LC/MS m/z 251.9 $[\text{M}+\text{H}]^+$.

Preparation 26. Synthesis of 4-bromo-2-(methylsulfonylmethyl)pyridine

[00253] Step 1: 4-bromo-2-(methylsulfonylmethyl)pyridine (550 mg, 2.199 mmol) was dissolved in tetrahydrofuran (9.999 mL) and cooled in an ice bath. [bis(trimethylsilyl)amino]sodium (4.398 mL of 1 M, 4.398 mmol) was added drop wise over 5 minutes. Iodomethane (936.4 mg, 410.7 μ L, 6.597 mmol) was then added and the mixture allowed to warm to ambient temperature. The mixture was stirred at ambient temperature for 15 minutes then diluted with ethyl acetate, organic layer was washed with water. Organic extracts were dried over MgSO_4 , filtered and concentrated *in vacuo* to a solid. The product was purified by column chromatography on silica gel loaded with dichloromethane and eluted with 40 to 60% diethyl ether/petroleum ether. Product fractions were combined and concentrated *in vacuo* to give the sub-titled product (250 mg, 40.87%) ^1H NMR (400.0 MHz, CDCl_3) δ 3.00 (s, 3H), 4.40 (s, 2H), 7.58 (d, 1H), 7.7 (s, 1H), 8.48 (d, 1H); LC/MS m/z 251.9 $[\text{M}+\text{H}]^+$.


Preparation 27. Synthesis of 4-bromo-2-(methylsulfonylmethyl)pyridine

[00254] Step 1: 4-bromo-2-(1-methyl-1-methylsulfonyl-ethyl)pyridine (100 mg, 0.3595 mmol) was dissolved in dioxane (2.26 mL) followed by the addition of bis(pinacolato)diboron (182.4 mg, 0.7183 mmol), $[\text{PdCl}_2(\text{dppf})]$.dichloromethane (58.66 mg, 0.07183 mmol) and potassium acetate (105.7 mg, 1.077 mmol). The mixture was then heated at 100 $^\circ\text{C}$ for 3 hours. Taken onto the next step as is. (116.9 mg, assumed yield 100%).

[00255] The following boronates were prepared using procedures analogous to that described above.

tert-butyl 4-((2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)propan-2-yl)sulfonyl) piperidine-1-carboxylate LC/MS m/z 413.10 $[M+H]^+$.

SCHEME E




[00256] Scheme E depicts a general method for making intermediates of Formula **E-vi**. Commercially available Bromo intermediates of Formula **E-i** are carbonylated using standard conditions known to those skilled in the art such as, but not limited to, treatment with carbon monoxide gas, under palladium catalysis in the presence of a base to form intermediates of Formula **E-ii**. Intermediates of Formula **E-ii** are then reduced using standard conditions known to those skilled in the art such as, but not limited to treatment with lithium aluminium hydride to give intermediates of Formula **E-iii**. Intermediates of Formula **E-iii** are then oxidised to the corresponding aldehyde using standard conditions known to those skilled in the art such as, but not limited to treatment with manganese dioxide, Dess-martin periodane or TPAP to give intermediates of Formula **E-iv**. Reaction of intermediates of Formula **E-iv** with hydroxylamine gives oxime intermediates of Formula **E-v**. Reaction of oxime intermediates of Formula **E-v** with NCS yields intermediates of Formula **E-vi**.

Preparation 28 -32 relate to Scheme E


Preparation 28. Synthesis of Di *tert*-butyl 2-(4-methoxycarbonylphenyl)piperazine-1,4-dicarboxylate

94



[00257] Step 1: carbon monoxide(g) was bubbled through a reaction mixture containing triethylamine (687.9 mg, 947.5 μ L, 6.798 mmol), di *tert*-butyl 2-(4-bromophenyl)piperazine-1,4-dicarboxylate (1.5 g, 3.399 mmol) and [PdCl₂(dppf)].dichloromethane (555.2 mg, 0.6798 mmol) in methanol (45.00 mL) and the reaction mixture sealed and heated at 65 °C for 24 hours. The reaction mixture was cooled and filtered through a celite pad and the catalyst washed with methanol. The combined filtrates were concentrated *in vacuo* to leave a orange/red oil. Purified by column chromatography (ISCO Companion, 80 g column) dry loaded and eluted with 2.5 to 50% ethyl acetate/petroleum ether. Product fractions were combined and concentrated *in vacuo* to give the sub-title product as a white solid. (1.03 g, 72% yield). ¹H NMR (400.0 MHz, CDCl₃) δ 1.44 - 1.46 (m, 18H), 3.01 (br s, 2H), 3.37 - 3.42 (m, 1H), 3.93 - 4.00 (m, 5H), 4.44 (br s, 1H), 5.30 (br s, 1H), 7.39 - 7.41 (m, 2H) and 8.02 (d, 2H) ppm; TLC (petroleum ether: ethyl acetate, 4:1 v/v) R_f = 0.23

Preparation 29. Synthesis of Di *tert*-butyl 2-[4-(hydroxymethyl)phenyl]piperazine-1,4-dicarboxylate




[00258] Step 1: Di *tert*-butyl 2-(4-methoxycarbonylphenyl)piperazine-1,4-dicarboxylate (1.03 g, 2.449 mmol) was dissolved in tetrahydrofuran (10.30 mL) and lithium boranuide (106.7 mg, 4.898 mmol) was added portion wise. The reaction was heated at 65 °C over 18 hours. The reaction mixture was cooled to ambient temperature then poured onto crushed ice and whilst stirring 1 M hydrochloric acid was added drop wise until no effervescence was observed. The mixture was stirred for 1 hour then saturated aqueous sodium bicarbonate was added until the mixture was at pH 8. The aqueous layer was extracted with ethyl acetate (x 3) and the combined organic extracts were washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. Purified by column chromatography (ISCO Companion, 40 g column)

loaded with dichloromethane and eluted with 10 to 100% ethyl acetate/petroleum ether.


Product fractions were combined and concentrated *in vacuo* to give the sub-title product as a white solid. (754 mg, 78.4% yield). ^1H NMR (400.0 MHz, CDCl_3) δ 1.45 - 1.48 (m, 18H), 2.99 (br s, 2H), 3.33 - 3.37 (m, 1H), 3.95 - 3.98 (m, 2H), 4.45 - 4.48 (m, 1H), 4.70 (d, 2H), 5.30 (br s, 1H) and 7.33 - 7.35 (m, 4H) ppm; TLC (petroleum ether:ethyl acetate, 1:1 v/v) R_f = 0.48

Preparation 30. Synthesis of Di *tert*-butyl 2-(4-formylphenyl)piperazine-1,4-dicarboxylate



[00259] Step 1: Di *tert*-butyl 2-[4-(hydroxymethyl)phenyl]piperazine-1,4-dicarboxylate (750 mg, 1.911 mmol) was dissolved in dichloromethane (12.00 mL) and dioxomanganese (1.993 g, 396.5 μL , 22.93 mmol) was added. The reaction was stirred at ambient temperature for 22 hours. Reaction followed by TLC. Reaction mixture was filtered through a pad of celite and washed with dichloromethane. Purified by column chromatography (ISCO Companion, 40 g column) dry loaded and eluted with 5 to 50% ethyl acetate/petroleum ether. Product fractions were combined and concentrated *in vacuo* to give the sub-title product. (699 mg, 94% yield). ^1H NMR (400.0 MHz, CDCl_3) δ 1.43 - 1.47 (m, 18H), 3.01 (br s, 2H), 3.43 - 3.44 (m, 1H), 3.98 - 4.01 (m, 2H), 4.44 (br s, 1H), 5.32 (br s, 1H), 7.49 - 7.51 (m, 2H), 7.87 (d, 2H) and 10.03 (s, 1H) ppm; TLC (petroleum ether: ethyl acetate, 1:1 v/v) R_f = 0.61

Preparation 31. Synthesis of (*E*)-Di-*tert*-butyl 2-(4-((hydroxyimino)methyl)phenyl)piperazine-1,4-dicarboxylate



[00260] Step 1: Hydroxylamine 50% solution in water (236.5 μL of 50 %w/v, 3.580 mmol) was added to a stirred solution of di *tert*-butyl 2-(4-formylphenyl)piperazine-1,4-dicarboxylate (699 mg, 1.790 mmol) in ethanol (20 mL) at ambient temperature. Stirred at ambient temperature for 1 hour. The reaction mixture was concentrated *in vacuo* and the

residue taken up in water and extracted with ethyl acetate (x 3). The combined organic extracts were dried over MgSO_4 , filtered and concentrated *in vacuo* to give a white foam. Taken onto the next step as is (725.8 mg, assume 100% yield).

[00261] The following Oximes were prepared using procedures analogous to that described above and converted to chloro-oximes *in-situ*.

3-methylthiophene-2-carbaldehyde oxime ^1H NMR (400.0 MHz, DMSO-d_6) δ 2.36 (s, 3H), 6.97 (d, 1H), 7.62 (d, 1H), 7.82 (s, 1H) and 11.79 (s, 1H) ppm; LC/MS m/z 141.90 $[\text{M}+\text{H}]^+$.

2-methylbenzaldehyde oxime ^1H NMR (400.0 MHz, DMSO-d_6) δ 2.38 (s, 3H), 7.29 - 7.19 (m, 3H), 7.62 (d, $J = 7.7$ Hz, 1H), 8.32 (s, 1H) and 11.28 (s, 1H) ppm; LC/MS m/z 135.90 $[\text{M}+\text{H}]^+$.

2-fluorobenzaldehyde oxime ^1H NMR (400.0 MHz, DMSO-d_6) δ 7.29 - 7.22 (m, 2H), 7.47 - 7.42 (m, 1H), 7.77 - 7.73 (m, 1H), 8.23 (s, 1H) and 11.61 (s, 1H) ppm F NMR (376.0 MHz, DMSO-d_6) δ -119.39 ppm LC/MS m/z 139.90 $[\text{M}+\text{H}]^+$.

4-hydroxybenzaldehyde oxime ^1H NMR (400.0 MHz, DMSO-d_6) δ 6.80 - 6.76 (m, 2H), 7.42 - 7.39 (m, 2H), 8.00 (s, 1H), 9.75 (s, 1H) and 10.84 (s, 1H) ppm; LC/MS m/z 137.90 $[\text{M}+\text{H}]^+$.
thiophene-2-carbaldehyde oxime ^1H NMR (400.0 MHz, DMSO-d_6) δ 7.09 (dd, 0.4H), 7.14 (dd, 0.6H), 7.29 (dd, 0.4H), 7.48 (dd, 0.6H), 7.53 (dd, 0.4H), 7.74 (dd, 0.6H), 7.85 (s, 0.6H), 8.33 (s, 0.4H), 11.16 (s, 0.4H) and 11.87 (s, 0.6H) ppm; LC/MS m/z 127.80 $[\text{M}+\text{H}]^+$.


2-methoxybenzaldehyde oxime ^1H NMR (400.0 MHz, DMSO-d_6) δ 3.82 (s, 3H), 6.96 (t, 1H), 7.07 (d, 1H), 7.40 - 7.35 (m, 1H), 7.65 (dd, 1H), 8.29 (s, 1H) and 11.22 (s, 1H) ppm; LC/MS m/z 152.00 $[\text{M}+\text{H}]^+$.

2-hydroxybenzaldehyde oxime ^1H NMR (400.0 MHz, DMSO-d_6) δ 6.89 - 6.84 (m, 2H), 7.22 (dt, 1H), 7.48 (dd, 1H), 8.33 (s, 1H), 10.09 (s, 1H) and 11.32 (s, 1H) ppm LC/MS m/z 137.90 $[\text{M}+\text{H}]^+$.

4-(hydroxymethyl)benzaldehyde oxime ^1H NMR (400.0 MHz, DMSO-d_6) δ 4.51 (d, 2H), 5.25 (t, 1H), 7.34 (d, 2H), 7.54 (d, 2H), 8.12 (s, 1H) and 11.16 (s, 1H) ppm; LC/MS m/z 152.00 $[\text{M}+\text{H}]^+$.

1H-indole-4-carbaldehyde oxime ^1H NMR (400.0 MHz, DMSO- d_6) δ 6.88 (t, 1H), 7.11 (t, 1H), 7.17 (d, 1H), 7.45 - 7.42 (m, 2H), 8.37 (s, 1H), 11.10 (s, 1H) and 11.31 (s, 1H) ppm; LC/MS m/z 161.00 $[\text{M}+\text{H}]^+$.

Preparation 32. Synthesis of Di *tert*-butyl 2-[4-[(Z)-C-chloro-*N*-hydroxycarbonimidoyl]phenyl]piperazine-1,4-dicarboxylate



[00262] Step 1: *N*-chlorosuccinimide (239.0 mg, 1.790 mmol) was added to a stirred suspension of (*E*)-di-*tert*-butyl 2-(4-((hydroxyimino)methyl)phenyl)piperazine-1,4-dicarboxylate (725.8 mg, 1.790 mmol) in *N,N*-dimethyl formamide (10 mL). The reaction was then heated at 55 °C for 1 hour. The reaction was cooled to ambient temperature and diluted with water. The reaction mixture was extracted with ethyl acetate (x 3). Organic extracts were combined, dried over MgSO_4 , filtered and concentrated *in vacuo*. The sub-titled compound was used directly in the next step without further purification. (787.5 mg, assume 100% yield).


The following Chloro-oximes were prepared using procedures analogous to that described above.

tert-butyl *N*-[[4-[(Z)-C-chloro-*N*-hydroxy-carbonimidoyl]phenyl]methyl]-*N*-methyl-carbamate ^1H NMR (400.0 MHz, DMSO- d_6) δ 1.48 (s, 9H), 2.90 – 2.99 (m, 3H), 4.50 (br s, 2H), 7.25 (br s, 2H), 7.77 – 7.79 (m, 2H) and 9.50 – 9.54 (br s, 1H) ppm

(Z)-*N*-hydroxybenzimidoyl chloride LC/MS m/z 155.90 $[\text{M}+\text{H}]^+$.

SCHEME F

Preparation 33. Synthesis of *tert*-butyl *N*-[1-[4-[(*Z*)-*C*-chloro-*N*-hydroxy-carbonimidoyl]phenyl]-2-fluoro-ethyl]carbamate



[00263] Scheme F depicts the preparation of intermediate **F-x**, a chloro oxime substituted with a Boc protected 4 (α - fluoromethyl)benzylamine

[00264] Step 1: Tetrachlorotitanium (16.85 mL of 1 M, 16.85 mmol) in dichloromethane was added to a solution of ethyl 4-acetylbenzoate (5.4 g, 28.09 mmol) and isopropyl amine (6.644 g, 9.657 mL, 112.4 mmol) in diethyl ether (100 mL) at 0 °C and the reaction mixture allowed to warm to ambient temperature over 15 hours. The reaction mixture was poured into a biphasic mixture of aqueous 0.5 M sodium hydroxide and diethyl ether (4:1, 150 mL) and the layers separated. The aqueous phase was extracted with diethyl ether (x 2) and the combined organic phases dried (MgSO₄/K₂CO₃ 10:1), filtered and concentrated *in vacuo* to give ethyl 4-(1-(isopropylimino)ethyl)benzoate as a pale yellow oil (6.7 g, quantitative). ¹H NMR (400.0 MHz, DMSO-d₆) δ 1.15 (d, J = 6.3 Hz, 6H), 1.33 (t, J = 7.2 Hz, 3H), 2.25 (s,

3H), 3.88 (sept, 1H), 4.33 (q, J = 7.1 Hz, 2H) and 7.91 - 7.97 (m, 4H) ppm; LC/MS m/z 234.2 [M+H]⁺.

[00265] Step 2: A mixture of *N*-(benzenesulfonyl)-*N*-fluoro-benzenesulfonamide (2.027 g, 6.429 mmol), potassium carbonate (592.3 mg, 4.286 mmol) and 4A Molecular Sieves (2.6 g) (dried at 120 °C before use) in anhydrous acetonitrile (15 mL)/*N,N*-dimethylformamide (3 mL) were stirred vigorously in an oven dried flask at 0 °C for 15 minutes under an atmosphere of nitrogen. Ethyl 4-(1-(isopropylimino)ethyl)benzoate (0.5 g, 2.143 mmol) in acetonitrile (1 mL) was added drop wise and the reaction was stirred at 0 °C for a further 2 hours. An excess of *N,N*-diethylethanamine (2.5 mL, 17.94 mmol) was added and after 2 minutes the solids were removed by filtration through celite and the residue washed with diethyl ether. The filtrate was poured into 0.5 M sodium hydroxide and the layers separated. The aqueous phase was extracted with diethyl ether (x 2) and the combined organic extracts washed with brine (x 2), dried (MgSO₄: K₂CO₃, 10:1), filtered and concentrated *in vacuo*. The crude residue ethyl 4-(2-fluoro-1-(isopropylimino)ethyl)benzoate was used directly in the next step. (577.1 mg, assumed 100% yield). ¹H NMR (400.0 MHz, DMSO-d₆) δ 1.08 (d, 3.6H), 1.17 (d, 2.4H), 1.33 (t, 3H), 3.37 - 3.43 (m, 1H), 4.33 (q, 2H), 5.10 (d, 1H), 5.45 (d, 1H), 7.44 - 7.46 (m, 1H) and 7.87 - 8.03 (m, 3H) ppm.

[00266] Step 3: Aqueous hydrogen chloride (100 mL of 2 M, 200.0 mmol) was added to a stirred solution of ethyl 4-(2-fluoro-1-(isopropylimino)ethyl)benzoate (7.059 g, 28.09 mmol) in dichloromethane (100 mL) and the reaction stirred at ambient temperature for 4 hours. The layers were separated and the aqueous phase extracted with dichloromethane (x 2). The combined organic extracts were dried over MgSO₄, filtered and concentrated *in vacuo*. Purification by column chromatography (ISCO Companion, 120 g column) dry loaded and eluted with 0 to 30% ethyl acetate/petroleum ether to give ethyl 4-(2-fluoroacetyl)benzoate as a yellow solid, which was used without further purification. (5.2013 g, assumed 88.08% yield). ¹H NMR (400.0 MHz, DMSO-d₆) δ 1.34 (t, 3H), 4.36 (q, 2H), 5.88 (d, 2H), 8.02 (d, 2H) and 8.10 (d, 2H) ppm; F NMR (376.0 MHz, DMSO-d₆) δ -127.20 ppm; LC/MS m/z 211.25 [M+H]⁺.

[00267] Step 4: Ammonium acetate (386.2 mg, 330.1 μL, 5.010 mmol) was added to a stirred solution of ethyl 4-(2-fluoroacetyl)benzoate (351 mg, 1.670 mmol) in methanol (10 mL)/dichloromethane (5 mL) and the resultant mixture stirred at ambient temperature under nitrogen for 1.75 hours. Sodium cyanoborane (209.9 mg, 1.640 mL, 3.340 mmol) was added and the mixture stirred for a further 21 hours. Saturated aqueous sodium bicarbonate solution was added and the reaction stirred for 10 minutes. The reaction mixture was

extracted with dichloromethane (x 3) and the combined organic extracts were dried over MgSO_4 , filtered and concentrated *in vacuo*. The crude residue ethyl 4-(1-amino-2-fluoro-ethyl)benzoate was used in the following step without further purification. (331.3 mg, 93.91%). LC/MS m/z 212.2 $[\text{M}+\text{H}]^+$.

[00268] Step 5: Di *tert* butyl dicarbonate (400.9 mg, 422.0 μL , 1.837 mmol) was added to a stirred solution of ethyl 4-(1-amino-2-fluoro-ethyl)benzoate (352.8 mg, 1.670 mmol) and *N,N*-diethylethanamine (185.9 mg, 256.1 μL , 1.837 mmol) in dichloromethane (10 mL) and the reaction stirred at ambient temperature for 3.5 hours. The reaction mixture was washed with saturated aqueous sodium bicarbonate solution (x 2) and brine (x 1) and the organic extract dried (MgSO_4), filtered and concentrated *in vacuo*. Purification by column chromatography (ISCO Companion, 24 g column) loaded in dichloromethane eluted with 0 to 40% ethyl acetate/petroleum ether. Product fractions were combined and concentrated *in vacuo* to give ethyl 4-[1-(*tert*-butoxycarbonylamino)-2-fluoro-ethyl]benzoate as a white solid (166 mg, 32%). ^1H NMR (400.0 MHz, DMSO-d_6) δ 1.32 (t, 3H), 1.99 (s, 9H), 4.32 (q, 2H), 4.41 - 4.44 (m, 1H), 4.53 - 4.56 (m, 1H), 4.90 - 4.99 (m, 1H), 7.51 (d, 2H), 7.79 (d, 2H) and 7.94 (d, 1H) ppm; LC/MS m/z 256.2 $[\text{M}+\text{H}]^+$.

[00269] Step 6: Lithium boranuide (208.9 mg, 9.588 mmol) was added to a stirred solution ethyl 4-[1-(*tert*-butoxycarbonylamino)-2-fluoro-ethyl]benzoate (1.99 g, 6.392 mmol) in tetrahydrofuran (40 mL) and the reaction warmed to 65 $^\circ\text{C}$ for 15 hours. The reaction mixture was cooled to ambient temperature then poured onto crushed ice whilst stirring, 1 M hydrogen chloride solution was added drop wise until no effervescence was observed. The mixture was stirred for 1 hour then saturated aqueous sodium bicarbonate solution was added until the mixture was at pH 8. The aqueous layer was extracted with ethyl acetate (x 3) and the combined organic extracts dried over MgSO_4 , filtered and concentrated *in vacuo*. Purification by column chromatography (ISCO Companion, 120 g column) loaded in dichloromethane, eluted with 0 to 100% ethyl acetate /petroleum ether. Product fractions were combined and concentrated *in vacuo* to give *tert*-butyl *N*-[2-fluoro-1-[4-(hydroxymethyl)phenyl]ethyl]carbamate as a white solid (1.15 g, 67%). ^1H NMR (400.0 MHz, DMSO-d_6) δ 1.37 (s, 9H), 4.44 - 4.49 (m, 4H), 4.80 - 4.89 (m, 1H), 5.16 (t, 1H), 7.27 - 7.38 (m, 4H) and 7.65 (d, 1H) ppm; LC/MS m/z 214.0 $[\text{M}+\text{H}]^+$.


[00270] Step 7: dioxomanganese (4.455 g, 886.4 μL , 51.24 mmol) was added to a stirred solution of *tert*-butyl *N*-[2-fluoro-1-[4-(hydroxymethyl)phenyl]ethyl]carbamate (1.15 g, 4.270 mmol) in dichloromethane (100 mL) and the reaction allowed to stir at ambient

temperature for 65 hours. The reaction mixture was filtered through celite and washed with dichloromethane. The filtrate was concentrated *in vacuo* to give *tert*-butyl *N*-[2-fluoro-1-(4-formylphenyl)ethyl]carbamate as a colourless oil (930 mg, 82%). ¹H NMR (400.0 MHz, DMSO-d₆) δ 1.37 (s, 9H), 4.43 - 4.46 (m, 1H), 4.54 - 4.58 (m, 1H), 4.95 - 5.05 (m, 1H), 7.60 (d, 2H), 7.81 (d, 1H), 7.90 (d, 2H) and 10.00 (s, 1H) ppm; LC/MS *m/z* 212.0 [M+H]⁺.

[00271] Step 8: Hydroxylamine (459.6 μL of 50 %w/v, 6.958 mmol) was added to a stirred solution of *tert*-butyl *N*-[2-fluoro-1-(4-formylphenyl)ethyl]carbamate (930 mg, 3.479 mmol) in ethanol (100 mL) and the reaction mixture stirred at ambient temperature for 4 hours. The reaction mixture was concentrated *in vacuo* and the residue taken up in water and extracted with ethyl acetate (x 3). The combined organic extracts were dried over MgSO₄, filtered and concentrated *in vacuo* to give *tert*-butyl (2-fluoro-1-(4-((hydroxyimino)methyl)phenyl)ethyl)carbamate as an impure white solid (1058.2 mg, >100%). ¹H NMR (400.0 MHz, DMSO-d₆) 1.37 (s, 9H), 4.38 - 4.41 (m, 1H), 4.49 - 4.53 (m, 1H), 4.83 - 4.92 (m, 1H), 7.38 (d, 2H), 7.56 (d, 2H), 7.70 (d, 1H), 8.11 (d, 1H) and 11.24 (s, 1H) ppm; LC/MS *m/z* 227.0 [M+H]⁺.

[00272] Step 9: *N*-Chlorosuccinimide (464.6 mg, 3.479 mmol) was added to a stirred solution of *tert*-butyl (2-fluoro-1-(4-((hydroxyimino)methyl)phenyl)ethyl)carbamate (982.2 mg, 3.479 mmol) in *N,N*-dimethylformamide (5 mL) and the reaction warmed to 55 °C for 30 minutes. The reaction was cooled to ambient temperature and diluted with water. The mixture was extracted with ethyl acetate (x 3), dried over MgSO₄, filtered and concentrated *in vacuo*. The residue *tert*-butyl *N*-[1-[4-[(*Z*)-*C*-chloro-*N*-hydroxy-carbonimidoyl]phenyl]-2-fluoro-ethyl]carbamate was used directly in the cyclisation step without further purification. ¹H NMR (400.0 MHz, DMSO-d₆) δ 1.37 (s, 9H), 4.40 - 4.46 (m, 1H), 4.52 - 4.57 (m, 1H), 4.89 - 4.94 (m, 1H), 7.38 (d, 1H), 7.45 - 7.49 (m, 2H), 7.72 - 7.78 (m, 2H) and 12.41 (s, 1H) ppm; LC/MS *m/z* 317.0 [M+H]⁺.

SCHEME G




[00273] Compounds of formula G-vi can be made according to the steps outlined in Scheme G. Reductive amination between compound G-i and an amine (e.g., Y¹-NH₂), leads to compound G-ii. Conditions for reductive amination include, for example, combining compound G-i with Y¹-NH₂ in methanol to form an imine intermediate which is reduced with NaBH₄ to form compound G-ii. Compound G-ii can then be protected with nitrogen protecting groups known to those skilled in the art. For example, compound G-ii can be combined with (Boc)₂O and Et₃N in DCM to form compound G-iii (wherein PG = Boc).

[00274] Compound G-iii can be combined with hydroxylamine hydrochloride under suitable oxime formation conditions to form compound G-iv. Suitable oxime formation conditions include either a one-step procedure or a two-step procedure. The one-step procedure comprises stirring 1 equivalent of compound G-iii with a 1.1 equivalents of NH₂OH.HCl in a 10:1 v/v mixture of THF/water. The two step procedure comprises first deprotecting the ketal group of compound G-iii into an aldehyde under suitable deprotection conditions, and then forming an oxime under suitable two-step oxime formation conditions to form compound G-iv.

[00275] Compound G-iv can be combined with the BOC-protected aminopyrazine shown in Scheme A under suitable isoxazole formation conditions to form compound G-v. Compound G-iv is transformed and engaged in a [3+2] cycloaddition to form the isoxazole G-v. This transformation can be conducted in one pot but requires two distinct steps. The first step is an oxidation of the oxime functional group into a nitrone, or a similar intermediate with the same degree of oxidation, for example a chlorooxime. This reactive species then reacts with an alkyne in a [3+2] cycloaddition to form the isoxazole adduct.

[00276] Finally, compound G-v undergoes a metal-assisted coupling reaction to form compound G-vi. For example, compound G-v can be combined with a boronic acid under Suzuki cross-coupling conditions to form the compound of formula G-vi.

Example 8: Synthesis of 2-(4-(5-amino-6-(3-(4-((tetrahydro-2*H*-pyran-4-ylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-yl)pyridin-2-yl)-2-methylpropanenitrile (**Compound I-53**)



Method 1:

[00277] To a solution of tetrahydropyran-4-amine (100 g, 988.7 mmol) in MeOH (3.922 L) was added 4-(diethoxymethyl)benzaldehyde (196.1 g, 941.6 mmol) over 2 min at RT. The reaction mixture was stirred at RT for 80 min, until the aldimine formation was complete (as seen by NMR). NaBH₄ (44.49 g, 1.176 mol) was carefully added over 45 min, maintaining the temperature between 24 °C and 27 °C by mean of an ice bath. After 75 min at RT, the reaction has gone to completion. The reaction mixture was quenched with 1M NaOH (1 L). The reaction mixture was partitioned between brine (2.5 L) and TBDME (4 L then 2 x 1 L). The organic phase was washed with brine (500 mL) and concentrated in vacuo. The crude mixture was redissolved in DCM (2 L). The aqueous phase was separated, the organic phase

was dried over MgSO₄, filtered and concentrated in vacuo to give the title compound as a yellow oil (252.99 g, 91%).

Method 2:

[00278] A solution of N-[[4-(diethoxymethyl)phenyl]methyl] tetrahydropyran-4-amine (252.99 g, 862.3 mmol) and BOC anhydride (191.9 g, 202.0 mL, 879.5 mmol) in DCM (2.530 L) was cooled down to 3.3 °C. Et₃N (89.00 g, 122.6 mL, 879.5 mmol) was added over 4 min, keeping the internal temperature below 5 °C. The bath was removed 45 min after the end of the addition. And the reaction mixture was stirred at RT overnight. The reaction mixture was sequentially washed with 0.5 M citric acid (1 L), saturated NaHCO₃ solution (1 L) and brine (1 L). The organic phase was dried (MgSO₄), filtered and concentrated in vacuo to give a colourless oil (372.38 g, 110%). ¹H NMR (400.0 MHz, DMSO); MS (ES⁺)

Method 3:

[00279] tert-butyl N-[[4-(diethoxymethyl)phenyl]methyl]-N-tetrahydropyran-4-yl-carbamate (372.38 g, 946.3 mmol) was dissolved in THF (5 L) and water (500 mL). Hydroxylamine hydrochloride (72.34 g, 1.041 mol) was added in one portion and the reaction mixture was stirred overnight at RT. The reaction mixture was partitioned between DCM (5 L) and water. The combined organic extract was washed with water (1L x 2). The organic phase was concentrated in vacuo to a volume of about 2L. The organic layer was dried over MgSO₄, filtered and concentrated in vacuo to give a sticky colourless oil that crystallized on standing under vacuo. (334.42g, 106%). ¹H NMR (400.0 MHz, CDCl₃); MS (ES⁺)

Method 4:

[00280] tert-butyl N-[[4-[(E)-hydroxyiminomethyl]phenyl]methyl]-N-tetrahydropyran-4-yl-carbamate (334.13 g, 999.2 mmol) was dissolved in isopropyl acetate (3.0 L) (the mixture was warmed to 40 °C to allow all the solids to go into solution). N-chlorosuccinimide (140.1 g, 1.049 mol) was added portionwise over 5 min and the reaction mixture was heated to 55 °C (external block temperature). After 45 min at 55°C The reaction had gone to completion. The reaction mixture was cooled down to RT. The solids were filtered off and rinsed with Isopropyl acetate (1 L). Combined organic extract was sequentially washed with water (1.5 L, 5 times) and brine, dried over MgSO₄, filtered and concentrated in vacuo to give a viscous yellow oil (355.9 g; 96%). ¹H NMR (400.0 MHz, CDCl₃); MS (ES⁺)

Method 5:

[00281] Et₃N (76.97 g, 106.0 mL, 760.6 mmol) was added over 20 minutes to a solution of tert-butyl N-(5-bromo-3-ethynyl-pyrazin-2-yl)-N-tert-butoxycarbonyl-carbamate (233.0 g, 585.1 mmol) and tert-butyl N-[[4-[(Z)-C-chloro-N-hydroxy-carbonimidoyl]phenyl]methyl]-N-tetrahydropyran-4-yl-carbamate (269.8 g, 731.4 mmol) in DCM (2.330 L) at RT. During addition of triethylamine, the exotherm was stabilised by cooling the mixture in an ice bath, then the reaction mixture was gradually warmed up to RT and the mixture was stirred at RT overnight. The reaction mixture was sequentially washed with water (1.5 L, 3 times) and brine. The organic extract was dried over MgSO₄, filtered and partially concentrated in vacuo. Heptane (1.5L) was added and the concentration was continued yielding 547.63 g of a yellow-orange solid.

[00282] 542.12 g was taken up into ~2 vol (1 L) of ethyl acetate. The mixture was heated to 74-75 °C internally and stirred until all the solid went into solution. Heptane (3.2 L) was added slowly via addition funnel to the hot solution keeping the internal temperature between 71 °C and 72 °C. At the end of the addition, the dark brown solution was seeded with some recrystallised product, and the reaction mixture was allowed to cool down to RT without any stirring to crystallise O/N. The solid was filtered off and rinsed with heptane (2 x 250 mL), then dried in vacuo to yield 307.38 g of the title product (72 %). 1H NMR (400.0 MHz, CDCl₃); MS (ES+) ss

Method 6:

[00283] tert-butyl N-[[4-[5-[3-[bis(tert-butoxycarbonyl)amino]-6-bromo-pyrazin-2-yl]isoxazol-3-yl]phenyl]methyl]-N-tetrahydropyran-4-yl-carbamate (303 g, 414.7 mmol) and 2-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl] propanenitrile (112.9 g, 414.7 mmol) were suspended in MeCN (2 L) and H₂O (1 L). Na₂CO₃ (414.7 mL of 2 M, 829.4 mmol) followed by Pd[P(tBu)₃]₂ (21.19 g, 41.47 mmol) were added and the reaction mixture was degassed with N₂ for 1 h. The reaction mixture was placed under a nitrogen atmosphere and heated at 70 °C (block temperature) for 4 h (internal temperature fluctuated between 60 °C and 61 °C). The reaction was cooled down to room temperature and stirred at RT overnight. The reaction mixture was partitioned between EtOAc (2 L) and water (500 mL). The combined organic extract was washed with brine (500 mL), filtered through a short pad of celite and concentrated under reduced pressure to a volume of about 3 L. The solution was dried over MgSO₄, filtered and partially concentrated in vacuo. iPrOH (1.5 L) was added

and the solvent was removed in vacuo to yield the desired product as a light brown foam (405 g).

[00284] 400 g was taken up into ~5 vol (2 L) of iPrOH and the mixture was heated to 80 °C until all the solid went into solution. The dark brown solution was seeded, and the reaction mixture was allowed to slowly cool down to RT overnight. The solid was filtered off and rinsed with iPrOH (2 x 250 mL) and Petroleum ether (2x200 mL). The resulting solid was slurried in petroleum ether (2.5 L), filtered off and dried in vacuo. The resulting solid was dissolved in DCM (2.5 L) and stirred slowly for 1 h with 30 g of SPM32 (3-mercaptopropyl ethyl sulfide silica). The silica was filtered through a pad of florisil and rinsed with DCM. The procedure was repeated twice, then the DCM solution was concentrated in vacuo to give 238.02 g of a light yellow solid.

Method 7:

[00285] tert-butyl N-[[4-[5-[3-[bis(tert-butoxycarbonyl)amino]-6-[2-(1-cyano-1-methyl-ethyl)-4-pyridyl]pyrazin-2-yl]isoxazol-3-yl]phenyl]methyl]-N-tetrahydropyran-4-yl-carbamate (238 g, 299.0 mmol) was dissolved in DCM (2.380 L). TFA (500 mL, 6.490 mol) was added at RT over 3 min. The reaction mixture was stirred at RT for 3.5 h. The reaction mixture was concentrated under reduced pressure then azeotroped with heptane (2x300ml). The oil was then slurried in abs. EtOH (2.5 L) and filtered. The solid was dissolved in a mixture of ethanol (1.190 L) and water (1.190 L). potassium carbonate (124.0 g, 897.0 mmol) in water (357.0 mL) was added to the solution and the mixture was stirred at RT overnight.

[00286] The solid was filtered off, was washed with water (2.5 L), and dried at 50 °C in vacuo to give 108.82 g of the title compound as a yellow powder. (73 %)

Example 9: Cellular ATR Inhibition Assay:

[00287] Compounds can be screened for their ability to inhibit intracellular ATR using an immunofluorescence microscopy assay to detect phosphorylation of the ATR substrate histone H2AX in hydroxyurea treated cells. HT29 cells are plated at 14,000 cells per well in 96-well black imaging plates (BD 353219) in McCoy's 5A media (Sigma M8403) supplemented with 10% foetal bovine serum (JRH Biosciences 12003), Penicillin/Streptomycin solution diluted 1:100 (Sigma P7539), and 2mM L-glutamine (Sigma G7513), and allowed to adhere overnight at 37°C in 5% CO₂. Compounds are then added to the cell media from a final concentration of 25µM in 3-fold serial dilutions and the

cells are incubated at 37°C in 5% CO₂. After 15min, hydroxyurea (Sigma H8627) is added to a final concentration of 2mM.

[00288] After 45min of treatment with hydroxyurea, the cells are washed in PBS, fixed for 10min in 4% formaldehyde diluted in PBS (Polysciences Inc 18814), washed in 0.2% Tween-20 in PBS (wash buffer), and permeabilised for 10min in 0.5% Triton X-100 in PBS, all at room temperature. The cells are then washed once in wash buffer and blocked for 30min at room temperature in 10% goat serum (Sigma G9023) diluted in wash buffer (block buffer). To detect H2AX phosphorylation levels, the cells are then incubated for 1h at room temperature in primary antibody (mouse monoclonal anti-phosphorylated histone H2AX Ser139 antibody; Upstate 05-636) diluted 1:250 in block buffer. The cells are then washed five times in wash buffer before incubation for 1h at room temperature in the dark in a mixture of secondary antibody (goat anti-mouse Alexa Fluor 488 conjugated antibody; Invitrogen A11029) and Hoechst stain (Invitrogen H3570); diluted 1:500 and 1:5000, respectively, in wash buffer. The cells are then washed five times in wash buffer and finally 100ul PBS is added to each well before imaging.

[00289] Cells are imaged for Alexa Fluor 488 and Hoechst intensity using the BD Pathway 855 Bioimager and Attovision software (BD Biosciences, Version 1.6/855) to quantify phosphorylated H2AX Ser139 and DNA staining, respectively. The percentage of phosphorylated H2AX-positive nuclei in a montage of 9 images at 20x magnification is then calculated for each well using BD Image Data Explorer software (BD Biosciences Version 2.2.15). Phosphorylated H2AX-positive nuclei are defined as Hoechst-positive regions of interest containing Alexa Fluor 488 intensity at 1.75-fold the average Alexa Fluor 488 intensity in cells not treated with hydroxyurea. The percentage of H2AX positive nuclei is finally plotted against concentration for each compound and IC₅₀s for intracellular ATR inhibition are determined using Prism software (GraphPad Prism version 3.0cx for Macintosh, GraphPad Software, San Diego California, USA).

[00290] The compounds described herein can also be tested according to other methods known in the art (see Sarkaria et al, "Inhibition of ATM and ATR Kinase Activities by the Radiosensitizing Agent, Caffeine: *Cancer Research* 59: 4375-5382 (1999); Hickson et al, "Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM" *Cancer Research* 64: 9152-9159 (2004); Kim et al, "Substrate Specificities and Identification of Putative Substrates of ATM Kinase Family Members" *The Journal of Biological Chemistry*, 274(53): 37538-37543 (1999); and Chiang

et al, "Determination of the catalytic activities of mTOR and other members of the phosphoinositide-3-kinase-related kinase family" *Methods Mol. Biol.* 281:125-41 (2004)).

Example 10: ATR Inhibition Assay:

[00291] Compounds were screened for their ability to inhibit ATR kinase using a radioactive-phosphate incorporation assay. Assays were carried out in a mixture of 50mM Tris/HCl (pH 7.5), 10mM MgCl₂ and 1mM DTT. Final substrate concentrations were 10μM [γ-33P]ATP (3mCi 33P ATP/mmol ATP, Perkin Elmer) and 800 μM target peptide (ASELPASQPQPFSAKKK).

[00292] Assays were carried out at 25°C in the presence of 5 nM full-length ATR. An assay stock buffer solution was prepared containing all of the reagents listed above, with the exception of ATP and the test compound of interest. 13.5 μL of the stock solution was placed in a 96 well plate followed by addition of 2 μL of DMSO stock containing serial dilutions of the test compound (typically starting from a final concentration of 15 μM with 3-fold serial dilutions) in duplicate (final DMSO concentration 7%). The plate was pre-incubated for 10 minutes at 25°C and the reaction initiated by addition of 15 μL [γ-33P]ATP (final concentration 10 μM).

[00293] The reaction was stopped after 24 hours by the addition of 30μL 0.1M phosphoric acid containing 2mM ATP. A multiscreen phosphocellulose filter 96-well plate (Millipore, Cat no. MAPHN0B50) was pretreated with 100μL 0.2M phosphoric acid prior to the addition of 45μL of the stopped assay mixture. The plate was washed with 5 x 200μL 0.2M phosphoric acid. After drying, 100 μL Optiphase 'SuperMix' liquid scintillation cocktail (Perkin Elmer) was added to the well prior to scintillation counting (1450 Microbeta Liquid Scintillation Counter, Wallac).

[00294] After removing mean background values for all of the data points, Ki(app) data were calculated from non-linear regression analysis of the initial rate data using the Prism software package (GraphPad Prism version 3.0cx for Macintosh, GraphPad Software, San Diego California, USA).

[00295] Below is a chart showing the ATR Inhibition Ki values of compounds of the disclosure. Compounds with a Ki value of ≤ 1 nM are marked with "++++." Compounds with a Ki value > 5 nM but ≤ 1 nM are marked with "+++." Compounds with a Ki value > 5 nM but ≤ 20 nM are marked with "++." Compounds with a Ki value > 20 nM but ≤ 100 nM are marked with "+".

Compound Analytical Data and ATR Inhibition Data

Compounds I-1 through I-139 were synthesized according to the methods described in the schemes and examples herein.

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-1	426.6	0.65	H NMR (400.0 MHz, DMSO) d 9.05 (s, 1H), 8.85 (s, 1H), 8.70 (d, J = 5.2 Hz, 1H), 8.20 (s, 1H), 8.12 - 8.08 (m, 3H), 7.82 (s, 1H), 7.68 (d, J = 8.2 Hz, 2H), 7.34 (s, 1H), 4.24 (t, J = 5.8 Hz, 2H), 2.63 (t, J = 5.3 Hz, 3H) and 1.80 (s, 6H) ppm	++++
I-2	454.7	0.72	H NMR (400.0 MHz, DMSO) d 9.02 (s, 1H), 8.85 (s, 2H), 8.70 (d, J = 5.2 Hz, 1H), 8.15 (s, 1H), 8.11 - 8.06 (m, 3H), 7.78 (s, 1H), 7.68 (d, J = 8.2 Hz, 2H), 7.31 (s, 1H), 4.24 (t, J = 5.8 Hz, 2H), 2.63 (t, J = 5.3 Hz, 3H), 2.21 - 2.05 (m, 4H) and 0.85 (t, J = 7.3 Hz, 6H) ppm	++++
I-3	426.2	0.64		++++
I-4	427	0.63	H NMR (400.0 MHz, DMSO) d 9.18 (s, 1H), 8.91 (s, 2H), 8.73 (d, J = 5.2 Hz, 1H), 8.41 (s, 1H), 8.25 (d, J = 8.3 Hz, 2H), 8.12 (dd, J = 1.5, 5.3 Hz, 1H), 7.76 (d, J = 8.3 Hz, 2H), 4.28 (t, J = 5.4 Hz, 2H), 2.64 (t, J = 5.0 Hz, 3H) and 1.80 (s, 6H) ppm	++++
I-5	383.2	1.61	H NMR (400.0 MHz, DMSO) d 9.03 (s, 1H), 8.68 (d, 1H), 8.19 (s, 1H), 8.09 (dd, 1H), 8.04-8.01 (m, 2H), 7.79 (s, 1H), 7.61-7.54 (m, 3H), 7.33 (br s, 2H) and 1.80 (s, 6H) ppm	++++
I-6	424.2	1.11	H NMR (400.0 MHz, DMSO) d 9.04 (s, 1H), 8.71 (d, 1H), 8.19 (s, 1H), 8.11 (dd, 1H), 8.04 - 8.02 (m, 2H), 7.79 (s, 1H), 7.62 - 7.56 (m, 3H), 7.34 (br s, 2H), 3.14 (br d, 2H), 2.90 (br t, 2H), 2.21 (br d, 2H) and 2.11 (td, 2H) ppm	+++
I-7	425.2	1.58	H NMR (400.0 MHz, DMSO) d 9.06 (s, 1H), 8.72 (d, 1H), 8.22 (s, 1H), 8.12 (dd, 1H), 8.04 - 8.02 (m, 2H), 7.80 (s, 1H), 7.62 - 7.54 (m, 3H), 7.34 (br s, 2H), 4.09 - 4.04 (m, 2H), 3.75 - 3.68 (m, 2H) and 2.28 - 2.24 (m, 4H) ppm	++++
I-8	403.2	1.67	H NMR (400.0 MHz, DMSO) d 9.04 (s, 1H), 8.68 (d, 1H), 8.21 (s, 1H), 8.08 (dd, 1H), 7.71 (d, 1H), 7.47 (s, 1H), 7.34 (br s, 2H), 7.12 (d, 1H), 2.52 (s, 3H) and 1.79 (s, 6H) ppm	++++
I-9	468.2	0.62	DMSO 2.2-2.25 (2H,m), 2.5-2.55 (2H,m), 3.7-3.75 (2H,m), 4.0-4.08 (2H,m), 4.2-4.27 (2H,m), 7.35-7.4 (2H,brs), 7.67 (2H,d), 7.8 (1H,s), 8.1-8.17 (3H,m), 8.2 (1H,sd), 8.7 (1H,d), 8.8 (2H,brs), 9.08 (1H,s)	++++

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-10	444.2	0.53	DMSO 1.6 (6H,s), 2.6-2.7 (3H,m), 4.2-4.25 (2H,m), 7.0-7.01 (2H,m), 7.3-7.35 (2H,m), 7.7 (2H,d), 7.8 (1H,s), 7.95-7.8 (1H,m), 8.01-8.04 (1H,m), 8.1 (2H,d), 8.6 (1H,d), 8.7-8.8 (2H,m), 9.0 (1H,s)	+++++
I-11	472.2	0.58	DMSO 1.5 (6H,s), 2.4-2.5 (3H,m) 2.6-2.7 (3H,m), 4.2-4.25 (2H,m), 7.25-7.3 (2H,m), 7.65 (2H,d), 7.8 (1H,s), 7.92-7.95 (1H,m), 7.97-8.0 (1H,m), 8.13 (2H,d), 8.6 (1H,d), 8.8-8.9 (2H,m), 9.02 (1H,s)	+++++
I-12	424.2	1.11	H NMR (400.0 MHz, DMSO) d 9.03 (s, 1H), 8.69 (d, 1H), 8.19 (s, 1H), 8.09 (dd, 1H), 8.04 - 8.01 (m, 2H), 7.78 (s, 1H), 7.60 - 7.56 (m, 3H), 7.33 (s, 2H), 3.42 (d, 2H), 3.00 (d, 2H), 2.58 - 2.54 (m, 1H), 2.35 - 2.31 (m, 1H), 2.25 - 2.18 (m, 1H) and 1.80 - 1.73 (m, 2H) ppm	+++
I-13	486.2	0.51	DMSO 2.2-2.25 (2H,m), 2.45-2.5 (2H,m), 2.65-2.7 (3H,m), 3.6-3.75 (4H,m), 4.28-4.33 (2H,m), 7.18-7.2 (1H,m), 7.27-7.3 (1H,m), 7.35-7.39 (1H,m), 7.7 (2H,d), 7.85 (1H,s), 8.05 (1H,d), 8.1 (1H,s), 8.18 (2H,d), 8.7 (1H,d), 8.88 (2H,brs), 9.05 (1H,s)	+++++
I-14	479.2	0.59	DMSO 1.9 (6H,s), 2.5-2.55 (3H,m), 2.9 (3H,s), 4.2-4.25 (2H,m), 7.35 (2H,brs), 7.68 (2H,d) 7.8 (1H,s), 8.1-8.15 (3H,m), 8.28-8.3 (1H,m), 8.7 (1H,d), 8.8-8.86 (2H,brs), 9.05 (1H,s)	+++++
I-15	465.1	0.54	MeOH 1.95 (3H,d), 2.8 (3H,s), 3.0 (3H,s), 3.38-3.42 (3H,m), 4.3 (2H,s), 4.7-4.8 (1H,m) 7.35 (1H,m), 7.65-7.7 (3H,m) 8.1-8.15 (3H,m), 8.3-8.32 (1H,m), 8.7 (1H,d), 8.8 (1H,s)	+++++
I-16	444.2	0.74	dmso d6 1.80 (6H, s), 4.13-4.25 (1H, m), 4.30-4.42 (1H, m), 4.43-4.52 (1H, m), 7.33 (2H, br s) 7.62 (2H, d), 7.78 (1H, s), 7.99 (2H, d), 8.09 (1H, d), 8.20 (1H, s), 8.69 (2H, d), 9.04 (1H, s)	+++++
I-17	482.2	0.74	dmso d6 1.65-1.75 (1H, m), 1.80 (6H, s), 1.90-2.00 (1H, m), 3.24-3.32 (1H, m), 3.41-3.50 (1H, m), 3.61-3.82 (5H, m), 7.32 (2H, br s), 7.53 (2H, d), 7.77 (1H, s), 7.96 (2H, d), 8.09 (1H, d), 8.19 (1H, s), 8.68 (1H, d), 9.03 (1H, s)	+++++
I-18	468.2	0.76	CDCl3 1.78 (6H, s), 3.76 (2H, s), 3.91-4.00 (1H, m), 4.38 (2H, t), 4.75 (2H, t), 6.00 (2H, br s), 7.35 (1H, s), 7.39 (2H, d), 7.74 (1H, d), 7.82 (2H, d), 8.12 (1H, s), 8.61 (1H, s), 8.63 (1H, d)	+++++
I-19	482.2	0.74	dmso d6 1.65-1.75 (1H, m), 1.80 (6H, s), 1.90-2.00 (1H, m), 3.24-3.32 (1H, m), 3.41-3.50 (1H, m), 3.61-3.82 (5H, m), 7.32 (2H, br s), 7.53 (2H, d), 7.77 (1H, s), 7.96 (2H, d), 8.09 (1H, d), 8.19 (1H, s), 8.68 (1H, d), 9.03 (1H, s)	+++++

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-20	470.2	0.7	CD3OD 0.95 (6H,s), 2.48.2.53 (8H,m), 6.72-6.75 (3H,m), 6.8 (1H,s), 7.18-7.26 (3H,m), 7.3 (1H,s), 7.8 (1H,d), 8.08 (1H,s),	++
I-21	514.3	0.79	MeOH 1.8 (6H,s), 3.4-3.5 (3H,m), 3.62-3.65 (2H,m), 3.9-4.0 (3H,m), 7.52-7.57 (3H,m) 7.6 (1H,s), 7.97-8.03 (2H,m), 8.2 (1H,d), 8.3 (1H,s), 8.65 (1H,d), 8.9 (1H,s)	++
I-22	436.1	0.86	DMSO 1.95 (6H,s), 3.0 (3H,s), 7.35 (2H,brs), 7.65-7.7 (3H,m), 7.85 (1H,s), 8.1-8.15 (2H,m), 8.2 (1H,d), 8.35 (1H,s), 8.8 (1H,d), 9.1 (1H,s)	++++
I-23	505.2	0.74	dmso d6 1.35-1.47 (4H, m), 1.88 (6H, s), 2.27-2.37 (2H, m), 2.80-2.90 (2H, m), 3.43-3.52 (1H, m), 7.30 (2H, br s), 7.53-7.41 (3H, m), 7.77 (1H, s), 8.02-8.04 (2H, dd), 8.10-8.12 (1H, dd), 8.32 (1H, s), 8.71 (1H, d), 9.03 (1H, s)	+++
I-24	444.2	1.13	H NMR (400.0 MHz, DMSO) d 9.06 (s, 1H), 8.79 (br s, 1H), 8.76 (d, 1H), 8.56 (br s, 1H), 8.30 (s, 1H), 8.17 (dd, 1H), 7.73 (d, 1H), 7.46 (s, 1H), 7.38 (s, 2H), 7.15 (d, 1H), 3.57 (br d, 2H), 3.21 (br q, 2H), 2.56 - 2.42 (m, 4H) and 2.54 (s, 3H) ppm	+++
I-25	438.2	1.14	H NMR (400.0 MHz, DMSO) d 9.04 (s, 1H), 8.73 (d, 1H), 8.60 (br s, 1H), 8.55 (br s, 1H), 8.26 (s, 1H), 8.15 (dd, 1H), 7.72 (d, 1H), 7.55 (s, 1H), 7.48 - 7.39 (m, 3H), 7.35 (s, 2H), 3.54 (br d, 2H), 3.19 (br q, 2H), 2.55 - 2.49 (m, 2H), 2.53 (s, 3H) and 2.46 - 2.37 (m, 2H) ppm	++
I-26	440.2	1.09	H NMR (400.0 MHz, DMSO) d 10.18 (s, 1H), 9.01 (s, 1H), 8.76 (brs, 1H), 8.74 (d, 1H), 8.56 (br s, 1H), 8.25 (s, 1H), 8.11 (dd, 1H), 7.82 (dd, 1H), 7.62 (s, 1H), 7.39 - 7.35 (m, 1H), 7.31 (s, 2H), 7.07 (d, 1H), 6.98 (t, 1H), 3.55 (br d, 2H), 3.19 (br q, 2H) and 2.54 - 2.40 (m, 4H) ppm	+++
I-27	454.2	1.11	H NMR (400.0 MHz, DMSO) d 8.92 (s, 1H), 8.68 (br s, 1H), 8.62 (d, 1H), 8.44 (br s, 1H), 8.20 (s, 1H), 8.02 (dd, 1H), 7.76 (dd, 1H), 7.47 - 7.42 (m, 1H), 7.43 (s, 1H), 7.22 (s, 2H), 7.15 (d, 1H), 7.02 (t, 1H), 3.83 (s, 3H), 3.45 (br d, 2H), 3.08 (br d, 2H) and 2.44 - 2.34 (m, 4H) ppm	+++
I-28	442.2	1.11	H NMR (400.0 MHz, DMSO) d 9.04 (s, 1H), 8.77 (br s, 1H), 8.74 (d, 1H), 8.57 (br s, 1H), 8.27 (s, 1H), 8.14 (dd, 1H), 8.03 (td, 1H), 7.67 - 7.64 (m, 1H), 7.58 (d, 1H), 7.50 - 7.41 (m, 2H), 7.37 (s, 2H), 3.55 (br d, 2H), 3.23 - 3.15 (m, 2H) and 2.55 - 2.40 (m, 4H) ppm	+++

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-29	468.2	1.12	H NMR (400.0 MHz, DMSO) d 9.03 (s, 1H), 8.75 (br s, 1H), 8.72 (d, 1H), 8.54 (br s, 1H), 8.26 (s, 1H), 8.13 (dd, 1H), 7.41 (t, 1H), 7.32 (s, 2H), 7.28 (s, 1H), 7.01 (dd, 2H), 3.76 (s, 3H), 3.54 (br d, 2H), 3.18 (br q, 2H), 2.54 - 2.39 (m, 4H) and 2.23 (s, 3H) ppm	+
I-30	430.2	1.09	H NMR (400.0 MHz, DMSO) d 9.04 (s, 1H), 8.76 (br s, 1H), 8.74 (d, 1H), 8.58 (br s, 1H), 8.25 (s, 1H), 8.14 (dd, 1H), 7.84 (dd, 1H), 7.81 (d, 1H), 7.33 (s, 2H), 7.29 (dd, 1H), 7.18 (s, 1H), 3.55 (br d, 2H), 3.20 (br t, 2H) and 2.57 - 2.40 (m, 4H) ppm	++++
I-31	454.2	0.98	H NMR (400.0 MHz, DMSO) d 9.03 (s, 1H), 8.76 (br s, 1H), 8.74 (d, 1H), 8.56 (br s, 1H), 8.26 (s, 1H), 8.16 (dd, 1H), 7.97 (d, 2H), 7.75 (s, 1H), 7.52 (d, 2H), 7.34 (s, 2H), 5.34 (br s, 1H), 4.60 (s, 2H), 3.55 (br d, 2H), 3.24 - 3.19 (m, 2H) and 2.57 - 2.41 (m, 4H) ppm	+++
I-32	440.2	1	H NMR (400.0 MHz, DMSO) d 9.99 (s, 1H), 9.02 (s, 1H), 8.76 (br s, 1H), 8.73 (d, 1H), 8.55 (br s, 1H), 8.25 (s, 1H), 8.15 (dd, 1H), 7.83 (d, 2H), 7.64 (s, 1H), 7.31 (s, 2H), 6.94 (d, 2H), 3.56 - 3.53 (m, 2H), 3.20 (br q, 2H) and 2.56 - 2.39 (m, 4H) ppm	+++
I-33	463.2	1.08	H NMR (400.0 MHz, DMSO) d 11.39 (br s, 1H), 9.03 (s, 1H), 8.76 (br s, 1H), 8.74 (d, 1H), 8.57 (br s, 1H), 8.27 (s, 1H), 8.23 (s, 1H), 8.17 (dd, 1H), 7.76 (dd, 1H), 7.75 (s, 1H), 7.56 (d, 1H), 7.47 (t, 1H), 7.33 (br s, 2H), 6.57 (s, 1H), 3.55 (br d, 2H), 3.20 (br d, 2H) and 2.54 - 2.45 (m, 4H) ppm	+++
I-34	480.1	0.74	DMSO d6 1.66-1.75 (1H, m), 1.75-1.89 (4H, m), 1.89-2.00 (1H, m), 2.40 (1H, br s), 3.26-3.32 (2H, m), 3.40-3.48 (1H, m), 3.62-3.81 (5H, m), 7.29 (2H, br s), 7.53 (2H, d), 7.73 (1H, s), 7.95 (2H, d), 8.01 (1H, d), 8.10 (1H, s), 8.59 (1H, d), 8.98 (1H, s)	++++
I-35	494.2	0.76	DMSO d6 1.68-1.75 (1H, m), 1.90-2.00 (1H, m), 2.03-2.13 (1H, s), 2.25-2.36 (1H, m), 2.41 (1H, br s), 2.72-2.80 (2H, m), 2.82-2.91 (2H, m), 7.30 (2H, br s), 7.54 (2H, d), 7.76 (1H, s), 7.96 (2H, d), 8.09-8.11 (1H, m), 8.20 (1H, s), 8.71 (1H, d), 9.04 (1H, s)	++++
I-36	508.2	0.81	dmso d6 1.65-1.75 (1H, m), 1.89-2.00 (5H, m), 2.35-2.45 (4H, m), 3.25-3.33 (2H, m), 3.42-3.48 (1H, m), 3.60-3.81 (5H, m), 7.29 (2H, br s), 7.54 (2H, d), 7.75 (1H, s), 7.96 (2H, d), 8.08 (1H, d), 8.21 (1H, s), 8.67 (1H, d), 9.02 (1H, s)	++++

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-37	438.2	1.11	H NMR (400.0 MHz, DMSO) d 8.93 (s, 1H), 8.59 (d, 1H), 8.12 (s, 1H), 8.00 (dd, 1H), 7.94 - 7.91 (m, 2H), 7.68 (s, 1H), 7.51 - 7.44 (m, 3H), 7.21 (br s, 2H), 3.22 - 3.20 (m, 1H), 2.75 (br d, 1H), 2.68 (br d, 1H), 2.21 - 2.19 (m, 1H), 2.20 (s, 3H) and 1.96 - 1.71 (m, 4H) ppm	++++
I-38	459.1	0.83	DMSO 1.6 (6H,s), 3.25 (3H,s), 3.25-3.3 (2H,m), 3.4-3.5 (2H,m), 7.4 (2H,brs), 7.5-7.6 (3H,m), 7.7 (1H,s), 8.0-8.05 (2H,m), 8.07-8.12 (2H,m), 8.65 (1H,d), 9.0 (1H,s)	++
I-39	429.4	0.84	DMSO 1.6 (6H,s), 2.5-2.6 (6H,m), 7.3 (2H,brs), 7.5-7.6 (3H,m), 7.8 (1H,s), 7.95-8.05 (4H,m), 8.63 (1H,d), 9.0 (1H,s)	+++
I-40	458.2	0.7	DMSO 1.6 (6H,s), 1.6-1.7 (2H,m), 2.7-2.8 (2H,m), 3.1-3.2 (2H,m), 3.35-3.4 (1H,m), 7.27 (2H,brs), 7.55-7.65 (6H,m), 7.75 (1H,s), 7.97-8.05 (4H,m), 8.62 (1H,d), 9.0 (1H,s)	+++
I-41	467.2	0.62	H NMR (400.0 MHz, DMSO) d 9.02 (s, 1H), 8.69 (d, J = 5.5 Hz, 1H), 8.19 (s, 1H), 8.09 (dd, J = 1.5, 5.3 Hz, 1H), 7.95 (d, J = 8.2 Hz, 2H), 7.75 (s, 1H), 7.56 (d, J = 8.2 Hz, 2H), 7.29 (s, 2H, NH ₂), 3.71 - 3.68 (m, 1H), 2.92 - 2.85 (m, 2H), 2.80 - 2.72 (m, 2H), 2.62 - 2.56 (m, 1H), 2.41 (t, 1H) and 1.80 (s, 6H) ppm	++++
I-42	524.1	0.7	dmso d6 1.65-1.75 (1H, m), 1.90-2.00 (1H, m), 2.20-2.31 (4H, m)m 3.25-3.33 (1H, m), 3.42-3.48 (1H, m), 3.60-3.80 (7H, m), 4.02-4.09 (1H, m), 7.31 (2H, br s), 7.54 (2H, d), 7.76 (1H, s), 7.96 (2H, d), 8.12 (1H, t), 8.22 (1H, s), 8.72 (1H, q), 9.04 (1H, s)	++++
I-43	439	2.11	H NMR (400.0 MHz, DMSO) d 9.18 (s, 1H), 8.77 (d, J = 5.3 Hz, 1H), 8.39 (bs, 3H), 8.38 (s, 1H), 8.24 (d, J = 8.4 Hz, 2H), 8.13 (dd, J = 1.5, 5.2 Hz, 1H), 7.77 (d, J = 8.4 Hz, 2H), 4.59 (m, 1H), 2.94 - 2.87 (m, 2H), 2.80 - 2.73 (m, 2H), 2.35 (m, 1H), 2.17 - 2.08 (m, 1H) and 1.56 (d, J = 6.8 Hz, 3H) ppm	++++
I-44	427	2.03	9.17 (s, 1H), 8.72 (d, J=4.8Hz, 1H), 8.40 (s, 1H), 8.39 (bs, 3H), 8.24 (d, J=8.4Hz, 2H), 8.12 (dd, J=5.2Hz, J=1.6Hz, 1H), 7.76 (d, J=8.45Hz, 2H), 4.6 (m, 1H), 1.803 (s, 6H), 1.56 (d, J=6.8Hz, 3H)	++++
I-45	401.1	0.77	DMSO 1.6 (6H,s), 7.1-7.2 (2H,m), 7.4 (1H,brs), 7.55-7.6 (3H,m), 7.8 (1H,s), 8.0-8.05 (2H,m), 8.1-8.2 (2H,m), 8.7 (1H,d), 9.07 (1H,s)	+++
I-46	445.1	0.75	MeOH 1.8 (6H,s), 3.4 (2H,t), 3.7 (2H,t), 7.53-7.57 (3H,m), 7.62 (1H,s), 8.0-8.05 (2H,m), 8.42 (1H,d), 8.48 (1H,s), 8.7 (1H,d), 9.03 (1H,s)	++++

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-47	441.2	0.83	MeOH 1.7 (6H,s), 1.9-1.95 (2H,m), 3.7-3.75 (2H,m), 3.85-3.9 (2H,m), 7.55-7.58 (3H,m), 7.67 (1H,s), 8.05-8.1 (2H,m), 8.35-8.4 (2H,m), 8.68 (1H,d), 9.1 (1H,s)	++
I-48	452	2.56	H NMR (400.0 MHz, DMSO) d 9.10 (m, 2H), 9.05 (s, 1H), 8.69 (d, J = 5.4 Hz, 1H), 8.20 (s, 1H), 8.11 (m, 3H), 7.84 (s, 1H), 7.70 (d, J = 8.2 Hz, 2H), 7.36 (bs, 2H), 4.35 (s, 2H), 2.08 (s, 1H), 1.80 (s, 6H) and 0.83 - 0.78 (m, 4H) ppm	+++++
I-49	412.1	0.59	DMSO 1.62 (3H,d), 2.6-2.65 (2H,m), 4.2-4.25 (2H,m), 4.5 (1H,q), 7.3 (2H,brs), 7.68 (2H,d), 7.83 (1H,s), 8.1-8.3 (4H,m), 8.8 (1H,d), 8.82 (2H,brs), 8.98 (1H,s)	+++++
I-50	369.1	0.86	DMSO 1.6 (3H,d), 4.5 (1H,q), 7.3 (2H,brs), 7.55-7.62 (3H,m), 7.8 (1H,s), 8.0-8.05 (2H,m), 8.06-8.1 (1H,m), 8.12-8.14 (1H,m), 8.7 (1H,d), 8.97 (1H,s)	+++++
I-51	399.2	1.4	H NMR (400.0 MHz, DMSO) d 10.00 (s, 1H), 9.02 (s, 1H), 8.68 (d, 1H), 8.19 (s, 1H), 8.08 (dd, 1H), 7.84 (d, 2H), 7.66 (s, 1H), 7.30 (s, 2H), 6.93 (d, 2H) and 1.80 (s, 6H) ppm	+++++
I-52	439	2	H NMR (400.0 MHz, DMSO) d 9.17 (s, 1H), 9.15 (bs, 2H), 8.72 (d, J = 5.2 Hz, 1H), 8.43 (s, 1H), 8.11 (dd, J = 1.5, 5.1 Hz, 1H), 8.06 - 8.03 (m, 2H), 7.52 (d, J = 8.0 Hz, 1H), 4.43 (s, 2H), 3.48 (m, 2H), 3.16 (t, J = 6.0 Hz, 2H) and 1.80 (s, 6H) ppm	+++
I-53	496	2.28	H NMR (400.0 MHz, DMSO) d 9.05 (s, 1H), 8.95 (bs, 2H), 8.70 (d, J = 4.8, 1H), 8.20 (s, 1H), 8.12 (d, J = 4 Hz, 2H), 7.83 (s, 1H), 7.72 (d, J = 8 Hz, 2H), 7.34 (bs, 2H), 4.30 (m, 2H), 3.95 (m, 2H), 3.35 (m, 1H), 2.04 (m, 2H), 1.80 (s, 6H) and 1.61 (m, 2H) ppm	+++++
I-54	445.2	1.09	H NMR (400.0 MHz, DMSO) d 9.15 (s, 1H), 8.73 (d, 1H), 8.30 (s, 1H), 8.07 (dd, 1H), 7.92 (d, 1H), 7.92 (br s, 2H), 7.23 (d, 1H), 3.11 - 3.07 (m, 2H), 2.90 - 2.83 (m, 2H), 2.71 (s, 3H) and 2.10 - 2.07 (m, 4H) ppm	++
I-55	439.1	0.64	1H (DMSO) d 1.80 (6H, s), 3.13 (2H, t), 3.47 (2H, m), 4.44 (2H, m), 7.53 (1H, d), 8.05-8.08 (2H, m), 8.12 (1H, dd), 8.43 (1H, s), 8.72 (1H, d), 9.08 (2H, br s) and 9.18 (1H, s) ppm	+++++
I-56	471	2.18	H NMR (400.0 MHz, DMSO) d 9.79 (bs, 1H), 9.15 (s, 1H), 8.72 (d, J = 5.2 Hz, 1H), 8.37 (s, 1H), 8.15 (dd, J = 1.7, 7.1 Hz, 2H), 8.10 (dd, J = 1.5, 5.3 Hz, 1H), 7.28 - 7.25 (m, 2H), 4.49 - 4.46 (m, 2H), 3.59 (m, 2H), 2.91 (s, 6H) and 1.80 (s, 6H) ppm	+++++

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-57	427.2	0.63	H NMR (400.0 MHz, DMSO) d 9.16 (s, 1H), 8.72 (d, 1H), 8.36 (s, 1H), 8.11 - 8.07 (m, 3H), 7.49 (d, 2H), 2.86 - 2.57 (m, 4H) and 1.80 (s, 6H) ppm	++++
I-58	468.2	0.61	H NMR (400.0 MHz, DMSO) d 9.19 (s, 1H), 8.73 (d, 1H), 8.37 (d, 2H), 8.27 - 8.25 (m, 1H), 8.12 (dd, 1H), 7.84 - 7.78 (m, 2H), 4.76 (d, 1H), 3.80 (d, 2H), 3.68 - 3.60 (m, 3H), 3.53 - 3.39 (m, 2H), 3.32 - 3.27 (m, 1H) and 1.81 (s, 6H) ppm	++
I-59	442	2.01	H NMR (400.0 MHz, DMSO) d 9.13 (s, 1H), 8.71 (d, J = 5.0 Hz, 1H), 8.36 (s, 1H), 8.09 (dd, J = 1.5, 5.1 Hz, 1H), 7.93 (d, J = 8.8 Hz, 2H), 7.83 (s, 3H), 6.81 (d, J = 8.8 Hz, 2H), 3.41 (t, J = 6.4 Hz, 2H), 3.02 (d, J = 6.0 Hz, 2H) and 1.80 (s, 6H) ppm	++++
I-60	468.4	0.8	H NMR (400.0 MHz, DMSO) d 9.83 - 9.80 (m, 1H), 9.72 (br s, 1H), 9.05 (s, 1H), 8.69 (d, 1H), 8.20 (s, 1H), 8.13 - 8.09 (m, 3H), 7.84 - 7.80 (m, 3H), 7.35 (br s, 1H), 4.60 (t, 1H), 4.09 - 3.82 (masked signals, 4H), 3.39 - 3.28 (m, 2H) and 1.80 (s, 6H) ppm	++++
I-61	482.1	0.68	H NMR (400.0 MHz, DMSO) d 9.13 (s, 1H), 8.72 (d, 1H), 8.37 (s, 1H), 8.09 (dd, 1H), 8.01 (d, 4H), 7.14 (d, 2H), 3.86 (d, 1H), 3.66 (d, 1H), 3.35 - 3.28 (br m, 1H), 3.18 - 3.09 (m, 2H), 1.85 - 1.83 (m, 1H) and 1.80 (s, 6H) ppm	++++
I-62	468.1	0.66	H NMR (400.0 MHz, DMSO) d 9.13 (s, 1H), 8.72 (d, 1H), 8.36 (s, 1H), 8.09 (dd, 3H), 8.00 (d, 2H), 6.78 (d, 2H), 4.02 (br s, 1H), 3.68 (dd, 1H), 3.59 (q, 1H), 3.48 (dd, 1H), 3.43 (dd, 1H), 2.42 - 2.33 (m, 1H), 2.15 - 2.08 (m, 1H) and 1.80 (s, 6H) ppm	++++
I-63	443.9	0.68	DMSO 1.6 (6H,s), 2.85-2.9 (2H,m), 3.3-3.35 (2H,m), 7.3 (2H,brs), 7.55-7.6 (3H,m), 7.7-7.8 (4H,m), 8.0-8.05 (3H,m), 8.1 (1H,s), 8.6 (1H,d), 9.02 (1H,s)	+++
I-64	482.2	0.68	H NMR (400.0 MHz, DMSO) d 9.12 (s, 1H), 8.71 (d, 1H), 8.36 (s, 1H), 8.08 - 8.00 (m, 4H), 7.13 (d, 2H), 3.86 (d, 1H), 3.65 (d, 1H), 3.32 - 3.29 (br m, 1H), 3.18 - 3.08 (m, 2H), 2.03 - 2.00 (m, 1H) and 1.85 - 1.38 (m, 7H) ppm	+++
I-65	458.2	0.7	DMSO 1.6 (6H,s), 2.62 (3H,t), 2.95-3.0 (2H,m), 3.35-3.4 (2H,m), 7.3 (2H,brs), 7.55-7.6 (3H,m), 7.7-7.8 (2H,m), 8.0-8.05 (3H,m), 8.1 (1H,s), 8.4 (2H,brs), 8.6 (1H,d), 9.02 (1H,s)	++
I-66	427.2	0.64	H NMR (400.0 MHz, DMSO) d 9.17 (s, 1H), 8.72 (d, 1H), 8.40 (s, 1H), 8.11 (dd, 1H), 8.02 - 7.99 (m, 2H), 7.59 - 7.53 (m, 2H), 2.87 - 2.84 (m, 2H), 2.81 - 2.77 (m, 2H) and 1.80 (s, 6H) ppm	++++

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-67	514.5	0.64	H NMR (400.0 MHz, DMSO) d 9.05 (s, 1H), 8.71 (br s, 2H), 8.70 (d, 1H), 8.20 (s, 1H), 8.12 - 8.08 (m, 3H), 7.82 (s, 1H), 7.71 (d, 2H), 7.34 (s, 2H), 4.94 (br s, 1H), 4.28 (br t, 2H), 3.51 (dd, 1H), 3.49 - 3.38 (m, 2H), 3.33 (dd, 1H), 3.26 (s, 3H), 3.03 - 2.97 (m, 2H), 2.17 - 2.11 (m, 1H) and 1.80 (s, 6H) ppm	++++
I-68	482.2	0.7	DMSO 1.8 (6H,s), 2.02-2.18 (3H,m), 2.88-2.93 (1H,m), 2.94-2.98 (1H,m), 3.4-3.5 (2H,m), 4.02-4.12 (2H,m), 6.88 (2H,d), 7.82-7.88 (3H,m), 7.98 (2H,d), 8.08-8.11 (1H,m), 8.37 (1H,s), 8.72 (1H,d), 9.13 (1H,s),	++
I-69	497	2.22	H NMR (400.0 MHz, DMSO) d 9.88 (bs, 1H), 9.16 (s, 1H), 8.72 (d, J = 5.2 Hz, 1H), 8.37 (s, 1H), 8.15 (d, J = 8.8 Hz, 2H), 8.10 (dd, J = 5.2, 1.2 Hz, 1H), 7.27 (d, J = 8.8 Hz, 2H), 4.46 - 4.44 (m, 2H), 3.67 - 3.65 (m, 4H), 3.16 (d, J = 3.3 Hz, 2H), 2.06 (m, 2H), 1.91 - 1.89 (m, 2H) and 1.80 (s, 6H) ppm	++++
I-70	460	2.01	H NMR (400.0 MHz, DMSO) d 9.14 (s, 1H), 8.72 (d, J = 5.1 Hz, 1H), 8.32 (s, 1H), 8.07 (dd, J = 1.5, 5.3 Hz, 1H), 7.89 (t, J = 8.4 Hz, 1H), 7.83 ((bs, 3H)), 7.03 ((bs, 1H)), 6.69 - 6.66 (m, 2H), 3.43 (m, 2H), 3.01 (m, 2H) and 1.81 (s, 6H) ppm	++++
I-71	468.2	0.8	H NMR (400.0 MHz, DMSO) d 10.08 - 10.03 (m, 1H), 9.82 (d, 1H), 9.05 (s, 1H), 8.69 (d, 1H), 8.20 (s, 1H), 8.13 - 8.09 (m, 3H), 7.85 - 7.83 (m, 3H), 7.35 (br s, 1H), 4.66 - 4.57 (masked signal, 1H), 4.08 - 4.03 (m, 2H), 3.97 - 3.91 (m, 1H), 3.86 (t, 1H), 3.37 - 3.28 (m, 2H) and 1.80 (s, 6H) ppm	+++
I-72	456.2	0.67	DMSO 1.8 (6H,s), 3.08 (3H,s), 3.32-3.38 (2H,m), 3.62-3.68 (2H,m), 6.98 (2H,d), 7.75-7.85 (3H,brs), 7.98 (2H,d), 8.08-8.11 (1H,m), 8.38 (1H,s), 8.72 (1H,d), 9.12 (1H,s),	+++
I-73	468.2	0.65	H NMR (400.0 MHz, DMSO) d 9.13 (s, 1H), 8.88 (s, 2H), 8.72 (d, 1H), 8.36 (s, 1H), 8.09 (dd, 1H), 8.03 (d, 2H), 7.21 (d, 2H), 3.60 - 3.57 (m, 4H), 3.28 (s, 4H) and 1.80 (s, 6H) ppm	++++
I-74	450.2	1.15	H NMR (400.0 MHz, DMSO) d 10.10 (s, 1H), 9.09 (s, 1H), 8.76 (d, 1H), 8.43 (s, 1H), 8.22 (dd, 1H), 8.03 (dd, 2H), 7.80 (s, 1H), 7.62 - 7.57 (m, 3H), 7.37 (s, 2H), 4.69 (br d, 1H), 4.02 (br d, 1H), 3.54 - 3.49 (m, 1H), 3.38 - 3.33 (m, 1H), 3.24 - 3.19 (m, 2H), 3.10 - 3.06 (m, 1H), 2.40 - 2.33 (m, 1H), 2.21 - 2.14 (m, 1H), 1.83 - 1.77 (m, 1H) and 1.41 - 1.31 (m, 1H) ppm	++++

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-75	460	2.4	H NMR (400.0 MHz, DMSO) d 9.18 (s, 1H), 8.73 (d, J = 5.3 Hz, 1H), 8.38 (s, 1H), 8.11 (dd, J = 1.5, 5.2 Hz, 1H), 8.03 (dd, J = 6.6, 8.7 Hz, 1H), 7.84 (m, 4H), 6.92 (dd, J = 2.3, 12.6 Hz, 1H), 6.66 (d, J = 2.2 Hz, 1H), 3.68 (d, J = 6.3 Hz, 2H), 3.07 (d, J = 5.9 Hz, 2H) and 1.80 (s, 6H) ppm	++
I-76	482.2	0.67	H NMR (400.0 MHz, DMSO) d 9.12 (s, 1H), 8.72 (d, 1H), 8.34 (s, 1H), 8.09 (dd, 1H), 7.95 (d, 2H), 7.11 (d, 2H), 3.88 (d, 2H), 2.95 (td, 2H), 2.85 - 2.78 (m, 1H), 1.80 (s, 6H), 1.80 - 1.78 (masked signal, 2H), 1.70 (br s, 2H) and 1.33 - 1.21 (m, 2H) ppm	+++
I-77	468.2	0.7	H NMR (400.0 MHz, DMSO) d 9.14 (s, 1H), 8.72 (d, 1H), 8.34 (s, 1H), 8.09 (dd, 1H), 7.43 - 7.36 (m, 2H), 7.18 (s, 1H), 6.79 (d, 1H), 3.63 (quintet, 1H), 3.52 - 3.42 (m, 2H), 3.37 - 3.32 (masked signal, 1H), 3.00 (dd, 1H), 2.20 - 2.08 (m, 1H), 1.97 - 1.89 (br m, 1H) and 1.80 (s, 6H) ppm	++++
I-78	470.2	0.67	DMSO 1.8 (6H,s), 2.6-2.65 (3H,m), 3.1 (3H,s), 3.15-3.2 (2H,m), 3.6-3.65 (2H,m), 6.95 (2H,d), 8.0 (2H,d), 8.08-8.11 (1H,m), 8.38 (1H,s), 8.45 (1H,brs), 8.72 (1H,d), 9.12 (1H,s),	++++
I-79	453	2.09	H NMR (400.0 MHz, DMSO) d 9.55 (bs, 1H), 9.18 (s, 1H), 8.88 (bs, 1H), 8.73 (d, J = 5.0 Hz, 1H), 8.40 (s, 1H), 8.25 (d, J = 8.4 Hz, 2H), 8.11 (dd, J = 1.5, 5.2 Hz, 1H), 7.77 (d, J = 8.4 Hz, 2H), 4.71 (m, 1H), 3.39 (m, 2H), 2.10 (m, 4H) and 1.80 (s, 6H) ppm	++++
I-80	439	2	H NMR (400.0 MHz, DMSO) d 9.17 (s, 1H), 8.73 (d, J = 5.6 Hz, 1H), 8.40 (s, 1H), 8.20 (d, J = 8.3 Hz, 2H), 8.11 (dd, J = 1.6, 5.3 Hz, 1H), 7.70 (d, J = 8.3 Hz, 2H), 4.34 - 4.14 (m, 5H) and 1.80 (s, 6H) ppm	+++
I-81	425.1	0.62	1H (DMSO) d 1.80 (6H, s), 4.65 (4H, t), 7.70 (1H, d), 8.11 (1H, m), 8.17 (1H, m), 8.19 (1H, m), 8.40 (1H, s), 8.72 (1H, s), 9.18 (1H, s) and 9.47 (2H, br s) ppm	+++
I-82	468.2	0.61	1H NMR (DMSO) d 1.80 (6H, s), 3.23-3.37 (4H, m), 3.55-3.76 (4H, m), 4.62 (1H, m), 7.79 (2H, d), 8.12 (1H, dd), 8.28 (2H, m), 8.42 (1H, s), 8.73 (2H, d) and 9.20 (1H, s) ppm	+++
I-83	496	1.08	H NMR (400.0 MHz, DMSO) d 9.05 (s, 1H), 9.03 (bs, 2H), 8.69 (d, J = 5.2 Hz, 1H), 8.20 (s, 1H), 8.13 - 8.08 (m, 3H), 7.83 (s, 1H), 7.74 (d, J = 8.2 Hz, 2H), 7.34 (bs, 2H), 4.43 (d, J = 6.2 Hz, 2H), 4.33 (m, 2H), 4.25 (d, J = 6.3 Hz, 2H), 3.30 (m, 2H), 1.80 (s, 6H) and 1.36 (s, 3H) ppm	++++

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-84	454.2	0.66	DMSO 1.8 (6H,s), 3.85-3.94 (2H,m), 4.3-4.4 (2H,m), 4.48-4.53 (1H,m), 6.78-6.83 (2H,m), 7.3 (1H,s), 7.4-7.5 (2H,m), 8.08-8.11 (1H,m), 8.32 (1H,s), 8.7-8.8 (3H,m), 9.18 (1H,s),	+++
I-85	473.3	0.71	DMSO 1.6 (6H,s), 2.80-2.83 (6H,m), 3.1-3.2 (2H,m), 3.4-3.5 (2H,m), 7.35 (2H,brs), 7.5-7.6 (3H,m), 7.75-7.8 (2H,m), 8.0-8.12 (4H,m), 8.6 (1H,d), 9.02 (1H,s), 9.2 (1H,brs)	++
I-86	482.2	0.75	H NMR (400.0 MHz, DMSO) d 9.12 (s, 1H), 8.72 (d, 1H), 8.35 (s, 1H), 8.09 (dd, 1H), 7.97 (d, 2H), 7.13 (d, 2H), 3.35 (t, 4H), 2.46 (t, 4H), 2.24 (s, 3H) and 1.80 (s, 6H) ppm	+++
I-87	457.2	0.71	DMSO 1.8 (6H,s), 3.4 (3H,s), 3.7-3.75 (2H,m), 4.7-4.75 (1H,m), 8.25 (2H,d), 8.1-8.15 (1H,m), 8.25 (2H,d), 8.4 (1H,s), 8.55-8.6 (2H,m), 8.72 (1H,d), 9.2 (1H,s)	++++
I-88	468.2	0.67	H NMR (400.0 MHz, DMSO) d 9.11 (s, 1H), 8.72 (d, 1H), 8.36 (s, 1H), 8.09 (dd, 1H), 7.95 (d, 2H), 6.69 (d, 2H), 3.66 (quintet, 1H), 3.54 - 3.47 (m, 2H), 3.42 - 3.32 (m, 1H), 3.06 (dd, 1H), 2.16 - 2.08 (m, 1H), 1.92 (d, 1H) and 1.80 (s, 6H) ppm	++++
I-89	453	2.14	H NMR (400.0 MHz, DMSO) d 9.52 (bs, 1H), 9.19 (s, 1H), 8.90 (bs, 1H), 8.73 (d, J = 5.2 Hz, 1H), 8.37 (d, J = 0.7 Hz, 1H), 8.29 (s, 1H), 8.22 (dd, J = 1.2, 7.5 Hz, 1H), 8.12 (dd, J = 1.5, 5.3 Hz, 1H), 7.80 (dd, J = 7.8, 17.8 Hz, 1H), 7.75 (s, 1H), 4.75 (m, 1H), 3.42 (m, 2H), 2.14 - 2.08 (m, 4H) and 1.81 (s, 6H) ppm	++
I-90	468.2	0.7	H NMR (400.0 MHz, DMSO) d 9.15 (s, 1H), 8.72 (d, 1H), 8.34 (s, 1H), 8.10 (dd, 1H), 7.43 - 7.37 (m, 2H), 7.19 (s, 1H), 6.81 - 6.79 (m, 1H), 3.63 (quintet, 1H), 3.52 - 3.44 (m, 2H), 3.38 - 3.32 (masked signal, 1H), 3.00 (dd, 1H), 2.12 (sextet, 1H), 1.80 (s, 6H) and 1.80 - 1.73 (masked signal, 1H) ppm	++++
I-91			(DMSO) d 0.73 (2H, t), 0.96 (1H, t), 1.57-1.70 (2H, m), 2.78 (2H, m), 2.92 (4H, m), 3.27-3.46 (4H, m), 3.65 (1H, m), 3.82 (1H, m), 7.33 (2H, br s), 7.56-7.61 (3H, m), 7.79 (1H, m), 8.02 (2H, m), 8.19-8.32 (2H, m), 8.68 (1H, m), 9.01 (1H, m) and 9.44 (1H, m) ppm rotamers observed	++
I-92	484.2	0.74	DMSO 1.8 (6H,s), 2.85 (6H,d), 3.05 (3H,s), 3.25-3.3 (2H,m), 3.8-3.85 (2H,m), 6.97 (2H,d), 7.98 (2H,d), 8.1-8.13 (1H,m), 8.38 (1H,s), 8.72 (1H,d), 9.12 (1H,s), 9.4 (1H,brs)	+++

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-93	496	2.51	H NMR (400.0 MHz, DMSO) d 9.05 (s, 1H), 8.97 (bs, 2H), 8.70 (d, J = 5.1 Hz, 1H), 8.20 (s, 1H), 8.13 - 8.08 (m, 3H), 7.83 (s, 1H), 7.73 (d, J = 8.3 Hz, 2H), 7.34 (bs, 2H), 4.32 (d, J = 5.0 Hz, 2H), 3.95 (m, 1H), 3.71 (m, 1H), 3.59 - 3.50 (m, 1H), 3.54 (m, 2H), 3.27 (m, 1H), 1.80 (s, 6H), 1.75 (m, 2H) and 1.55 (m, 1H) ppm	++++
I-94	425.2	1.07	H NMR (400.0 MHz, DMSO) d 9.18 (s, 1H), 8.77 (d, 1H), 8.59 (br s, 2H), 8.47 (s, 1H), 8.20 - 8.17 (m, 3H), 7.98 (br s, 2H), 7.74 - 7.65 (m, 3H), 3.57 (br d, 2H), 3.22 (br s, 2H) and 2.52 - 2.48 (m, 4H) ppm	++
I-95	439	2.09	H NMR (400.0 MHz, DMSO) d 9.18 (s, 1H), 8.95 (bs, 1H), 8.73 (d, J = 5.0 Hz, 1H), 8.60 (bs, 1H), 8.40 (d, J = 0.7 Hz, 1H), 8.15 - 8.11 (m, 3H), 7.77 (d, J = 7.6 Hz, 1H), 7.71 (t, J = 7.6 Hz, 1H), 4.37 - 4.17 (m, 5H) and 1.81 (s, 6H) ppm	+++
I-96	445.1	0.64	1H (DMSO) d 1.80 (6H, s), 3.18 (2H, t), 3.51 (2H, t), 4.31 (2H, s), 7.85 (1H, s), 8.07 (1H, dd), 8.30 (1H, s), 8.72 (1H, d), 9.11 (2H, br s) and 9.16 (1H, s) ppm	++++
I-97	482.2	0.74	dmso d6 1.65-1.75 (1H, m), 1.80 (6H, s), 1.90-2.00 (1H, m), 3.24-3.32 (1H, m), 3.41-3.50 (1H, m), 3.61-3.82 (5H, m), 7.32 (2H, br s), 7.53 (2H, d), 7.77 (1H, s), 7.96 (2H, d), 8.09 (1H, d), 8.19 (1H, s), 8.68 (1H, d), 9.03 (1H, s)	++++
I-98	482.2	0.67	DMSO 1.65-1.72 (1H,m), 1.8 (6H,s), 1.9-2.0 (2H,m), 2.1-2.2 (1H,m), 3.2-3.3 (2H,m), 3.4-3.5 (1H,m), 6.75-6.8 (1H,m), 6.85 (2H,d), 7.92 (1H,d), 8.08-8.11 (1H,m), 8.38 (1H,s), 8.4-8.45 (1H,m), 8.71 (1H,d), 8.8-8.9 (1H,m), 9.13 (1H,s),	++++
I-99	469	2.38	H NMR (400.0 MHz, DMSO) d 9.15 (s, 1H), 8.72 (d, J = 5.1 Hz, 1H), 8.37 (s, 1H), 8.13 - 8.09 (m, 3H), 7.69 (d, J = 8.2 Hz, 2H), 3.94 (dd, J = 2.6, 9.9 Hz, 1H), 3.78 (d, J = 10.5 Hz, 2H), 3.52 - 3.47 (m, 1H), 3.21 (t, J = 10.4 Hz, 1H), 2.91 (m, 2H) and 1.80 (s, 6H) ppm	+
I-100	496.2	0.69	H NMR (400.0 MHz, DMSO) d 9.17 (s, 1H), 8.72 (d, 1H), 8.37 (s, 1H), 8.14 - 8.12 (m, 3H), 7.58 (d, 2H), 3.58 (s, 2H), 2.41 - 2.33 (br m, 8H), 2.16 (s, 3H) and 1.80 (s, 6H) ppm	++
I-101	431.1	1.04	H NMR (400.0 MHz, DMSO) d 9.15 (s, 1H), 8.74 (d, 1H), 8.34 (s, 1H), 8.09 (dd, 1H), 8.06 (dd, 1H), 7.98 (dd, 1H), 7.92 (br s, 2H), 7.38 (dd, 1H), 3.12 - 3.08 (m, 2H), 2.96 - 2.83 (m, 2H) and 2.13 - 2.09 (m, 4H) ppm	+++

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-102	482	1.06	H NMR (400.0 MHz, DMSO) d 9.03 (s, 1H), 8.68 (d, J = 5.6 Hz, 1H), 8.19 (s, 1H), 8.08 (dd, J = 1.6, 5.2 Hz, 1H), 7.96 (d, J = 8.2 Hz, 2H), 7.77 (s, 1H), 7.52 (d, J = 8.2 Hz, 2H), 7.32 (bs, 2H), 4.62 (dd, J = 5.9, 7.6 Hz, 2H), 4.26 (t, J = 5.9 Hz, 2H), 3.77 (s, 2H), 3.04 (m, 1H), 2.78 (d, J = 7.4 Hz, 2H) and 1.80 (s, 6H) ppm	++++
I-103	488	2.74	H NMR (400.0 MHz, DMSO) d 9.52 (bs, 1H), 9.18 (s, 1H), 8.73 (d, J = 5.3 Hz, 1H), 8.38 (s, 1H), 8.12 (dd, J = 1.5, 5.2 Hz, 1H), 8.04 (dd, J = 6.6, 8.7 Hz, 1H), 7.82 (m, 1H), 6.95 (dd, J = 2.3, 12.5 Hz, 1H), 6.68 (d, J = 2.1 Hz, 1H), 3.81 (d, J = 6.3 Hz, 2H), 3.37 (d, J = 4.1 Hz, 2H), 2.89 (d, J = 3.0 Hz, 6H) and 1.80 (s, 6H) ppm	+
I-104	468.2	0.66	DMSO 1.8 (6H,s), 3.0-3.1 (1H,m), 3.4-3.5 (2H,m), 3.77-3.83 (2H,m), 4.05-4.15 (2H,m), 6.58 (2H,d), 6.78 (1H,d), 7.78-7.88 (3H,m), 7.9 (1H,d), 7.98 (2H,d), 8.08-8.11 (1H,m), 8.38 (1H,s), 8.73 (1H,d), 9.13 (1H,s),	++++
I-105	483	1.07	H NMR (400.0 MHz, DMSO) d 9.16 (s, 1H), 8.72 (d, J = 5.2 Hz, 1H), 8.37 (s, 1H), 8.13 - 8.10 (m, 3H), 7.61 (d, J = 8.1 Hz, 2H), 4.63 (dd, J = 6.0, 7.6 Hz, 2H), 4.27 (t, J = 5.9 Hz, 2H), 3.82 (s, 2H), 3.05 (qt, J = 6.80 Hz, 1H), 2.80 (d, J = 7.4 Hz, 2H) and 1.80 (s, 6H) ppm	++++
I-106	469.1	0.65	H NMR (400.0 MHz, DMSO) d 9.15 (s, 1H), 8.72 (d, 1H), 8.34 (s, 1H), 8.11 - 8.08 (m, 3H), 7.16 (d, 2H), 5.02 - 4.99 (br m, 1H), 3.17 (d, 1H), 3.12 (dd, 1H), 2.96 - 2.89 (m, 2H), 2.84 - 2.78 (m, 1H), 2.08 (sextet, 1H) and 1.80 (s, 6H) ppm	+++
I-107	454.1	0.64	DMSO 1.8 (6H,s), 3.85-3.94 (2H,m), 4.3-4.4 (2H,m), 4.5-4.55 (1H,m), 6.78 (2H,d), 7.3 (1H,d), 7.93 (2H,d), 8.08-8.11 (1H,m), 8.38 (1H,s), 8.7-8.75 (3H,m), 9.13 (1H,s),	++++
I-108	488	2.18	H NMR (400.0 MHz, DMSO) d 9.43 (bs, 1H), 9.13 (s, 1H), 8.71 (d, J = 5.6 Hz, 1H), 8.31 (s, 1H), 8.07 (dd, J = 1.5, 5.3 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.90 (t, J = 8.8 Hz, 1H), 7.04 (m, 1H), 6.73 - 6.68 (m, 2H), 3.55 (m, 2H), 3.28 (m, 2H), 2.86 (d, J = 4.5 Hz, 6H) and 1.80 (s, 6H) ppm	++++
I-109	467.2	0.67	DMSO 1.8 (6H,s), 1.8-1.9 (2H,m), 2.0-2.1 (2H,m), 3.0-3.1 (2H,m), 3.4-3.48 (2H,m), 7.55 (2H,d), 8.1-8.13 (1H,m), 8.16 (2H,d), 8.25-8.35 (1H,vbrs), 8.38 (1H,s), 8.53-8.6 (1H,m), 8.72 (1H,d), 9.17 (1H,s)	+++

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-110	454.1	0.7	DMSO 1.8 (6H,s), 3.88-3.92 (2H,m), 4.2-4.3 (3H,m), 6.82-6.87 (1H,m), 7.16-7.19 (1H,m), 7.45 (1H,t), 7.53-7.57 (1H,m), 8.1-8.14 (1H,m), 8.32-8.4 (4H,m), 8.72 (1H,d), 9.18 (1H,s)	++++
I-111	445.1	0.67	1H (DMSO) d 1.75 (6H, s), 2.93 (2H, t), 3.41 (2H, m), 4.46 (2H, m), 7.79 (1H, s), 8.03 (1H, m), 8.26 (1H, s), 8.66 (1H, m), 9.11 (1H, s) and 9.17 (2H, br s) ppm	++++
I-112	443	2.01	H NMR (400.0 MHz, DMSO) d 9.15 (s, 1H), 8.72 (d, J = 5.2 Hz, 1H), 8.36 (s, 1H), 8.14 (d, J = 8.8 Hz, 2H), 8.10 (dd, J = 5.2 Hz, J = 1.6 Hz, 1H), 8.04 (bs, 3H), 7.25 (d, J = 8.8 Hz, 2H), 4.31 (t, J = 5.0 Hz, 2H), 3.30 (m, 2H) and 1.80 (s, 6H) ppm	++++
I-113	455.16	1.05	DMSO 1.81 (6H,s), 4.03-4.13 (2H,m), , 4.48-4.58 (2H,m), 5.2-5.25 (1H,m), 7.15 (2H,d), 8.1-8.18 (3H,m), 8.38 (1H,s), 8.72 (1H,d), 8.85 (1H,brs), 9.07 (1H,brs), 9.15 (1H,s)	++++
I-114	470.2	0.67	DMSO 1.8 (6H,s), 2.85 (6H,d), 3.2-3.25 (2H,m), 3.55-3.6 (2H,m), 6.72 (1H,brs), 6.85 (2H,d), 8.1-8.13 (1H,m), 8.38 (1H,s), 8.72 (2H,d), 9.12 (1H,s), 9.4 (1H,brs)	+++
I-115	431.1	0.99	DMSO 1.25 (3H,t), 1.65 (6H,s), 4.15 (2H,q), 7.3 (1H,brs), 7.55-7.6 (2H,m), 7.78 (1H,s), 7.95-8.05 (3H,m), 8.6 (1H,d), 9.0 (1H,s)	+++
I-116	512.2	1.06	DMSO 1.81 (6H,s), 3.15-3.22 (2H,m), 3.3-3.35 (2H,m), 3.5-3.65 (6H,m), 4.0-4.05 (2H,m), 6.75-6.8 (1H,m), 6.83 (2H,d), 7.92 (2H,d), 8.1 (1H,d), 8.38 (1H,s), 8.72 (1H,d), 9.25 (1H,s), 9.75 (1H,brs)	++++
I-117	456.2	0.65	DMSO 1.8 (6H,s), 2.6-2.68 (3H,m), 3.1-3.2 (2H,m), 3.42-3.48 (2H,m), 6.7 (1H,brs), 6.82 (2H,d), 7.92 (2H,d), 8.1-8.13 (1H,m), 8.32 (1H,s), 8.42 (1H,brs), 8.72 (1H,d), 9.12 (1H,s),	++++
I-118	439.2	0.96	DMSO 1.81 (6H,s), 2.3-2.4 (2H,m), 3.95-4.03 (4H,m), 6.55 (2H,d), 7.95 (2H,d), 8.07-8.1 (1H,m), 8.38 (1H,s), 8.72 (1H,d), 9.12 (1H,s),	+++
I-119	469.2	0.65	H NMR (400.0 MHz, DMSO) d 9.15 (s, 1H), 8.72 (d, 1H), 8.34 (s, 1H), 8.11 - 8.08 (m, 3H), 7.16 (d, 2H), 5.00 (t, 1H), 3.17 (d, 1H), 3.12 (dd, 1H), 2.96 - 2.89 (m, 2H), 2.84 - 2.78 (m, 1H), 2.08 (sextet, 1H) and 1.80 (s, 6H) ppm	+++
I-120	443.2	0.74	DMSO 1.8 (6H,s), 3.2-3.25 (2H,m), 3.55-3.6 (2H,m), 6.8 (2H,d), 7.88 (2H,d), 8.1-8.13 (1H,m), 8.38 (1H,s), 8.72 (1H,d), 9.12 (1H,s),	++++

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-121	469.2	1.06	DMSO 1.81 (6H,s), 2.95-3.0 (3H,m), 4.1-4.2 (1H,m), 4.25-4.35 (1H,m), , 4.42-4.48 (1H,m), 4.72-4.81 (1H,m), 5.15-5.2 (0.5H,m), 5.28-5.33 (0.5H,m), 7.1-7.2 (2H,m), 8.1-8.2 (3H,m), 8.38 (1H,s), 8.72 (1H,d), 9.1 (1H,s), 9.75 (0.5H, brs), 10.25 (0.5H, brs)	++++
I-122	497.2	1.06	H NMR (400.0 MHz, DMSO) d 9.19 (s, 1H), 9.18 (br s, 2H), 8.73 (d, 1H), 8.42 (s, 1H), 8.25 (d, 2H), 8.13 (dd, 1H), 8.00 (br s, 2H), 7.84 (d, 2H), 4.39 - 4.30 (m, 2H), 3.98 (dd, 1H), 3.62 - 3.56 (m, 2H), 3.50 - 3.46 (m, 1H), 3.23 (br s, 1H), 2.12 (br s, 1H), 1.80 (s, 6H), 1.80 - 1.78 (m, 2H) and 1.55 - 1.52 (m, 1H) ppm	++++
I-123	454.2	0.69	DMSO 1.8 (6H,s), 3.9-4.0 (2H,m), 4.25-4.3 (2H,m), 6.8 (2H,d), 7.85 (2H,d), 8.1-8.13 (1H,m), 8.38 (1H,s), 8.72 (1H,d), 9.12 (1H,s),	++++
I-124	515	1.05		++++
I-125	482.2	0.68	H NMR (400.0 MHz, DMSO) d 9.16 (s, 1H), 8.72 (d, 1H), 8.37 (s, 1H), 8.10 (dd, 1H), 7.91 (s, 2H), 7.62 - 7.58 (m, 2H), 7.49 (t, 1H), 7.30 (dd, 1H), 4.07 (d, 2H), 3.34 - 3.25 (br m, 1H), 2.91 (t, 2H), 2.01 (d, 2H), 1.80 (s, 6H) and 1.64 (qd, 2H) ppm	++
I-126	497.2	1.05	H NMR (400.0 MHz, DMSO) d 9.34 (br d, 2H), 9.19 (s, 1H), 8.73 (d, 1H), 8.41 (s, 1H), 8.25 (d, 2H), 8.13 (dd, 1H), 7.99 (br s, 2H), 7.86 (d, 2H), 4.33 (br t, 2H), 3.95 (dd, 2H), 3.36 - 3.30 (m, 3H), 2.06 (br dd, 2H), 1.80 (s, 6H) and 1.69 (qd, 2H) ppm	++++
I-127	470.1	0.58	H NMR (400.0 MHz, DMSO) d 8.98 (s, 2H), 8.63 (d, J = 5.4 Hz, 1H), 8.13 (s, 1H), 8.04 (s, 1H), 8.02 (qn, J = 1.7 Hz, 3H), 7.76 (s, 1H), 7.62 (d, J = 8.3 Hz, 2H), 7.28 (s, 2H), 4.20 (s, 2H), 3.87 (s, 2H) and 1.73 (s, 6H) ppm	++
I-128	465.2	1.17	DMSO 1.8 (6H,s), 2.75-2.8 (2H,m), 3.4-3.45 (2H,m), 3.8-3.85 (2H,m), 7.8 (2H,d), 8.1-8.13 (1H,m), 8.2 (2H,d), 8.4 (1H,s), 8.7 (1H,d), 8.85 (2H,brs), 9.18 (1H,s),	++++
I-129	452.1	1.06	MeOH 1.85 (6H,s), 4.2 (4H,s), 8.03-8.08 (1H,m), 8.1 (2H,d), 8.5 (2H,d), 8.55 (1H,s), 8.7 (1H,d), 9.02 (1H,s)	+++
I-130	456.2	0.67	DMSO 1.22 (3H,d), 1.8 (6H,s), 2.9-3.0 (1H,m), 3.32-3.38 (2H,m), 6.83 (2H,d), 7.78-7.85 (3H,brs), 7.93 (2H,d), 8.08-8.11 (1H,m), 8.38 (1H,s), 8.72 (1H,d), 9.12 (1H,s),	++++
I-131	482.2	0.82	DMSO 1.85 (6H,s), 3.01 (6H,s), 4.18-4.22 (2H,m), 4.3-4.33 (1H,m), 4.38-4.42 (2H,m), 6.75 (2H,d), 8.03-8.08 (1H,m), 8.12 (2H,d), 8.52 (1H,s), 8.72 (1H,d), 8.95 (1H,s),	++++

Cmpd No.	LCMS ES +	LCMS (Rt min)	HNMR	ATR Ki
I-132	459.2	0.9	(DMSO) d 0.66 (1.5H, t), 0.94 (1.5H, t), 3.13 (1.5H, s), 3.27 (2H, m), 3.29-3.32 (2.5H, m), 3.46 (3H, m), 3.61 (2H, m), 7.30 (2H, br s), 7.56-7.60 (3H, m), 7.80 (1H, m), 8.02-8.05 (2H, m), 8.15-8.17 (2H, m), 8.64-8.66 (1H, m) and 9.02 (1H, m) ppm rotamers observed	+++
I-133	455.2	1.03	H NMR (400.0 MHz, DMSO) d 9.14 (s, 1H), 8.73 (d, 1H), 8.28 (s, 1H), 8.07 (dd, 1H), 8.05 (br s, 2H), 8.03 (dd, 1H), 7.68 (dt, 1H), 7.35 (d, 1H), 7.19 (t, 1H), 4.00 (s, 3H), 3.10 - 3.07 (m, 2H), 2.89 - 2.82 (m, 2H) and 2.11 - 2.08 (m, 4H) ppm	++++
I-134	420	2.97	H NMR (400.0 MHz, DMSO) d 9.17 (s, 1H), 8.72 (d, J = 5.4 Hz, 1H), 8.29 - 8.25 (m, 2H), 8.07 (dd, J = 1.5, 5.2 Hz, 1H), 7.67 (td, J = 9.2, 2.3, 1H), 7.40 (td, J = 9.2, 2.3 Hz, 1H) and 1.80 (s, 6H) ppm	+++
I-135	459.2	0.69	¹ H NMR (500 MHz, DMSO) ? 9.06 (s, 1H), 8.99 (s, 2H), 8.68 (d, J = 5.7 Hz, 1H), 8.33 (s, 1H), 8.20 (d, J = 6.6 Hz, 1H), 8.13 (d, J = 8.4 Hz, 2H), 7.84 (s, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.46 (s, 2H), 4.78 (s, 2H), 4.34 - 4.22 (m, 2H), 3.97 (dd, J = 10.9, 4.5 Hz, 2H), 3.39 (s, 1H), 3.35 (t, J = 11.1 Hz, 3H), 2.05 (dd, J = 12.8, 3.2 Hz, 2H), 1.63 (qd, J = 12.6, 5.1 Hz, 2H).	++++
I-136	468.4	0.74	¹ H NMR (400 MHz, DMSO) ? 8.97 (s, 1H), 8.91 (s, 2H), 8.67 (d, J = 5.3 Hz, 1H), 8.19 - 8.09 (m, 3H), 8.07 (d, J = 5.3 Hz, 1H), 7.84 (s, 1H), 7.72 (d, J = 8.3 Hz, 2H), 7.33 (s, 2H), 4.34 - 4.26 (m, 4H), 3.96 (dd, J = 11.3, 3.9 Hz, 2H), 3.64-3.60 (m, 1H), 3.34 (t, J = 11.5 Hz, 2H), 2.05 (d, J = 13.0 Hz, 2H), 1.62 (ddd, J = 16.6, 11.8, 4.3 Hz, 2H).	++++
I-137	469.2	0.7	¹ H NMR (400 MHz, DMSO) ? 9.11 (s, 1H), 9.00 (s, 2H), 8.69 (d, J = 5.2 Hz, 1H), 8.29 (d, J = 8.3 Hz, 2H), 8.22 (s, 1H), 8.10 (dd, J = 5.3, 1.5 Hz, 1H), 7.81 (d, J = 8.3 Hz, 2H), 4.41 - 4.28 (m, 4H), 3.96 (dd, J = 11.3, 3.8 Hz, 2H), 3.45 - 3.28 (m, 3H), 2.05 (d, J = 10.2 Hz, 2H), 1.63 (qd, J = 12.1, 4.4 Hz, 2H).	++++
I-138	514	1.15	H NMR (400.0 MHz, DMSO) d 9.07 (s, 2H), 8.77 (d, J = 2.1 Hz, 1H), 8.54 (d, J = 5.0 Hz, 1H), 8.15 - 8.11 (m, 3H), 7.86 (s, 1H), 7.72 (d, J = 8.3 Hz, 2H), 7.45 (s, 1H), 4.30 (t, J = 5.7 Hz, 2H), 3.95 (dd, J = 3.9, 11.1 Hz, 2H), 3.36 - 3.31 (m, 3H), 2.06 - 2.03 (m, 2H), 1.82 (s, 6H) and 1.63 (dd, J = 4.4, 12.1 Hz, 2H) ppm	+++
I-139	500	1.13		++

Example 11: Cisplatin Sensitization Assay

[00296] Compounds can be screened for their ability to sensitize HCT116 colorectal cancer cells to Cisplatin using a 96h cell viability (MTS) assay. HCT116 cells, which possess a defect in ATM signaling to Cisplatin (see, Kim et al.; *Oncogene* 21:3864 (2002); see also, Takemura et al.; *JBC* 281:30814 (2006)) are plated at 470 cells per well in 96-well polystyrene plates (Costar 3596) in 150µl of McCoy's 5A media (Sigma M8403) supplemented with 10% foetal bovine serum (JRH Biosciences 12003), Penicillin/Streptomycin solution diluted 1:100 (Sigma P7539), and 2mM L-glutamine (Sigma G7513), and allowed to adhere overnight at 37°C in 5% CO₂. Compounds and Cisplatin are then both added simultaneously to the cell media in 2-fold serial dilutions from a top final concentration of 10µM as a full matrix of concentrations in a final cell volume of 200µl, and the cells are then incubated at 37°C in 5% CO₂. After 96h, 40µl of MTS reagent (Promega G358a) is added to each well and the cells are incubated for 1h at 37°C in 5% CO₂. Finally, absorbance is measured at 490nm using a SpectraMax Plus 384 reader (Molecular Devices) and the concentration of compound required to reduce the IC₅₀ of Cisplatin alone by at least 3-fold (to 1 decimal place) can be reported.

Example 12: Single Agent HCT116 Activity

[00297] Compounds can be screened for single agent activity against HCT116 colorectal cancer cells using a 96h cell viability (MTS) assay. HCT116 are plated at 470 cells per well in 96-well polystyrene plates (Costar 3596) in 150µl of McCoy's 5A media (Sigma M8403) supplemented with 10% foetal bovine serum (JRH Biosciences 12003), Penicillin/Streptomycin solution diluted 1:100 (Sigma P7539), and 2mM L-glutamine (Sigma G7513), and allowed to adhere overnight at 37°C in 5% CO₂. Compounds are then added to the cell media in 2-fold serial dilutions from a top final concentration of 10µM as a full matrix of concentrations in a final cell volume of 200µl, and the cells are then incubated at 37°C in 5% CO₂. After 96h, 40µl of MTS reagent (Promega G358a) is added to each well and the cells are incubated for 1h at 37°C in 5% CO₂. Finally, absorbance is measured at 490nm using a SpectraMax Plus 384 reader (Molecular Devices) and IC₅₀ values can be calculated.

Example 13: Pharmacokinetics

[00298] Noncompartmental pharmacokinetic parameters can be analyzed using Watson Bioanalytical LIMS (Version 7.4; Thermo Fisher Scientific) from either the blood or plasma samples. The following parameters can be estimated following intravenous (IV) dosing; terminal elimination half-life ($T_{1/2} = \ln(2)/\lambda_z$, where λ_z is the first order rate constant associated with the terminal (log-linear) portion of the curve.


[00299] The area under the curve (AUC_{last} = area under the curve from the time of dosing to the last measurable concentration). The area under the curve extrapolated to infinity ($AUC_{0-\infty} = AUC_{last} + C_{last}/\lambda_z$). The clearance (Cl; $Cl = Dose_{IV}/AUC_{0-\infty}$). The area under the first moment curve ($AUMC_{last}$ = area under the concentration times time versus time curve from the time of dosing to the last measurable concentration). The area under the first moment curve extrapolated to infinity ($AUMC_{0-\infty} = AUMC_{last} + C_{last} \times t/\lambda_z + C_{last}/\lambda_z^2$). The mean residence time ($MRT = AUMC_{0-\infty}/AUC_{0-\infty}$) and the steady state volume of distribution ($V_{dss} = MRT \times Cl$).

[00300] Clearance and volume of distribution can also be obtained using methods known to one of skill in the art (see e.g., Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists, Younggil Kwon, pp18-28 (Non-compartmental Approach)).

[00301] While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments that utilize the compounds, methods, and processes of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example herein.

CLAIMS

1. A compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein

Ring D is isoxazolyl or oxadiazolyl;

Ring A is a 5-6 membered monocyclic aryl or heteroaryl ring, wherein said heteroaryl ring has 1 heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur;

J is halo or C₁₋₆alkyl, wherein 0-1 methylene units of said C₁₋₆alkyl is replaced with -O-.

J¹ is halo or -(X)_q-Y;

X is C₁₋₁₀alkyl wherein 0-2 methylene units of said C₁₋₆alkyl are replaced with NR, O, or S; X is optionally substituted with 1-2 occurrences of C₁₋₃alkyl or halo;

Y is hydrogen, C₁₋₄alkyl, or a 3-6 membered saturated or partially unsaturated cycloaliphatic or heterocyclyl, wherein said heterocyclyl has 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C₁₋₃alkyl;

or J and J¹ join together to form a 5-7 heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C₁₋₃alkyl; wherein 0-1 methylene units of said C₁₋₃alkyl is replaced with -O-, -NR-, -S-, or -CO-.

p and q are each independently 0 or 1;

J² is H or C₁₋₆alkyl;

J³ is H or C₁₋₆alkyl;

or J² and J³ join together to form a 3-7 membered monocyclic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or a 8-10 membered bicyclic or bridged ring having 0-4 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein said monocyclic, bicyclic, or bridged ring is optionally substituted with 1-2 occurrences of halo or C₁₋₃alkyl;

J⁴ is CN, OH, or L-Z;

J⁵ is H or fluoro;

L is C(O), S(O)₂, or C(O)NR;

Z is (U)_tQ or C₁₋₆alkyl wherein 0-2 methylene units of said C₁₋₆alkyl are replaced with O or NR;

U is C₁₋₂alkyl;

t is 0 or 1;

Q is C₃₋₆cycloalkyl or 4-6 membered saturated or partially saturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; and

R is H or C₁₋₄alkyl.

2. The compound of claim 1, wherein

J is halo, C₁₋₄alkyl, or C₁₋₄alkoxy;

J¹ is -(X)_q-Y;

X is C₁₋₆alkyl wherein 0-2 methylene units of said C₁₋₆alkyl are replaced with NH, O, or S; X is optionally substituted with 1-2 occurrences of C₁₋₃alkyl or halo;

or J and J¹ join together to form a 5-7 heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C₁₋₃alkyl;

J⁴ is CN or L-Z;

L is C(O), S(O)₂, or C(O)NR;

Z is (U)_tQ or C₁₋₆alkyl wherein 0-2 methylene units of said C₁₋₆alkyl are replaced with O or NR;

U is C₁₋₂alkyl;

t is 0 or 1;

Q is C₃₋₆cycloalkyl or 4-6 membered saturated or partially saturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; and

R is H or C₁₋₄alkyl.

3. The compound of claim 2, wherein







J⁴ is CN or L-Z;

J⁵ is H;

J³ is C₁₋₆alkyl;


Y is hydrogen, C₁₋₄alkyl, or a 3-6 membered saturated or partially unsaturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and


sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C_{1-3} alkyl; and
 p is 0 or 1.

4. The compound of any one of claims 1-3, wherein Ring  is  or .
5. The compound of claim 4, wherein Ring A is phenyl or thienyl.
6. The compound of claim 5, wherein Ring A is phenyl.
7. The compound of claim 6, q is 1.
8. The compound of claim 7, wherein X is C_{1-6} alkyl wherein one methylene unit is replaced with NH or -O-.
9. The compound of claim 8, wherein X is -O- and Y is H or CH_3 .
10. The compound of claim 8, wherein X is $-CH_2NH-$.
11. The compound of claim 10, wherein Y is H, C_{1-4} alkyl, or a 5-6 membered saturated monocyclic heterocyclyl having 1-2 heteroatoms selected from the group consisting of O and N.
12. The compound of claim 11, wherein Y is C_{1-4} alkyl, cyclopropyl, or tetrahydrofuranyl.
13. The compound of claim 4, wherein J^1 is H, halo, CH_3 , OH, OCH_3 , CH_2OH , CH_2NHCH_3 , $CH_2CH_2NH_2$, $CH(NH_2)CH_2OCH_3$, $CH_2NHCH_2CH(CH_2OH)CH_2OCH_3$, $CH(CH_2F)NH_2$, $CH(CH_3)NH_2$, $NHCH_2CH_2NH_2$, $NHCH_2CH(CH_3)NH_2$, $NHCH_2CH_2N(CH_3)_2$, $NHCH_2CH_2NHCH_3$, $N(CH_3)CH_2CH_2NH_2$, $N(CH_3)CH_2CH_2NHCH_3$, $N(CH_3)CH_2CH_2N(CH_3)_2$, $NHCH_2CH_2OH$, $-OCH_2CH_2NH_2$, $-OCH_2CH_2N(CH_3)_2$, $CH_2NHCH_2C(O)OH$, $-CH_2-(\text{piperazinyl})$, $CH_2NH\text{-cyclopropyl}$, , , , $CH_2NH\text{-(tetrahydrofuranyl)}$, $CH_2NH\text{-(tetrahydropyranyl)}$, $CH_2NH\text{-(oxetanyl)}$, $CH_2NHCH_2\text{(oxetanyl)}$, $CH_2NH\text{(tetrahydropyranyl)}$, $-O\text{-(azetidiny)}$, $NHCH_2\text{(azetidiny)}$, $NHCH_2\text{(pyrrolidiny)}$, $-OCH_2CH_2\text{(pyrrolidiny)}$, $-O\text{-pyrrolidiny}$, $NH\text{-(azetidiny)}$, $-O\text{-(azetidiny)}$, $NHCH_2CH_2\text{(morpholiny)}$, $NHCH_2CH_2\text{(morpholiny)}$, azetidiny, pyrrolidiny, piperidiny, piperazinyl, or morpholiny (where said azetidiny,


pyrrolidinyl, piperidinyl, or piperazinyl, is optionally substituted with CH₃, CH₂NH₂ or NH₂, NH(CH₃), or N(CH₃)₂.

14. The compound of claim 13, wherein J¹ is H, CH₃, OH, OCH₃, CH₂OH, CH₂NHCH₃, CH₂NH-cyclopropyl, CH(CH₂F)NH₂, CH(CH₃)NH₂, CH₂NH-(tetrahydrofuranyl), CH₂NH-(oxetanyl), or piperazinyl.
15. The compound of claim 4, wherein p is 0.
16. The compound of claim 4, wherein p is 1 and J is halo, CH₃, OH, or OCH₃.
17. The compound of claim 4, wherein J and J¹ join together to form a 5-6 heterocyclyl having one nitrogen atom.
18. The compound according to claim 17, wherein Ring A, together with J and J¹, form an indole ring, isoindoline ring, or a tetrahydroisoquinolinyl ring.

19. The compound of claim 1 wherein Ring  is bonded as shown in formulae Ia or Ib:





20. The compound of claim 1 wherein




Ring A is phenyl; and


X is C₁₋₆alkyl wherein one methylene unit is replaced with NH or -O-.

21. The compound of claim 20, wherein Ring  is .
22. The compound of any one of claims 1-20 wherein J⁴ is CN.
23. The compound of any one of claims 1-20 wherein J⁴ is L-Z.
24. The compound of claim 22 or 23, wherein J² is H, C₁₋₄alkyl; and J³ is C₁₋₄alkyl.

25. The compound of claim 22 or 23, wherein J^2 and J^3 join together to form a 3-6 membered fully saturated monocyclic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur.
26. The compound of claim 22 or 23, wherein J^2 is hydrogen, methyl or ethyl; J^3 is methyl or ethyl; or J^2 and J^3 join together to form cyclopropyl, cyclobutyl, cyclopentyl, piperidinyl, or tetrahydropyranyl.
27. The compound of claim 22 or 23, wherein L is C(O), S(O)₂, or C(O)NR and Z is C₁₋₆alkyl, C₁₋₄alkyl)-N(R)₂, (C₁₋₄alkyl)-OR, OR, or wherein two R groups attached to the same nitrogen atom optionally join to form Q; Q is azetidiny, piperazinyl, morpholinyl, or piperidinyl.
28. The compound of any one of claims 1-20 wherein J^4 is CN, OH, C(O)NH₂, C(O)NHCH₃, C(O)NH(CH₃)₂, C(O)NHCH₂CH₂NH₂, C(O)NHCH₂CH₂NHCH₃, C(O)NHCH₂CH₂N(CH₃)₂, C(O)NHCH₂CH₂OH, C(O)NHCH₂CH₂OCH₃,



29. The compound of claim 26 wherein J^2 is methyl and J^3 is methyl.
30. The compound of claim 26 wherein J^2 and J^3 join together to form cyclopropyl, cyclobutyl, cyclopentyl, piperidinyl, or tetrahydropyranyl.
31. The compound of claim 1, wherein



Ring A is phenyl or thienyl;


J^2 is methyl and J^3 is methyl.

J^4 is CN;


p is 0; and

q is 1.


32. The compound of any one of claims 1, 20, or 31, wherein Ring



is




33. A compound selected from the following:



I-91

















and























I-132.

















34. The compound of claim 1, selected from the following:

















I-1	I-2	I-3	I-4
I-5	I-6	I-7	I-8
















			
I-9	I-10	I-11	I-12
			
I-13	I-14	I-15	I-16
			
I-17	I-18	I-19	I-20
			
I-21	I-22	I-23	I-24

			
I-25	I-26	I-27	I-28
			
I-29	I-30	I-31	I-32
			
I-33		I-34	
			
I-35		I-36	

















			
I-37	I-38	I-39	I-40
			
I-41	I-42		
			
I-43	I-44		

			
I-45	I-46	I-47	I-48
			
I-49	I-50	I-51	I-52
			
I-53	I-54	I-55	I-56
			
I-57	I-58	I-59	I-60

			
I-61	I-62	I-63	I-64
			
I-65	I-66	I-67	I-68
			
I-69	I-70	I-71	I-72
			
I-73	I-74	I-75	I-76

			
I-77	I-78	I-79	I-80
			
I-81	I-82	I-83	I-84
			
I-85	I-86	I-87	I-88
			
I-89	I-90	I-92	

I-93	I-94	I-95	I-96
I-97	I-98	I-99	I-100
I-101	I-102	I-103	I-104
I-105	I-106	I-107	I-108

			
I-109	I-110	I-111	I-112
			
I-113	I-114	I-115	I-116
			
I-117	I-118	I-119	I-120
			
I-121	I-122	I-123	I-124

I-125	I-126	I-127	I-128
I-129	I-130	I-131	
I-133	I-134	I-135	I-136
I-137	I-138	I-139	

35. A pharmaceutical composition comprising a compound of any one of claims 1-34 and a pharmaceutically acceptable carrier.
36. A method for treating cancer in a patient comprising administering a compound of any one of claims 1-34 or a pharmaceutically acceptable derivative thereof.
37. The method of claim 36, further comprising administering to said patient an additional therapeutic agent selected from a DNA-damaging agent; wherein said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said compound as a single dosage form or separately from said compound as part of a multiple dosage form.
38. The method of claim 37, wherein said DNA-damaging agent is selected chemotherapy or radiation treatment.
39. The method of claim 37, wherein said DNA-damaging agent is selected from ionizing radiation, radiomimetic neocarzinostatin, a platinating agent, a Topo I inhibitor, a Topo II inhibitor, an antimetabolite, an alkylating agent, an alkyl sulphonates, or an antibiotic.
40. The method of claim 39, wherein said DNA-damaging agent is selected from ionizing radiation, a platinating agent, a Topo I inhibitor, a Topo II inhibitor, or an antibiotic.
41. The method of claim 39, wherein said DNA-damaging agent is selected from ionizing radiation, a platinating agent, a Topo I inhibitor, a Topo II inhibitor, an antimetabolite, an alkylating agent, or an alkyl sulphonates.
42. The method of claim 41, wherein said platinating agent is selected from Cisplatin, Oxaliplatin, Carboplatin, Nedaplatin, Lobaplatin, Triplatin Tetranitrate, Picoplatin, Satraplatin, ProLindac and Aroplatin; said Topo I inhibitor is selected from Camptothecin, Topotecan, Irinotecan/SN38, Rubitecan and Belotecan; said Topo II inhibitor is selected from Etoposide, Daunorubicin, Doxorubicin, Aclarubicin, Epirubicin, Idarubicin, Amrubicin, Pirarubicin, Valrubicin, Zorubicin and Teniposide; said antimetabolite is selected from Aminopterin, Methotrexate, Pemetrexed, Raltitrexed, Pentostatin, Cladribine, Clofarabine, Fludarabine, Thioguanine, Mercaptopurine,

Fluorouracil, Capecitabine, Tegafur, Carmofur, Floxuridine, Cytarabine, Gemcitabine, Azacitidine and Hydroxyurea; said alkylating agent is selected from Mechlorethamine, Cyclophosphamide, Ifosfamide, Trofosfamide, Chlorambucil, Melphalan, Prednimustine, Bendamustine, Uramustine, Estramustine, Carmustine, Lomustine, Semustine, Fotemustine, Nimustine, Ranimustine, Streptozocin, Busulfan, Mannosulfan, Treosulfan, Carboquone, ThioTEPA, Triaziquone, Triethylenemelamine, Procarbazine, Dacarbazine, Temozolomide, Altretamine, Mitobronitol, Actinomycin, Bleomycin, Mitomycin and Plicamycin.

43. The method of claim 40, wherein said platinating agent is selected from Cisplatin, Oxaliplatin, Carboplatin, Nedaplatin, or Satraplatin; said Topo I inhibitor is selected from Camptothecin, Topotecan, irinotecan/SN38, rubitecan; said Topo II inhibitor is selected from Etoposide; said antimetabolite is selected from methotrexate, pemetrexed, Thioguanine, Fludarabine, Cladribine, Cytarabine, gemcitabine, 6-Mercaptopurine, or 5-Fluorouracil; said alkylating agent is selected from nitrogen mustards, nitrosoureas, triazenes, alkyl sulfonates, Procarbazine, or aziridines; and said antibiotic is selected from Hydroxyurea, Anthracyclines, Anthracenediones, or Streptomyces family.
44. The method of claim 40 wherein said DNA-damaging agent is a platinating agent or ionizing radiation.
45. The method of claim 39, wherein the antimetabolite is gemcitabine.
46. The method of claim 39, wherein the DNA-damaging agent is ionizing radiation.
47. The method of claim 39, wherein the DNA-damaging agent is a platinating agent selected from Cisplatin or Carboplatin.
48. The method of claim 39, wherein the DNA-damaging agent is a Topo II inhibitor selected from Etoposide.
49. The method of claim 39, wherein the DNA-damaging agent is an alkylating agent selected from Temozolomide.

50. The method of claim 39, wherein the additional therapeutic agent is selected from one or more of the following: Cisplatin, Carboplatin, gemcitabine, Etoposide, Temozolomide, or ionizing radiation.
51. The method of any one of claims 36-50, wherein said cancer is a solid tumor selected from the following cancers: Oral: buccal cavity, lip, tongue, mouth, pharynx; Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel or small intestines (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel or large intestines (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colon, colon-rectum, colorectal; rectum, Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, biliary passages; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocyoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteochondrogenous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian

carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma), breast; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis, Thyroid gland: papillary thyroid carcinoma, follicular thyroid carcinoma; medullary thyroid carcinoma, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma; and Adrenal glands: neuroblastoma.

52. The method of any one of claims 36-50, wherein said cancer is selected from lung cancer, head and neck cancer, pancreatic cancer, gastric cancer, and brain cancer.
53. The The method of any one of claims 36-50, wherein said cancer is selected from non-small cell lung cancer, small cell lung cancer, pancreatic cancer, biliary tract cancer, head and neck cancer, bladder cancer, colorectal cancer, glioblastoma, esophageal cancer, breast cancer, hepatocellular carcinoma, or ovarian cancer.
54. The method of claim 51, wherein said cancer is selected from a cancer of the lung or the pancreas.
55. The method of claim 53, wherein the additional therapeutic agent is Gemcitabine and the cancer is pancreatic cancer.
56. The method of claim 55, wherein the compound is compound I-53.
57. A method of treating pancreatic cancer comprising administering to a patient a compound of any one of claims 1-34 in combination with an additional therapeutic agent selected from Gemcitabine, radiation therapy, or both Gemcitabine and radiation therapy together.

58. A method of increasing the sensitivity of pancreatic cancer cells to a cancer therapy selected from chemotherapy or radiation therapy by administering to a patient a compound of any one of claims 1-34.
59. The method of claim 58, wherein the chemotherapy is gemcitabine.
60. The method of claim 58, wherein the cancer therapy is gemcitabine.
61. The method of claim 58, wherein the cancer therapy is radiation.
62. The method of claim 58, wherein the cancer therapy is gemcitabine and radiation.
63. A method of inhibiting phosphorylation of Chk1 (Ser 345) in a pancreatic cancer cell comprising administering a compound of any one of claims 1-34 in combination with gemcitabine (100 nM) and/or radiation (6 Gy).
64. A method of sensitizing pancreatic cancer cells to chemoradiation by administering a compound of any one of claims 1-34 in combination with chemoradiation.
65. The method of claim 64, wherein the chemoradiation is gemcitabine and radiation.
66. A method of radiosensitizing hypoxic pancreatic cancer cells by administering a compound of any one of claims 1-34 in combination with radiation therapy.
67. A method of sensitizing hypoxic pancreatic cancer cells by administering a compound of any one of claims 1-34 in combination with chemotherapy.
68. The method of any one of claims 63-67, wherein said cancer cell is a PSN-1, MiaPaCa-2 or PancM cancer cell.
69. A method of disrupting damage-induced cell cycle checkpoints by administering a compound of any one of claims 1-34 in combination with radiation therapy and/or gemcitabine.


70. A method of inhibiting repair of DNA damage by homologous recombination in a pancreatic cancer cell by administering a compound of any one of claims 1-34 in combination with radiation therapy and/or gemcitabine.
71. The method of any one of claims 63-70, wherein the compound is administered to a patient.
72. The method of any one of claims 63-70, wherein the compound is administered to a pancreatic cancer cell.
73. The method of claim 72, wherein the pancreatic cancer cells are derived from a pancreatic cell line selected from PSN-1, MiaPaCa-2 or Panc-1.
74. A method of treating non-small cell lung cancer comprising administering to a patient a compound of any one of claims 1-34 in combination with one or more of the following additional therapeutic agents: Cisplatin or Carboplatin, Etoposide, and ionizing radiation.
75. The method of claim 74, comprising administering to a patient a compound of any one of claims 1-34 in combination with Cisplatin or Carboplatin, Etoposide, and ionizing radiation.
76. A method of promoting cell death in cancer cells comprising administering to a patient a compound of any one of claims 1-34.
77. A method of preventing cell repair from DNA damage comprising administering to a patient a compound of any one of claims 1-34.
78. A method of inhibiting ATR in a biological sample comprising the step of contacting a compound of any one of claims 1-34 with said biological sample.
79. The method of claim 78, wherein said biological sample is a cell.
80. A method of sensitizing cells to DNA damaging agents comprising administering to a patient a compound of any one of claims 1-34.

81. The method of any one of claims 36-80, wherein said cell is a cancer cell having one or more defects in the ATM signaling cascade.
82. The method of claim 81, wherein said defect is altered expression or activity of one or more of the following: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1/BRIT1, CTIP, or SMC1.
83. The method of claim 82, wherein said defect is altered expression or activity of one or more of the following: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1 or H2AX.
84. The method of any one of claims 36-80, wherein said cell is a cancer cell expressing DNA damaging oncogenes.
85. The method of claim 84, wherein said cancer cell has altered expression or activity of one or more of the following: K-Ras, N-Ras, H-Ras, Raf, Myc, Mos, E2F, Cdc25A, CDC4, CDK2, Cyclin E, Cyclin A and Rb.
86. The method of any one of claims 36-80, wherein said cancer, cancer cell, or cell has a defect in a base excision repair protein.
87. The method of claim 86, wherein the base excision repair protein is UNG, SMUG1, MBD4, TDG, OGG1, MYH, NTH1, MPG, NEIL1, NEIL2, NEIL3 (DNA glycosylases); APE1, APEX2 (AP endonucleases); LIG1, LIG3 (DNA ligases I and III); XRCC1 (LIG3 accessory); PNK, PNKP (polynucleotide kinase and phosphatase); PARP1, PARP2(Poly(ADP-Ribose) Polymerases); PolB, PolG (polymerases); FEN1 (endonuclease) or Aprataxin.
88. The method of claim 87, wherein the base excision repair protein is PARP1, PARP2, or PolB.
89. The method of claim 88, wherein the base excision repair protein is PARP1 or PARP2.

90. The method of any one of claims 36-89, further comprising administering to said patient an additional therapeutic agent wherein said agent inhibits or modulates a base excision repair protein.
91. The method of claim 90, wherein the base excision repair protein is selected from UNG, SMUG1, MBD4, TDG, OGG1, MYH, NTH1, MPG, NEIL1, NEIL2, NEIL3 (DNA glycosylases); APE1, APEX2 (AP endonucleases); LIG1, LIG3 (DNA ligases I and III); XRCC1 (LIG3 accessory); PNK, PNKP (polynucleotide kinase and phosphatase); PARP1, PARP2 (Poly(ADP-Ribose) Polymerases); PolB, PolG (polymerases); FEN1 (endonuclease) or Aprataxin.
92. The method of claim 91, wherein the base excision repair protein is selected from PARP1, PARP2, PolB
93. The method of claim 92, wherein the base excision repair protein is selected from PARP1 or PARP2.
94. The method of claim 90, wherein said agent is selected from Olaparib (also known as AZD2281 or KU-0059436), Iniparib (also known as BSI-201 or SAR240550), Veliparib (also known as ABT-888), Rucaparib (also known as PF-01367338), CEP-9722, INO-1001, MK-4827, E7016, BMN673, or AZD2461.
95. Use of a compound of any one of claims 1-34 as a radio-sensitizer or a chemo-sensitizer.
96. Use of a compound according to any one of claims 1-34 as a single agent (monotherapy) for treating cancer.
97. Use of a compound according to any one of claims 1-34 for treating patients having cancer with a DNA-damage response (DDR) defect.
98. The use according to claim 97, wherein said defect is a mutation or loss of ATM, p53, CHK2, MRE11, RAD50, NBBut S1, 53BP1, MDC1, or H2AX.

99. The use according to claim 97, wherein said defect is a mutation or loss of ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1/BRIT1, CTIP, or SMC1.
100. Use of a compound according to any one of claims 1-34 for treating cancer.
101. The use of claim 100, wherein said compound is combined with an additional therapeutic agent selected from an agent in any one of claim 38-50 and 90-94.
102. The use of claim 100 or claim 101, wherein the cancer has a defect in a pathway selected from any one of the pathways described in claims 81-89 and 97-99.
103. Use of a compound of any one of claims 1-34 for the manufacture of a medicament for use as a radio-sensitizer or a chemo-sensitizer.
104. Use of a compound according to any one of claims 1-34 for the manufacture of a medicament for use as a single agent (monotherapy) for treating cancer.
105. Use of a compound according to any one of claims 1-34 for the manufacture of a medicament for treating patients having cancer with a DNA-damage response (DDR) defect.
106. The use according to claim 105, wherein said defect is a mutation or loss of ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, or H2AX.
107. The use according to claim 1-34 wherein said defect is a mutation or loss of ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1/BRIT1, CTIP, or SMC1.
108. Use of a compound according to 1-34 for the manufacture of a medicament for treating cancer.
109. The use of claim 105 or claim 108, wherein said compound is combined with an additional therapeutic agent selected from an agent in any one of claim 38-50 and 90-94.

110. The use of claim 105 or claim 108, wherein the cancer has a defect in a pathway selected from any one of the pathways described in claims 81-89 and 97-99.



I